US20180116710A1 - Methods of Sterilization and Treating Infection Using Irreversible Electroporation - Google Patents
Methods of Sterilization and Treating Infection Using Irreversible Electroporation Download PDFInfo
- Publication number
- US20180116710A1 US20180116710A1 US15/864,421 US201815864421A US2018116710A1 US 20180116710 A1 US20180116710 A1 US 20180116710A1 US 201815864421 A US201815864421 A US 201815864421A US 2018116710 A1 US2018116710 A1 US 2018116710A1
- Authority
- US
- United States
- Prior art keywords
- treatment
- probe
- probes
- tissue
- electrode
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
- A61B18/1477—Needle-like probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00571—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for achieving a particular surgical effect
- A61B2018/00577—Ablation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00571—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for achieving a particular surgical effect
- A61B2018/00613—Irreversible electroporation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/1206—Generators therefor
- A61B2018/124—Generators therefor switching the output to different electrodes, e.g. sequentially
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
- A61B2018/1467—Probes or electrodes therefor using more than two electrodes on a single probe
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B34/00—Computer-aided surgery; Manipulators or robots specially adapted for use in surgery
- A61B34/25—User interfaces for surgical systems
- A61B2034/252—User interfaces for surgical systems indicating steps of a surgical procedure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B34/00—Computer-aided surgery; Manipulators or robots specially adapted for use in surgery
- A61B34/25—User interfaces for surgical systems
- A61B2034/254—User interfaces for surgical systems being adapted depending on the stage of the surgical procedure
Definitions
- the present invention relates to methods of treating infections in mammals using irreversible electroporation (IRE) to destroy the pathogenic microorganisms comprising the infection and methods of sterilization of implanted medical devices using IRE.
- IRE irreversible electroporation
- Infections are caused by parasitic microorganisms such as viruses, bacteria or fungi which invade the host and rapidly reproduce.
- the body's natural immune system is designed to combat most infections. Some infections may become chronic, particularly if the host has a compromised immune system. Uncontrolled infections may cause serious health problems including death.
- Infections are frequently associated with wounds and may also occur in the locale of implanted devices such as ports, catheters, stents, artificial cartilaginous implants, orthopedic prosthetics, pacemakers, PICCs, prosthetic knee or hip implants, tooth implants, heart valves, spinal implants, and other types of plastic and/or metallic devices, to name a few. These medical devices can become infected after implanted into a patient. Long-term implants can be particularly susceptible to infection.
- Infection of implanted medical devices can constitute one of the most serious complications after surgery. Removing these infected medical devices can require lengthy procedures to remove and replace the old infected devices with a new device. Such procedures can involve steps such as removing the infected implant through surgical procedure, and/or administering antibiotics, waiting for any infection to heal, and then performing another surgical procedure to re-insert a new medical implant into the patient. In the case of cartilaginous implants, this may have to be repeated several times and may require administering not only a new cartilage implant but also numerous doses of antibiotics in order to enable the infection and the patient's skin to heal and then to reinsert a new artificial cartilage implant. Thus, multiple surgeries can be required.
- IRE irreversible electroporation
- This method avoids surgical methods that require removal surgery, a waiting period, then replacement of an infected medical device.
- This method can greatly improve outcomes, particularly for devices where infection may be catastrophic, i.e., a prosthetic knee or hip implant. It can also greatly improve costs and improve the longevity of implanted medical devices which are susceptible to infection, such as, for example, implantable ports.
- Such infection can be on or within a medical device that is implanted within a patient, as described above.
- a patient's tissue can be infected due to some other type of infection, for example, gangrene.
- IRE can be used to treat such infections and/or simultaneously sterilize an implanted medical device, as described herein to solve the above-mentioned problems.
- Electroporation is defined as a phenomenon that makes cell membranes permeable by exposing them to certain electric pulses. As a function of the electrical parameters, electroporation pulses can have two different effects on the permeability of the cell membrane.
- the permeabilization of the cell membrane can be reversible or irreversible as a function of the electrical parameters used.
- Reversible electroporation is the process by which the cellular membranes are made temporarily permeable. The cell membrane will reseal a certain time after the pulses cease, and the cell will survive.
- Reversible electroporation is most commonly used for the introduction of therapeutic or genetic material into the cell. Irreversible electroporation also creates pores in the cell membrane but these pores do not reseal, resulting in cell death.
- Irreversible electroporation has recently been discovered as a viable alternative for the ablation of undesired tissue. See, in particular, PCT Application No. PCT/US04/43477, filed Dec. 21, 2004.
- An important advantage of irreversible electroporation, as described in the above reference application, is that the undesired tissue is destroyed without creating a thermal effect.
- tissue is ablated with thermal effects, not only are the cells destroyed, but the connective structure (tissue scaffold) and the structure of blood vessels are also destroyed, and the proteins are denatured. This thermal mode of damage detrimentally affects the tissue, that is, it destroys the vasculature structure and bile ducts, and produces collateral damage.
- Irreversible and reversible electroporation without thermal effect to ablate tissue offers many advantages.
- One advantage is that it does not result in thermal damage to target tissue or other tissue surrounding the target tissue.
- Another advantage is that it only ablates cells and does not damage blood vessels or other non-cellular or non-living materials such as implanted medical devices.
- a method of treating an infection in patient that involves providing an ablation device, wherein the device comprises at least one electrode inserting the ablation device into a target tissue of the patient.
- the tissue at least partially surrounds an implanted medical device, and the outer surface of the medical device is at least partially covered by infectious cells.
- the method also involves positioning the at least one electrode in or near the implanted medical device and delivering electrical pulses to or near the implanted medical device sufficient to irreversibly electroporate the infectious cells.
- FIG. 1 illustrates several components that can be used with the present invention to treat a patient using IRE or to sterilize an implanted medical device.
- FIG. 2 is a schematic diagram of a treatment control computer of the present invention.
- FIG. 3 is a screen shot of an “Information” screen of a treatment control module showing various input boxes.
- FIG. 4 is a screen shot of a “Probe Selection” screen of the treatment control module showing a side view and top view of the bipolar probe and an example of the general shape of the treatment zone that can be generated by such a probe type.
- the “treatment zone”, as defined herein, can comprise infected tissue cells.
- FIG. 5 is a screen shot of a “Probe Selection” screen of the treatment control module showing a side view and top view of the two probe array and an example of the general shape of the treatment zone that can be generated by a two probe array.
- FIG. 6 is a screen shot of a “Probe Selection” screen of the treatment control module showing a side view and top view of the three probe array and an example of the general shape of the treatment zone that can be generated by a three probe array.
- FIG. 7 is a screen shot of a “Probe Selection” screen of the treatment control module showing a side view and top view of the four probe array and an example of the general shape of the treatment zone that can be generated by a four probe array.
- FIG. 8 is a screen shot of a “Probe Selection” screen of the treatment control module showing a side view and top view of the five probe array and an example of the general shape of the treatment zone that can generated by a five probe array.
- FIG. 9 is a screen shot of a “Probe Selection” screen of the treatment control module showing a side view and top view of the six probe array and an example of the general shape of the treatment zone that can be generated by a six probe array.
- FIG. 10 is a screen shot of a “Probe Placement Process” screen of the treatment control module.
- FIG. 11 is a screen shot of a “Probe Placement Process” screen of the treatment control module showing a rotation feature of the treatment control module.
- FIG. 12 is a screen shot of a “Probe Placement Process” screen of the treatment control module showing an automatic measurement feature of the treatment control module.
- FIG. 13 is a screen shot of a “Probe Placement Process” screen of the treatment control module showing examples of treatment zones that can be created between the electrodes.
- FIG. 14 is a screen shot of a “Probe Placement Process” screen of the treatment control module showing an example of a combined treatment zone generated by a four probe array.
- FIG. 15 illustrates an example of a three probe array defining three individual treatment zones, which combine to form a combined treatment region.
- FIG. 16 is an example of a spreadsheet of the E-field values that are determined for x, y coordinates on the grid, as will be further described below in reference to Example 2.
- FIG. 17 illustrates an example of a multi-dimensional lookup table and a method of interpolating treatment zones.
- FIG. 18 is a screen shot of a “Probe Placement Process” screen of the treatment control module showing an automatic probe placement feature of the treatment control module.
- FIGS. 19-22 are screen shots of the treatment control module illustrating an alternative embodiment of an automatic probe placement feature of the treatment control module.
- FIGS. 23-25 are screen shots of a “Probe Placement Process” screen of the treatment control module showing several examples of how a user can edit and modify the treatment parameters.
- FIG. 26 is a screen shot of a “Probe Placement Process” screen of the treatment control module showing an example of a treatment zone that is created by a six probe array after the “Autoset Probes” button has been depressed by a user.
- FIG. 27 is a screen shot of a “Pulse Generation” screen of the treatment control module showing the status of the treatment parameters before the treatment procedure has been initiated by a user.
- FIG. 28 is a screen shot of a “Pulse Generation” screen of the treatment control module showing the status of the treatment parameters during the treatment procedure.
- FIG. 29 illustrates details of the generator shown in FIG. 1 , including elements for detecting an over-current condition.
- FIG. 30 is a screen shot of a “Pulse Generation” screen of the treatment control module showing the status of the treatment parameters after the treatment procedure.
- FIG. 31 is a screen shot of a “Pulse Generation” screen of the treatment control module showing a dialogue box that pops up if the “continue procedure” button is pressed in the example.
- FIG. 32 is a screen shot of a “Pulse Generation” screen of the treatment control module showing the status of the treatment parameters during the re-treatment procedure.
- FIGS. 33-34 are screen shots of a “Pulse Generation” screen of the treatment control module showing examples of result graphs.
- FIG. 35 is a screen shot of a “Probe Placement Process” screen of the treatment control module showing the probe placement grid after treatment has been delivered by the probes.
- FIGS. 36A and 36B illustrate a method of treating infected tissue and/or sterilizing an implanted medical device, such, as for, example, a cartilaginous implant.
- FIG. 37 is a flowchart depicting the method steps for infectious cell ablation using irreversible electroporation methods described herein.
- FIG. 38 illustrates a treatment setup for a patient for synchronization of the delivery of electroporation pulses with a specific portion of the cardiac rhythm.
- any and all of the one, two, or more features and/or components disclosed or suggested herein, explicitly or implicitly, may be practiced and/or implemented in any combinations of two, three, or more thereof, whenever and wherever appropriate as understood by one of ordinary skill in the art.
- the various features and/or components disclosed herein are all illustrative for the underlying concepts, and thus are non-limiting to their actual descriptions. Any means for achieving substantially the same functions are considered as foreseeable alternatives and equivalents, and are thus fully described in writing and fully enabled.
- the various examples, illustrations, and embodiments described herein are by no means, in any degree or extent, limiting the broadest scopes of the claimed inventions presented herein or in any future applications claiming priority to the instant application.
- the methods involve using a medical device to deliver electrical pulses to the treatment zone that comprises an implanted medical device and potentially infectious cells within a non-thermal irreversible electroporation range.
- a probe comprising at least one electrode is adapted to receive from a voltage generator a plurality of electrical pulses in an amount sufficient to cause destruction of cells comprising the infection.
- the number of pulses, pulse length, pulse amplitude can be used to irreversibly electroporate a target tissue.
- Also presented herein is a method for sterilizing an implanted medical device using irreversible electroporation.
- FIGS. 1 through 35 The components that can be used with the present invention are illustrated in FIG. 1 .
- One or more probes 22 can deliver therapeutic energy and are powered by a voltage pulse generator 10 that generates high voltage pulses as therapeutic energy such as pulses capable of irreversibly electroporating the tissue cells.
- the voltage pulse generator 10 can include six separate receptacles for receiving up to six individual probes 22 which are adapted to be plugged into the respective receptacle.
- the receptacles are each labeled with a number in consecutive order.
- the voltage pulse generator 10 can have any number of receptacles for receiving more or less than six probes.
- each probe 22 includes either a monopolar electrode or bipolar electrodes having two electrodes separated by an insulating sleeve.
- the amount of exposure of the active portion of the electrode can be adjusted by retracting or advancing an insulating sleeve relative to the electrode. See, for example, U.S. Pat. No. 7,344,533, which is incorporated by reference herein.
- the generator 10 is connected to a treatment control computer 40 having input devices such as keyboard 12 and a pointing device 14 , and an output device such as a display device 11 for viewing an image of a target treatment area such as a target tissue 300 surrounded by a safety margin 301 .
- the therapeutic energy delivery device 20 is used to treat a target tissue 300 inside a patient 15 .
- the target tissue can comprise infectious cells and/or an implanted medical device comprising infectious cells.
- An imaging device 30 includes a monitor 31 for viewing the target tissue 300 inside the patient 15 in real time. Examples of imaging devices 30 include ultrasonic, CT, MRI and fluoroscopic devices as are known in the art.
- the present invention includes computer software (treatment control module 54 ) which assists a user to plan for, execute, and review the results of a medical treatment procedure, as will be discussed in more detail below.
- the treatment control module 54 assists a user to plan for a medical treatment procedure by enabling a user to more accurately position each of the probes 22 of the therapeutic energy delivery device 20 in relation to the target tissue 300 in a way that will generate the most effective treatment zone.
- the treatment control module 54 can display the anticipated treatment zone based on the position of the probes and the treatment parameters.
- the treatment control module 54 can display the progress of the treatment in real time and can display the results of the treatment procedure after it is completed. This information can be used to determine whether the treatment was successful and whether it is necessary to re-treat the patient.
- code For purposes of this application, the terms “code”, “software”, “program”, “application”, “software code”, “software module”, “module” and “software program” are used interchangeably to mean software instructions that are executable by a processor.
- the “user” can be a physician or other medical professional.
- the treatment control module 54 executed by a processor outputs various data including text and graphical data to the monitor 11 associated with the generator 10 .
- the treatment control computer 40 of the present invention manages planning of treatment for a patient.
- the computer 40 is connected to the communication link 52 through an I/O interface 42 such as a USB (universal serial bus) interface, which receives information from and sends information over the communication link 52 to the voltage generator 10 .
- the computer 40 includes memory storage 44 such as RAM, processor (CPU) 46 , program storage 48 such as ROM or EEPROM, and data storage 50 such as a hard disk, all commonly connected to each other through a bus 53 .
- the program storage 48 stores, among others, a treatment control module 54 which includes a user interface module that interacts with the user in planning for, executing and reviewing the result of a treatment. Any of the software program modules in the program storage 48 and data from the data storage 50 can be transferred to the memory 44 as needed and is executed by the CPU 46 .
- the computer 40 is built into the voltage generator 10 . In another embodiment, the computer 40 is a separate unit which is connected to the voltage generator through the communications link 52 . In a preferred embodiment, the communication link 52 is a USB link.
- the imaging device 30 is a stand alone device which is not connected to the computer 40 .
- the computer 40 is connected to the imaging device 30 through a communications link 53 .
- the communication link 53 is a USB link.
- the computer can determine the size and orientation of the target tissue 300 by analyzing the data such as the image data received from the imaging device 30 , and the computer 40 can display this information on the monitor 11 .
- the target tissue generated by the imaging device 30 can be directly displayed on the grid 200 of the monitor 11 of the computer running the treatment control module 54 .
- This embodiment would provide an accurate representation of the target tissue on the grid 200 , and may eliminate the step of manually inputting the dimensions of the target tissue in order to create the target tissue on the grid 200 . This embodiment would also be useful to provide an accurate representation of the target tissue if the target tissue has an irregular shape.
- treatment control module 54 The basic functionality of the computer software (treatment control module 54 ) will now be discussed in relation to the following example. It should be noted that the software can be used independently of the generator 10 . For example, the user can plan the treatment in a different computer as will be explained below and then save the treatment parameters to an external memory device, such as a USB flash drive (not shown). The data from the memory device relating to the treatment parameters can then be downloaded into the computer 40 to be used with the generator 10 for treatment.
- an external memory device such as a USB flash drive (not shown).
- the data from the memory device relating to the treatment parameters can then be downloaded into the computer 40 to be used with the generator 10 for treatment.
- the treatment control module 54 After the treatment control module 54 is initialized, it displays an “Information” screen with various input boxes as shown in FIG. 3 .
- a keyboard or other input device 12 together with a mouse or other pointing device 14 (see FIG. 1 ) are used to input the data. Any data that is inputted into the input boxes can be saved into internal or external memory along with a record of the treatment as described below for future reference.
- the basic patient information can be inputted, such as a patient ID number in input box 100 , the name of the patient in input box 101 , and the age of the patient in input box 102 .
- the user can enter clinical data, such as the clinical indication of the treatment in input box 114 .
- the date of the procedure is automatically displayed at 111 or can be inputted by the user in another embodiment.
- the user can enter other case information such as the name of the physician in input box 112 and any specific case notes in input box 113 .
- the dimensions of the target tissue 300 are determined from viewing it on the monitor 31 of the imaging device 30 (see FIG. 1 ) such as an ultrasonic imaging device and using known methods to calculate the dimensions from the image generated from the imaging device 30 .
- the dimensions of the target tissue 300 (length at input box 103 , width at input box 104 , and depth at input box 105 ) are inputted into the program.
- a safety margin is selected at input box 106 which will surround the entire target tissue 300 in three dimensions. According to the size of the safety margin that is selected, a target treatment region is automatically calculated and is displayed in boxes 107 , 108 , and 109 as shown.
- the safety margin value may be set to zero. For example, when treating a benign tumor, a safety margin may not be necessary.
- the user has indicated that the target tissue that will be treated has a length of 2 cm, width of 1 cm and a depth of 1 cm.
- the target treatment region has a length of 4 cm, width of 3 cm and a depth of 3 cm.
- the user can select the “ECG synchronization” option by clicking the circle in the box 110 in order to synchronize the pulses with an electrocardiogram (ECG) device, if such a device is being used during the procedure ( FIG. 38 ).
- ECG electrocardiogram
- the other options available for treatment that are included in box 110 can include an option for “90 PPM” (pulses per minute) or “240 PPM”.
- the user should select at least one of the three options provided in box 110 . After all of the necessary data has been inputted, the user clicks on the “Next” button with a pointing device 14 to proceed to the next screen described below.
- the treatment control module 54 will test this functionality to verify that the system is working properly.
- the treatment control module 54 can automatically detect whether an error has occurred during the testing phase of the ECG feature.
- the detectable errors include, but are not limited to, “no signal” (such as no pulses for 3.5 seconds) and “noisy” (such as pulses occurring at a rate greater than 120 beats per minute for at least 3.5 seconds).
- the treatment control module 54 can synchronize energy release with cardiac rhythm by analyzing cardiac output such as electrocardiogram results (or other cardiac function output) and sending synchronization signals to a controller of the pulse generator 10 .
- the control module 54 is also capable of generating internal flags such as a synchronization problem flag and a synchronization condition flag to indicate to users on a graphic user interface a synchronization status, so that energy pulse delivery can be synchronized with the cardiac rhythm for each beat (in real-time) or aborted as necessary for patient safety and treatment efficiency.
- control module 54 synchronizes energy pulses such as IRE (irreversible electroporation) pulses with a specific portion of the cardiac rhythm.
- the module uses the R-wave of the heartbeat and generates a control signal to the pulse generator 10 indicating that this portion of the heartbeat is optimal for release of IRE pulses.
- the S wave would be an optimal time for delivery of an energy pulse, but due to the fact that the S wave ends nebulously in some cases, the R wave is used as an indicator to start timing of energy release.
- the synchronization feature of the control module 54 allows for monitoring of heart signals so as to ensure that changes, maladies, and other alterations associated with the heartbeat are coordinated such that pulses from the pulse generator 10 are released at the proper time, and that if the heartbeat is out of its normal rhythm, that the release of energy is either altered or aborted.
- the user can select the type of therapeutic energy delivery device according to the number of probes that the user believes will be necessary to produce a treatment zone which will adequately cover the target tissue 300 and any safety margin 301 .
- the selection is made by clicking the circle next to each type of device, as shown in the “Probe Selection” screen, illustrated in FIGS. 4-9 .
- a “Probes Selection Status” box 199 identifies which of the receptacles, if any, on the generator 10 have been connected to a probe by displaying the phrase “Connected” or the like next to the corresponding probe number.
- each receptacle includes an RFID device and a connector (not shown) for each probe which connects to the receptacle and includes a compatible RFID device, so that the treatment control module 54 can detect whether or not an authorized probe has been connected to the receptacle on the generator 10 by detecting a connection of the compatible RFID devices. If an authorized probe is not connected to a receptacle on the generator, the phrase “Not Connected” or the like will appear next to the probe number.
- each probe shown in the “Probes Selection Status” box 199 can be used to indicate whether or not each receptacle on the generator is connected to a compatible probe. This feature allows the user to verify that the requisite number of probes is properly connected to the generator 10 before selecting a probe type for the treatment procedure. For example, if the treatment control module 54 detects a problem with the probe connection status (e.g. selecting a three probe array when only two probes are connected to the generator), it can notify the user by displaying an error message.
- a problem with the probe connection status e.g. selecting a three probe array when only two probes are connected to the generator
- the user can select which of the connected probes will be used to perform the treatment procedure, by clicking on the box next to the selected probes in the “Probes Selection Status” box 199 .
- the treatment control module 54 will automatically select probes in ascending numerical order, as they are labeled.
- FIG. 4 illustrates a side view 121 and top view 122 of the bipolar probe and an example of the general shape of the treatment zone that can be generated by such a probe type.
- the side view 121 shows an example of the general shape of the treatment zone that can be generated by an arrangement of two electrodes 123 separated by an insulation sleeve.
- FIG. 5 illustrates a side view 131 and top view 132 of the two probe array and an example of the general shape of the treatment zone that can be generated by a two probe array.
- the exposed portion of each of the electrodes as shown is 20 mm in length and the two probes are spaced from each other by 15 mm.
- FIG. 6 illustrates a side view 141 and top view 142 of the three probe array and an example of the general shape of the treatment zone that can be generated by a three probe array.
- the exposed portion of each of the electrodes as shown is 20 mm in length and each pair of the three probes are equally spaced from each other by 15 mm, as measured at three places (PLCS), meaning that there are three pairs (pairs 1-2, 2-3 and 1-3) where the spacing is equal to 15 mm.
- PLCS three places
- circle 150 is used to select a four probe array.
- FIG. 7 illustrates a side view 151 and top view 152 of the four probe array and an example of the general shape of the treatment zone that can be generated by a four probe array.
- the exposed portion of each of the electrodes as shown is 20 mm in length and each pair of the four probes are equally spaced from each other by 15 mm, as measured at four places (PLCS) along the perimeter.
- circle 160 is used to select a five probe array.
- FIG. 8 illustrates a side view 161 and top view 162 of the five probe array and an example of the general shape of the treatment zone that can be generated by a five probe array.
- the exposed portion of each of the electrodes as shown is 20 mm in length and each pair of the five probes are equally spaced from each other by 15 mm, as measured at seven places (PLCS).
- FIG. 9 illustrates a side view 171 and top view 172 of the six probe array and an example of the general shape of the treatment zone that can be generated by a six probe array.
- the exposed portion of each of the electrodes as shown is 20 mm in length and each pair of the six probes are equally spaced from each other by 15 mm, as measured at five places (PLCS) from the center probe.
- Each pair of the six probes are equally spaced from each other by 17 mm, as measured at 5 places (PLCS) along the perimeter.
- Other probe type selection can include a “six probe array 10 mm” and “six probe array 15 mm”, which refers to probe types utilizing a template which can be used to align a group of six needles in a fixed predetermined arrangement for treatment, wherein each pair of probes are equally spaced by 10 mm and 15 mm, respectively.
- probe device types having seven or more probes can be used.
- the user can select a probe type having a number of probes 22 which will work most effectively to treat the specific size and shape of the target tissue 300 together with a safety margin 301 .
- FIG. 10 illustrates a “Probe Placement Process” screen of one aspect of the invention.
- the screen illustrated by FIG. 10 shows a target tissue 300 according to the dimensions which were inputted on the “Information” screen (see FIG. 3 ) along with a safety margin 301 , if any, that was previously inputted.
- the target tissue 300 has a length of 2.0 cm and a width of 1.0 cm
- the device selected on the “Probe Selection” screen is a four probe array.
- the target tissue 300 is displayed near the center of an x-y grid 200 with the distance between two adjacent grid lines representing 1 mm.
- Each of the four probes 201 , 202 , 203 , 204 is displayed in the grid 200 and each probe can be manually positioned within the grid by clicking and dragging the probe with the pointing device 14 .
- Two fiducials 208 , 209 labeled “A” and “B”, respectively, are also displayed on the grid 200 and are used as a point of reference or a measure as will be described below.
- the amount of longitudinal exposure of the active electrode portion for each probe that has already been manually adjusted by the user as explained above can be manually inputted in input box 210 , which can be selected by the user according to the depth (z) of the target tissue.
- the treatment control module 54 can generate an estimated treatment zone according to the treatment parameters, and locations and depths of the probes.
- a second x-z grid is displayed on the monitor 11 of the computer running the treatment control module 54 .
- the treatment control module 54 can automatically calculate preferred values for the amount of longitudinal exposure of the active electrode portions based on the size and shape of the target tissue.
- the depth (z) of the electric field image can be calculated analytically or with interpolation and displayed on the x-z grid.
- the distribution of the electric field (i.e., expected treatment region) between two monopolar electrodes may “dip in” along the boundary line (see, for example, the peanut shaped treatment region in FIG. 13 where the width of the region is smaller in the middle) depending on the electrode location and the applied voltage, it is beneficial to have an x-z grid included on the monitor. For example, if this “dip” of the boundary line travels into, rather than surround, the target tissue region, then the targeted region may not be fully treated. As a default to ensure treatment of the entire target tissue region, the probe depth placement and the exposure length may be set unnecessarily higher to ensure erring on the safe side.
- the probe dock status is indicated in box 210 , by indicating if the probes are “docked” or “undocked”.
- the “UnDock Probes” button allows the user to “unplug” the probes from the generator while the “Probe Placement Process” screen is displayed without causing error messages.
- the user plugs the probes into the generator on the “Probe Selection” screen, and then the probes are “authorized” as being compatible probes according to the RFID devices, as discussed above.
- the software requires that all the selected probes remain plugged into the generator, or else the software will display an error message (e.g. “Probe #2 unplugged”, etc.), and will also force the user back to the “Probe Selection” screen.
- the treatment control module 54 automatically adjusts the voltage (treatment energy level) applied between the electrodes, as shown in column 222 .
- Box 280 allows a user to select between two different Volts/cm types, namely “Linear” or “Non-Linear Lookup”.
- the default Volts/cm setting is “Linear”, in which case the Voltage that is applied between a given pair of electrodes, as shown in column 222 , is determined by the following formula:
- Non-Linear Lookup the Voltage that is applied between the given pair of electrodes will be similar to the Voltage values for a “Linear” selection when a pair of electrodes are closely spaced together (e.g. within about 1 cm). However, as a pair of given electrodes are spaced farther from one another, a “Non-Linear Lookup” will produce lower Voltages between the given pair of electrodes as compared to the Voltage values for a “Linear” selection at any given distance.
- the “Non-Linear Lookup” feature is particularly useful for reducing “popping” during treatment.
- “Popping” refers to an audible popping noise that sometimes occurs, which is believed to be caused by a plasma discharge from high voltage gradients at the tip of the electrodes.
- the “Non-Linear Lookup” feature can also minimize any swelling of the tissue that might occur as a result of a treatment.
- the Voltage values used for the “Non-Linear Lookup” selection can be pre-determined based on animal experiments and other research.
- different tissue types can each have their own “Non-Linear Lookup” table.
- the tissue being treated is prostate tissue.
- the details of the treatment parameters are displayed in window 270 .
- the firing (switching) sequence between probes is listed automatically in window 270 .
- the firing sequence involves six steps beginning with between probes 1 and 2 , then probes 1 and 3 , then probes 2 and 3 , then probes 2 and 4 , then probes 3 and 4 , and then probes 4 and 1 .
- the polarity of each of the probes may switch from negative to positive according to step of the firing sequence.
- Column 220 displays which probe is the positive probe (according to a number assigned to each probe) for each step.
- Column 221 displays which probe is the negative probe (according to a number assigned to each probe) for each step.
- Column 222 displays the actual voltage generated between each probe during each step of the firing sequence. In the example, the maximum voltage that can be generated between probes is limited by the capabilities of the generator 10 , which in the example is limited to a maximum of 3000 Volts.
- Column 223 displays the length of each pulse that is generated between probes during each respective step of the firing sequence. In the example, the pulse length is predetermined and is the same for each respective step, and is set at 100 microseconds.
- Column 224 displays the number of pulses that is generated during each respective step of the firing sequence. In the example, the number of pulses is predetermined and is the same for each respective step, and is set at 90 pulses which are applied in a set of 10 pulses at a time.
- Column 225 displays the setting for Volts/cm according to the value selected at input box 211 .
- Column 226 displays the actual distance between the electrodes (measured in cm), which is automatically calculated according to the placement of each probe in the grid 200 .
- FIG. 11 illustrates a rotation feature of the treatment control module 54 .
- the user can rotate the image of target tissue 300 on the grid 200 about its center in order to approximate the actual orientation of the target tissue 300 within the body of the patient 15 (see FIG. 1 ), as shown by the imaging device 30 .
- the user can view the actual orientation of the target tissue 300 within the body of the patient 15 by viewing the monitor 31 of the imaging device 30 shown in FIG. 1 .
- the user can rotate the target tissue 300 on the grid 200 in order to match the orientation of the target tissue 300 shown on the monitor 31 of the imaging device 30 .
- the user can click on a tab 250 (to select the tab) with a pointing device 14 and drag the tab 250 to a new location which will rotate the target tissue 300 .
- the user can alternatively click on any part of the safety margin 301 or the target tissue 300 and drag it to rotate the target tissue 300 .
- the user can manually input the treatment zone rotation angle in input box 251 , which represents the degree of rotation of the target tissue 300 measured from the horizontal “x” axis on the grid 200 .
- FIG. 12 illustrates an automatic measurement feature of the treatment control module 54 .
- the treatment control module 54 automatically and continuously displays the distance (cm) from that electrode 201 to each of the other electrodes 202 (distance displayed in box 230 ), 203 (distance displayed in box 232 ), 204 (distance displayed in box 233 ) as the probe is being dragged.
- the treatment control module 54 also displays the distance (cm) from that electrode 201 to the closest point on the outer surface of the target tissue 300 (distance displayed in box 234 ).
- the treatment control module 54 also displays the distance (cm) from that electrode 201 to fiducial “A” 208 (distance displayed in box 235 ), fiducial “B” 209 (distance displayed in box 236 ).
- the treatment control module 54 also displays the distance (cm) from fiducial “A” 208 to fiducial “B” 209 with the distance being displayed in box 237 . This feature assists the user in placing the electrodes in preferred locations. This feature is especially beneficial if the imaging device 30 (see FIG. 1 ) allows the calculation of measurements as is known in the art.
- FIG. 13 illustrates examples of the treatment zones that are automatically created between the electrodes by the treatment control module 54 .
- the treatment control module 54 automatically calculates the treatment zones which are created and displays the area of the treatment zone.
- the monitor 11 of the generator 10 is in color and the color of the treatment zones 306 , 307 , the target tissue 300 , and the safety margin 301 are all different to easily differentiate them from one another.
- the target tissue 300 is yellow and the safety margin 301 is blue.
- the treatment control module 54 can be programmed to adjust the color of the target tissue 300 and/or the boundary line of the target tissue 300 if the treatment zones 306 , 307 do not effectively cover the target tissue, which could otherwise result in a clinical failure.
- the treatment control module 54 can be programmed to display a boundary line 320 that surrounds the areas of the treatment zones 306 , 307 in a highlighted manner so that the outer boundaries of the treatment zones are readily identifiable.
- the boundary line is a black line having sufficient thickness to provide a sharp contrast against the displayed target tissue and the grid.
- FIG. 14 illustrates a combined treatment region that is created by a four probe array 201 , 202 , 203 , 204 .
- the control module 54 displays a boundary line 320 to identify the outer boundary of the combined treatment zone.
- the control module 54 also displays a boundary line 320 to identify one or more inner boundaries of the combined treatment zone, if applicable. This allows the user to easily identify the presence of any incomplete treatment coverage areas of the target tissue 300 .
- the inner boundary line 320 is especially useful to identify incomplete treatment areas that may have not otherwise been readily detectable on the computer screen. Since even a few surviving infectious cells can be detrimental in terms of recurrence of infection, this feature is especially important when treating an area with an implanted medical device having infectious cells.
- the treatment control module can be programmed to calculate and display the area of the combined treatment regions on the grid 200 by one of the following three methods, although other methods can be used.
- Each of the following methods determines a boundary line surrounding a treatment zone that is created between a pair of electrodes.
- a combined treatment region can be displayed on the x-y grid.
- FIG. 15 illustrates three electrodes 201 , 202 , 203 defining three individual treatment zones 311 , 312 , 313 , which combine to form a combined treatment region 315 which is shown with hatched lines.
- the monitor can further include an x-z grid to illustrate the depth of the target tissue and the shape of treatment region.
- the shape of the treatment zone in the x-z grid will vary according to the selected amounts of electrode exposure for each probe and can be determined by one or more methods.
- the treatment boundary line that is created between two points on the x-y grid can be rotated about an axis joining the two points in order to generate the treatment region boundary line on the x-z grid.
- several points may be selected along the exposed length of the active electrode portion for each probe at various depths (z).
- a three-dimensional combined treatment region can then be generated by determining the boundary line on the x-y grid between each individual pair of points and then rotating the boundary line along the axis joining each pair of points.
- the resulting boundary lines can be combined to create a three dimensional image that is displayed on the monitor.
- the following is an alternate method for determining a boundary line on the x-z grid, thereby determining a three dimensional treatment region.
- This example describes a two probe array with the probes being inserted in a parallel relationship and with the probes having the same amount of exposed portions of the electrode.
- the exposed portions of each probe start at the same “uppermost” depth (z) and end at the same “lowermost” depth (z).
- a treatment zone boundary line is created in the x-y plane at the uppermost depth (z).
- the treatment zone boundary line is repeatedly created stepwise for all subsequently lower depths (z), preferably evenly spaced, until the lowermost depth (z) is reached.
- the result is a 3-D volume (stacked set of treatment zone boundary lines) having a flat top surface and a flat bottom surface.
- two new focus points are selected, with the first focus point positioned midway between the probe positions in the x-y grid and near the uppermost depth (z) of the exposed electrode.
- the second focus point is also positioned midway between the probe positions in the x-y grid, but near the lowermost depth (z) of the exposed electrode.
- a treatment zone boundary line is created in the x-z grid using one of the methods described earlier. The actual placement of each focus point may be closer together, namely, not positioned in the uppermost and lowermost x-y planes defined by the exposed portions.
- each focus point should be selected so that the treatment zone boundary line that is created in the x-z grid closely matches the treatment zone boundary lines that were created in the uppermost and lowermost x-y grids.
- the treatment zone boundary line that was created in the x-z grid according to the two focus points is rotated about the axis joining the two focus points. This creates the shapes for the upper and lower 3-D volumes which are added to the flat top surface and the flat bottom surface described above.
- tissue properties are highly variable between tissue types, between individuals, and even within an individual. These changes may result from differences in body fat composition, hydration levels, and hormone cycles. Due to the large dependence of IRE (irreversible electroporation) treatments on tissue conductivity, it is imperative to have accurate values. Therefore, to obtain viable conductivity values prior to treatment, a low amplitude voltage pulse is used between the electrode conductors and the resultant impedance/conductance is measured as a way to determine pertinent tissue property data such as the predicted current. The value determined may then be implemented when assessing field strength and treatment protocol in real time. For example, the resulting impedance or predicted current can be used to set the default electric field density.
- IRE irreversible electroporation
- FEA finite element analysis
- FEA is used to relate each node to each of the other nodes by applying sets of partial differential equations.
- This type of a system can be coded by scratch, but most people use one of many commercial FEA programs that automatically define the mesh and create the equations given the model geometry and boundary conditions.
- Some FEA programs only work in one area of engineering, for example, heat transfer and others are known as mulitphysics. These systems can convert electricity to heat and can be used for studying the relationships between different types of energy.
- the FEA mesh is not homogeneous and areas of transition have increased mesh density.
- the time and resources (memory) required to solve the FEA problem are proportional to the number of nodes, so it is generally unwise to have a uniformly small mesh over the entire model.
- FEA users also try to limit the analysis to 2D problems and/or use planes of symmetry to limit the size of the model being considered because even a modest 2D model often requires 30 minutes to several hours to run.
- a 3D Model usually takes several hours to several days to run. A complicated model like a weather system or a crash simulation may take a super computer several days to complete.
- the purchase price of the FEA modeling software can cost several thousand dollars for a low end system to $30 k for a non-linear mulitphysics system.
- the systems that model the weather are custom made and cost tens of millions of dollars.
- the steps which are required for generating a treatment zone between a pair of treatment probes using finite element analysis include: (1) creating the geometry of interest (e.g., a plane of tissue with two circular electrodes); (2) defining the materials involved (e.g., tissue, metal); (3) defining the boundary conditions (e.g., Initial voltage, Initial temperature); (4) defining the system load (e.g., change the voltage of the electrodes to 3,000V); (5) determining the type of solver that will be used; (6) determining whether to use a time response or steady state solution; (7) running the model and wait for the analysis to finish; and (8) graphing the results.
- the geometry of interest e.g., a plane of tissue with two circular electrodes
- the materials involved e.g., tissue, metal
- boundary conditions e.g., Initial voltage, Initial temperature
- the system load e.g., change the voltage of the electrodes to 3,000V
- FEA FEA
- the system should allow a user to experiment with probe placement and should calculate a new treatment zone in less than a few seconds. Accordingly, the FEA model is not appropriate for such use and it would be desirable to find an analytic solution (closed form solution), which can calculate the treatment zones with only simple equations, but which closely approximate the solutions from a numerical model analysis such as the finite element analysis.
- the closed loop solutions should preferably generate the treatment zone calculation in a fraction of a second so as to allows a physician/user to experiment with probe placement in real time.
- closed loop analytical model analysis
- FEA numerical model analysis
- Analytical models are mathematical models that have a closed form solution, i.e., the solution to the equations used to describe changes in a system can be expressed as a mathematical analytic function.
- the following three methods represent non-limiting examples of such alternative closed loop solutions.
- a Cassini oval is a set (or locus) of points in the plane such that each point p on the oval bears a special relation to two other, fixed points q 1 and q 2 : the product of the distance from p to q 1 and the distance from p to q 2 is constant. That is, if the function dist(x,y) is defined to be the distance from a point x to a point y, then all points p on a Cassini oval satisfy the equation:
- the points q 1 and q 2 are called the foci of the oval.
- the shape of the oval depends on the ratio b/a. When b/a is greater than 1, the locus is a single, connected loop. When b/a is less than 1, the locus comprises two disconnected loops. When b/a is equal to 1, the locus is a lemniscate of Bernoulli.
- the Cassini equation provides a very efficient algorithm for plotting the boundary line of the treatment zone that was created between two probes on the grid 200 .
- the first probe is set as q 1 being the point (a,0) and the second probe is set as q 2 being the point ( ⁇ a,0).
- r 2 a 2 cos(2*theta)+/ ⁇ sqrt( b 4 ⁇ a 4 sin 2 (2*theta)) (5)
- V the Voltage (V) applied between the probes
- A the electric field density (V/cm) that is required to ablate the desired type of tissue according to known scientific values.
- r can be up to four separate values for each given value for theta.
- a cassini curve can be plotted by using eq. (5) above by solving for r, for each degree of theta from 0 degrees to 360 degrees.
- the curve from the cassini oval equation was calibrated as best as possible to the 650 V/cm contour line using two 1-mm diameter electrodes with an electrode spacing between 0.5-5 cm and an arbitrary applied voltage.
- q 1 and q 2 reference points could be moved to locations along the x-axis to points of ( ⁇ a,0).
- a voltage could then be selected, and an arbitrary scaling factor (“gain denominator”) would convert this voltage to the corresponding “b” used in eq. (4).
- the worksheet would then plot the resulting Cassini oval, which has a shape progression with applied voltage beginning as two circles around the electrodes that grow into irregular ellipses before converging into a single “peanut” shape that ultimately becomes an ellipse expanding from the original electrode locations.
- the Cassini oval creates a reasonable visualization that mimics the shape of numerical results for the field distribution.
- a calibration involving the b 4 term was necessary to develop the relationship between the analytical Cassini oval and the numerical results. This was done through a backwards calibration process defined as follows:
- a reference electric field density value was selected to be 650 V/cm
- the determined voltage was placed into the Cassini oval electronic worksheet for the same electrode geometry and the “gain denominator” was adjusted until the shape from the cassini oval matched that from the numerical solution.
- Table 1 incorporates all the steps above to yield a single, calibrated Cassini Oval output that analytically predicts the electric field distribution; providing a quick and simple solution for the prediction of IRE (irreversible electroporation) treatment regions that may be adjusted in real-time.
- the inputs are the electrode location (as a given “ ⁇ a” distance from the origin along the x-axis), the applied voltage to the energized electrode, and the desired electric field to visualize.
- the resulting output is a contour representing a threshold where the entire area within it has been subjected to an electric field ⁇ the one selected; and thus treated by IRE. It is important to remember that the analytical solution was calibrated for an electric field contour of 650 V/cm, and thus yields an accurate approximation for this value. Other field strength contours of interest still yield reasonable results that mimic the overall shape of the electric field. Overall, the analytical solution provided yields consistently good predictions for electric field strengths, and thus, treatment regions of IRE that may be used during treatment planning or analysis.
- FIG. 4 illustrates an exemplary bipolar electrode.
- the diameter of the probe is 0.065 cm
- the lengths of the two electrodes are respectively 0.295 cm and 0.276 cm, separated by an insulation sleeve of 0.315 cm in length.
- Adapting this scenario to the cassini oval presents some challenges because the distribution is now resulting from the two exposed cylinder lengths, rather than two distinct loci of points. This was solved by calibrating individual electric field contours for the same applied voltage and developing two equations that adjust the separation distance ( ⁇ a) and gain denominator (GD) according to the equations:
- E the electric field magnitude contour desired.
- Another closed loop method determines the E-field values (electric field density) for any x and y position on the grid based on the position of the probes, the diameter of the probes, and the voltage applied between the probes. To obtain the potential, temperature or field distribution, one can determine the analytical solution for a configuration.
- the solution to the Laplace Equation is linear
- analytical solutions can be scaled and super-imposed to determine the entire distribution. For example, if two electrodes are energized and two electrodes are set to ground, the solution can be determined by adding the solutions for the two-needle electrode configuration together.
- V o the applied Voltage (V) between the probes
- V/cm i.e. 650 V/cm
- This contour line can be used to therefore plot a boundary line of the treatment zone between two probes.
- the E-field values are determined for x, y coordinates on the grid, as shown in the spreadsheet at FIG. 16 .
- This method can also be used to determine the E-field values for devices having two plate electrodes or two concentric cylinders.
- a predetermined set of values that define the outer boundary of a plurality of predetermined treatment zones can be stored in memory as a data table and interpolation can be used to generate an actual treatment zone for a particular treatment area (e.g., tumor area).
- Interpolation is commonly used to determine values that are between values in a look up table. For example if a value half way between 5 and 10 in the first row of the lookup table (see Table 3 below) needs to be determined, a single interpolation (average of 5 and 10) is done to obtain 7.5. If a value between 15, 20, 25, and 30 needs to be determined, a double interpolation is done. A first interpolation is done between 15 and 20 to obtain 17.5 and between 25 and 30 to obtain 27.5. Then, a second interpolation is done between 17.5 and 27.5 to obtain 22.5.
- interpolation is not limited to finding the mid point between two points. Interpolation can be done on any point between two points. For example, interpolation can be done at 15% (i.e., 15% away from one point and 85% away from the other point) and 75% (i.e., 75% away from one point and 25% away from the other point).
- Numerical techniques such as Finite Element Analysis (FEA) which was described above, Finite Difference Methods, or Boundary Element Methods can be used to generate shapes that take into account multiple variables (applied voltage, electrode separation, desired field boundary, tissue specific constants, and the like). These shapes can be stored in a multidimensional array (i.e., a multi-dimensional lookup table) in either polar or Cartesian coordinates. When a specific treatment situation occurs, an interpolation between the known shapes as represented by the lookup table can be used to generate an estimate of an estimated treatment zone.
- FEA Finite Element Analysis
- FIG. 17 illustrates a multi-dimensional lookup table and a method of interpolating treatment zones.
- the multi-dimensional lookup table includes for each predetermined treatment zone a table or array of points that represent a particular treatment zone.
- the top left corner of FIG. 17 illustrates a lookup table for a predetermined treatment zone for 1 cm radius tumor area at 1700 Volts/cm electric field density for a pair of electrodes.
- the contour of the treatment zone is estimated by interpolating between two nearby zones (i.e., one for 1.5 cm radius tumor area at 1700 Volts and one for 2.0 cm radius tumor area at 1700 Volts).
- the contour of the treatment zone is estimated by double interpolation. First, the treatment zones for 1.75 cm, 2000 Volts and 0.175 cm at 2300 Volts are determined. Then, the treatment zone for 1.75 cm at 2150 Volts is determined based on the interpolation results (i.e., estimated zone for 1.75 cm at 2000 Volts and estimated zone for 1.75 cm at 2300 Volts).
- FIG. 18 illustrates an automatic probe placement feature of the treatment control module 54 . If the user clicks on the “Autoset Probes” button 240 with the pointing device 14 , the treatment control module 54 will automatically position the probes 201 , 202 , 203 , 204 in the most efficient way in order to treat the target tissue 300 .
- FIG. 18 illustrates the position of the probes 201 , 202 , 203 , 204 after the “Autoset Probes” button 240 has been depressed with the pointing device 14 .
- the automatic placement feature of the treatment control module 54 is further discussed below. This feature is carried out by the following algorithm.
- the algorithm functions to most efficiently place a given number of probes, which is based on the type of device which is selected in FIGS. 4-9 as discussed above (ranging from 2 to 6 probes,) in an optimal pattern to cover the defined treatment area (i.e., the combined target tissue 300 and the safety margin 301 ).
- the algorithm assumes that the combined target tissue 300 and safety margin 301 form a generally elliptical shape. This elliptical shape is determined from the dimensions of the target tissue zone (length and width), together with the desired safety margin which were inputted by the user (see FIG. 3 ).
- the algorithm uses the following formulas to calculate the most efficient placement of each of the probes on the grid 200 .
- the algorithm calculates the (x i ,y i ) location of each probe i on the grid 200 , relative to (0,0) origin, using the following two formulas:
- a the major axis of the elliptical shape (cm) that is selected at FIG. 3 ;
- b the minor axis of the elliptical shape (cm) that is selected at FIG. 3 ;
- ⁇ the rotational angle (degrees) of the ellipse as shown on treatment screen (see input box 251 at FIG. 11 )
- ⁇ i the angular offset (degrees) for each probe according to Table 2.1 below:
- ⁇ j the ratio of (the probe placement radius) to (the total radius to the edges of the target tissue), according Table 2.2 below:
- a device having 3 probes is used to treat a target tissue where:
- the automatic probe placement feature can be executed by the treatment control module 54 to reposition the probes on the grid 200 according to distance measurements which are taken from the actual position of the probes after they have been inserted into the patient.
- the user is allowed to enter any or all specific distance measurements taken between any pairs of treatment probes, and may also specify which probes may be repositioned on the grid 200 by the treatment control module 54 and which may not.
- the treatment control module 54 finds the minimal error in the positions of the probes that best match the positions seen on the imaging software by the user.
- probes It is very difficult with several probes to place them exactly on the treatment grid 200 at the proper distances that are measured on a CT or similar scan. Often times, two, three, or four probes should be moved or rotated as a group to maintain proper distances between the other probes on the treatment grid 200 . This can be a frustrating, time-consuming, and error-prone method of ensuring that the probe locations on the treatment grid 200 mirror the actual probe locations in the patient's body.
- the positions and distances of the probes are critical in treatment planning and delivery.
- the probes may only be placed at exact 1 mm locations on the treatment grid 200 so that they can easily be moved to “snap” to the grid 200 , which makes the optimal placements of the individual probes even more difficult.
- the main code of the software for this feature involves a “solver” algorithm which performs an iterative search based on the starting positions of the probes and the distances desired as input by the user.
- Some probes may be specified as “Locked” meaning that their positions are fixed relative to the grid 200 .
- the solver moves all probes in a 1 mm ⁇ 1 mm array in all possible positions and calculates the root mean square (RMS) error of the distances between the new probe locations and the desired probe locations on the grid 200 .
- the probe positions within each probes' bounding 1 mm box that offer the minimum RMS error to the total solution are taken as the “next” iteration of the algorithm.
- the solver then takes this new location and re-iterates to find a new, better set of positions on the grid 200 . The iterations continue until no improvement in the RMS error of the solution is found, at which point the solver quits and returns the optimal new positions that were found.
- This distance placement feature will be used by the user to directly input the probe distances and cause the optimal positions of the probes based on these distances to be displayed on the treatment grid 200 with a minimum of effort and error. This will allow better treatment planning and better treatments.
- the distance placement feature works best when the user places the probes in “approximately” the correct starting positions on the grid 200 before running the solver algorithm.
- FIG. 19 illustrates five probes 201 , 202 , 203 , 204 , 205 which form a five probe array to treat a target tissue.
- the five probes have been placed on the grid 200 by a user to plan the treatment of the target tissue on the “Probe Placement Process” screen.
- the user actually inserts the five probes into the patient according to the planned locations.
- certain anatomical structures of the patient may prevent the optimal placement of the probes, e.g., the location of the target tissue with respect to the location of the patient's ribs, etc.
- distance measurements are taken as shown in FIG. 20 . These measurements represent the actual position of the five probes in the patient.
- One way to measure the distances between probes is to use the imaging device 30 such as a ultrasonic imaging device which allows the user to select any two point on the display device 31 to automatically measure the distance as is well-known in the art.
- FIG. 21 illustrates an example of a pop-up window 333 that appears which includes input boxes for entering the measurement distances taken by the user.
- the user can select which probes to “lock” on the grid 200 , which will fix the location of those probes relative to the grid 200 .
- the user has “Locked” the position of the second probe (labelled #2) 202 .
- the treatment control module 54 then automatically adjusts the placement of the probes on the grid 200 which have not been “Locked” to best match the distance measurements taken.
- FIG. 22 shows the placement of the five probes 201 , 202 , 203 , 204 , 205 on the grid 200 after the program has been executed.
- FIG. 18 illustrates the four probe device after the “Autoset Probes” button has been depressed.
- the user may move any of the probes in the grid 200 .
- the treatment control module 54 automatically updates the voltage (treatment energy level) calculation in column 222 based on the distance between the probes and continuously displays the distance between the probe being moved and the other probes (see FIG. 12 ).
- the treatment control module 54 also automatically recalculates the size and boundary line 320 of the treatment zones in real time when a probe is moved on the grid 200 . Also, when the maximum voltage is achieved (e.g. 3000 Volts), that number as well as its corresponding distance value are highlighted (in different color, for example, relative to the other voltage values and distance values) in column 222 to alert the user.
- the maximum voltage e.g. 3000 Volts
- FIG. 26 illustrates the same target tissue 300 being treated by a six probe device after the “Autoset Probes” button has been depressed.
- the six probe device does a better job at covering the entire safety margin 305 surrounding the target tissue 300 .
- more rows of data appear in window 270 than compared with the four probe device discussed above because additional treatment pairs are executed. Because of the additional probes, the distance is smaller between respective probes to cover a similar ablation area. This is reflected in column 226 of window 270 .
- column 222 of window 270 which displays the voltage generated during each step of treatment.
- the maximum capability of the generator 10 is 3000 Volts. It is preferred to stay below the maximum capability of the generator if possible.
- Column 222 shows that with the six probe device the power delivered during each step is below 3000 Volts.
- the treatment control module 54 allows a user to manually edit some of the numbers in window 270 in order to tailor the treatment.
- the user first clicks on the “Edit” icon 281 with the pointing device 14 , as shown in FIG. 18 .
- the treatment control module 54 can change the colors of the particular boxes in window 270 which are able to be edited. For example, as shown in FIG. 23 , the treatment control module 54 can display the boxes which are able to be edited (columns 220 , 221 , 223 , 224 , 225 ) in a white color and can display the boxes which cannot be edited (columns 222 , 226 ) in a grey color.
- the data in an individual box can be edited by clicking on that particular box with the pointing device 14 .
- the value can be edited by either manually deleting and typing in new data with the keyboard 12 , or by adjusting the number up or down by clicking on the up arrow or down arrow that appears in the box with the pointing device 14 .
- the Volts/cm between probes “1” and “2” has been adjusted down from 1500 Volts/cm to 1000 Volts/cm. If a change is made to the data in window 270 which would affect the shape of the combined treatment zones 305 , then the treatment control module 54 automatically adjusts the depiction of the treatment zones 305 shown in grid 200 to reflect this. In the example shown in FIG. 23 , the area of the projected combined treatment region 305 has been diminished between probes “1” and “2” as shown. The ability to edit the treatment parameters as described can be particularly useful to a user in certain situations.
- a user can edit the treatment parameters in order to avoid areas that should be preserved, such as a location of a nerve or the like.
- the edits are saved to the treatment control module 54 by clicking on the “Apply” icon 282 with the pointing device 14 .
- the treatment control module 54 allows a user to manually add additional rows or delete rows from the window 270 in order to tailor the treatment.
- the user first clicks on the “+” icon 283 with the pointing device 14 , as shown in FIG. 24 .
- an additional row will appear at the bottom of the list in window 270 , which will indicate an additional pair of probes in which treatment will occur.
- an additional row has been added which indicates that treatment will occur between probe “1” and probe “3”. Referring to the grid 200 , this additional treatment pair indicates the diagonal treatment across the target tissue.
- a diagonal treatment was already present between probe “2” and probe “4” as indicated in window 270 .
- the treatment control module 54 automatically updates the anticipated combined treatment zone displayed in grid 200 . By comparing the grid 200 in FIG. 23 to the grid 200 in FIG. 24 , the effect of adding the additional treatment row between probe “1” and probe “4” can be visually understood and appreciated.
- To delete rows in window 270 the user first selects which row is to be deleted by clicking to the left of the selected row with the pointing device 14 . Next, the user clicks on the “-” icon 284 with the pointing device 14 , as shown in FIG. 24 , thereby deleting the selected row from window 270 .
- FIG. 25 illustrates the result when the “Non-linear Lookup” circle is selected in box 280 , when compared to FIG. 18 which illustrates the same number of probes, the same probe placement, and the same Default Setting (1500 V/cm), but instead when the “Linear” circle is selected in box 280 .
- FIG. 27 illustrates the status of the treatment before the treatment has been initiated. The following steps describe how the treatment is administered once the user has reached the “Pulse Generation” screen illustrated by FIG. 27 .
- the treatment control module 54 asks the user to “Click ‘Deliver test pulse’ to start” in window 420 in order to start the test signal (pulse) sequence.
- the control module 54 charges the pulse generator 10 to the test pulse voltage.
- the control module 54 applies a test pulse for each probe pair through the generator 10 .
- a test pulse is applied through pairs 1-2, 1-3, 2-3, 2-4, 3-4 and 4-1 as shown in FIG. 11 .
- this test pulse voltage is approximately 1/10 to 1 ⁇ 5 the maximum treatment voltage but no lower than 200 volts and no higher than 500 volts. (It should be noted that in a preferred embodiment, valid treatment voltages are between 500 to 3000 volts.)
- a test pulse of 400 volts is used for each pair of electrodes.
- the treatment control module 54 checks the current through a sensor 73 (see FIG. 29 ) for each probe pair to determine whether a treatment current will be too low (e.g., below approximately 300 milliamps) or too high (e.g., approximately 45 amps or more). Based on the current, the resistance R or conductance (1/R) of the tissue is calculated by the module 54 . Then, the voltage to be used to actually treat the tissue (see column 222 in FIG. 23 , for example) is divided by the resistance to obtain the treatment current draw to be used in the treatment.
- the system will give the user the option to “Proceed to Treatment” for each pair that was too low in current. If the current is determined to be too high (e.g., 45 amps or more of threshold maximum current draw), the control module 54 will indicate an error in the display device 11 and the user should change the treatment voltage and/or re-position the mis-aligned probes to reduce the current.
- the treatment control module 54 generally applies one test pulse for every pair listed in the treatment spreadsheet although more than one pulse can be applied to each pair. For example, if the user sets up treatment between pairs (1 to 2), (1 to 3) and (2 to 3) there will be three test pulses, one for each pair. There is no therapeutic value in the test pulse. The test pulse only checks the setup before full therapeutic treatment is applied. Each test pulse is intended to ensure that two conditions are met with each test pulse: first, that there is a valid connection between the selected treatment pairs, and second, that the current will not exceed the maximum output capability of the generator 10 (see FIG. 1 ).
- test pulse Another reason for the administration of a “test pulse” is to ensure that the patient is properly anesthetized.
- the patient Prior to treatment, the patient is administered general anesthesia in combination with a paralytic agent. If the patient is not paralyzed with anesthesia, then a noticeable muscle contraction will occur during administration of the “test pulse”. Since the test pulse is at approximately 10% to 20% of the therapeutic level, any muscle contraction displayed by the patient is not as much as it would be if full energy was applied. The user should be trained to watch for muscle movement during the test pulse.
- the treatment control module 54 can display a window which asks the user to confirm that there is no muscle movement being displayed by the patient by selecting an answer with the pointing device 14 .
- the treatment control module 54 will not continue to the next step unless the user presses a button with the pointing device to indicate that the patient did not display any muscle contraction during the test pulse.
- Irreversible electroporation requires that a paralytic agent is given as well as the normal anesthesia. These agents tend to have a short half-life and it is easy for the patient to be under medicated at the time of treatment. If the patient is under-medicated, it is possible that the patient could be injured from the severe muscle contraction that would occur from a full power treatment without a muscle blockade.
- the energies delivered by IRE are similar to a defibrillation pulse and the muscle contraction would also be similar.
- the system charges to the full therapeutic treatment voltage (as shown in window 430 ) and waits for instructions from the user to begin treatment.
- a user is required to press both foot pedals of a double foot pedal device (not shown) in order to activate treatment (the first pedal is used to arm the generator 10 , the second pedal is used to fire or start the treatment).
- This provides a type of safety check and prevents accidental activation of the treatment.
- the screen shown in FIG. 27 uses two buttons 422 , 423 instead of a double foot pedal device. Accordingly, the user will click on the “Arm” button 422 with the pointing device 14 to arm the probes. Then, the user will click on the “Pulse” button 423 with the pointing device 14 to initiate the treatment.
- the treatment control module 54 controls the generator 10 and administers a series of pulses according to the predetermined instructions illustrated in columns 220 , 221 , 222 , 223 , 224 .
- column 401 illustrates the number of pulses that have been delivered in real time until the total number of predetermined pulses has been delivered.
- Column 402 displays the status percentage of the treatment for each pair of electrodes. The treatment process runs until each step of the probe firing sequence has been accomplished. Audible beeps are generated during the treatment to track the operation of the generator 10 .
- Window 430 displays the status of the charge of the generator 10 during operation.
- Window 286 displays the total “Pulse progress” of the treatment.
- Window 420 displays further details of the treatment progress.
- the treatment control module 54 can include a feature that prevents the generator from exceeding its maximum current limit by reading the current every ten pulses and reducing the voltage by a predetermined percentage (e.g., 5% or 10%) if it approaches the maximum limit of the generator.
- a predetermined percentage e.g., 5% or 10%
- FIG. 29 illustrates one embodiment of a circuitry to detect an abnormality in the applied pulses such as a high current, low current, high voltage or low voltage condition.
- This circuitry is located within the generator 10 (see FIG. 1 ).
- a USB connection 52 carries instructions from the user computer 40 to a controller 71 .
- the controller can be a computer similar to the computer 40 as shown in FIG. 2 .
- the controller 71 can include a processor, ASIC (application-specific integrated circuit), microcontroller or wired logic.
- the controller 71 then sends the instructions to a pulse generation circuit 72 .
- the pulse generation circuit 72 generates the pulses and sends electrical energy to the probes. For clarity, only one pair of probes/electrodes are shown.
- the generator 10 can accommodate any number of probes/electrodes (e.g., 6 probes as shown in FIG. 4 ).
- the pulses are applied one pair of electrodes at a time, and then switched to another pair.
- the pulse generation circuit 72 includes a switch, preferably an electronic switch, which switches the probe pairs based on the instructions received from the computer 40 .
- a sensor 73 such as a sensor can sense the current or voltage between each pair of the probes in real time and communicate such information to the controller 71 , which in turn, communicates the information to the computer 40 .
- the sensor 73 If the sensor 73 detects an abnormal condition during treatment such as a high current or low current condition, then it will communicate with the controller 71 and the computer 40 which may cause the controller to send a signal to the pulse generation circuit 72 to discontinue the pulses for that particular pair of probes.
- an abnormal condition during treatment such as a high current or low current condition
- the treatment control module 54 can further include a feature that tracks the treatment progress and provides the user with an option to automatically retreat for low or missing pulses, or over-current pulses (see discussion below). Also, if the generator stops prematurely for any reason, the treatment control module 54 can restart at the same point where it terminated, and administer the missing treatment pulses as part of the same treatment.
- the treatment control module 54 is able to detect certain errors during treatment, which include, but are not limited to, “charge failure”, “hardware failure”, “high current failure”, and “low current failure”.
- a “high current” failure occurred during treatment between probe “1” and probe “2”.
- the total number of pulses that were delivered between probe “1” and probe “2” was 20 instead of 90. This is because a “high current” condition occurred sometime after the 20th pulse was delivered.
- the treatment control module 54 was able to react to this error by discontinuing the remainder of the pulses between probe “1” and probe “2”.
- column 402 displays whether the treatment was successful for each step of the treatment process by indicating a checkmark, or other indicia, if the step was successful and a lightning bolt, or other indicia, if the step encountered an error.
- the treatment between probe “1” and probe “2” indicates a “High Current” error in column 402 as discussed above.
- the treatment control module 54 tracks which pairs of probes have failed and automatically asks the user whether to “Continue Procedure” (by pressing button 426 ) or “Stop Procedure” (by pressing button 427 ). In this example, then the user chooses one of the following three options. 1) Accept the treatment as is (by pressing button 427 ).
- a dialogue box 428 will automatically pop up, which asks the user whether to “Adjust voltages for high current segments?” The user answers by clicking “Yes”, “No”, or “Cancel”. If the user clicks on the “Yes” button, then the treatment control module 54 will automatically reduce the treatment voltage by a predetermined percentage (e.g. 5% which can be set or changed by the user). If the user clicks on the “No” button, then the treatment control module 54 will keep the treatment voltage the same. Next, the treatment control module 54 will go back to the arm ready state. The user can then activate the treatment to re-treat only the missing pulses.
- a predetermined percentage e.g. 5% which can be set or changed by the user.
- This high-current detection and reapplication feature is particularly advantageous because (1) the software remembers which pairs have failed so that the user does not have to remember and (2) the treatment control module 54 is able to accurately keep track of which pulses were unsuccessful so that only the missing pulses are re-administered.
- FIG. 32 illustrates the “Pulse Generation” screen during re-treatment for the example. Again the pulse progress bar 286 is displayed and the status column 402 is updated again in real time. After the re-treatment has completed, the user will verify that the status of each probe pair is complete by checking column 402 .
- FIG. 33 illustrates such result graphs according to the results of the treatment from the example.
- a plurality of sets of pulses are applied, and more specifically 9 sets of 10 pulses per set are applied with each pulse having a pulse duration of 100 microseconds.
- the inter pulse spacing is not to scale.
- the inter pulse spacing is calculated based on the pulses per minute (PPM) which was selected on the “Information” screen (see FIG. 3 ).
- PPM pulses per minute
- the time between sets of pulses is about 3.5 seconds and can be a function of how long the capacitors need to charge. In another embodiment, the time between sets of pulses is less than 3.5 seconds or is completely eliminated.
- FIG. 34 illustrates the graph results after the user has clicked the chart to zoom in on the results.
- the user can further zoom in by clicking the voltage or current chart to show 10 pulses for a treatment probe pair.
- the graph results shown in FIGS. 33-34 are the results of a demonstration mode of the treatment control module 54 . It should be understood that during a real world treatment, the graph results would be less uniform.
- the shape of the pulses can also be used as an indicator of the degree of poration of the cells.
- FIG. 35 is a screen shot of a “Probe Placement Process” screen of the treatment control module showing the probe placement grid 200 after treatment has been delivered by a four probe array.
- the treated area 339 is saved by the module 54 in the memory 44 and is shown in a highlighted contrasting manner to the displayed target region 301 and the treatment region 305 defined by the probes.
- the treated area 339 is filled in with cross-hatched lines that are marked in any other way for distinguishing this area on the grid 200 .
- the treated area 339 is displayed in a different color to more easily distinguish it. This feature allows a user to plan for additional treatment of the target tissue 300 which is surrounded by the safety margin 301 . This feature is especially useful when the target tissue (treatment target area) requires more than one round of treatment to effectively cover the entire area.
- IRE irreversible electroporation
- other methods can include reversible electroporation, supraporation, RF ablation, cryo-ablation, microwave ablation, etc.
- Raporation uses much higher voltages and currents, in comparison to electroporation, but with shorter pulse widths.
- reversible electroporation as well as irreversible electroporation.
- Example embodiments for reversible electroporation can involve 1-8 pulses with a field strength of 1-100 V/cm.
- altering cellular structures adversely involve generators having a voltage range of 100 kV-300 kV operating with nano-second pulses with a maximum field strength of 2,000 V/cm to and in excess of 20,000 V/cm between electrodes. Certain embodiments can involve between 1-15 pulses between 5 microseconds and 62,000 milliseconds, while others can involve pulses of 75 microseconds to 20,000 milliseconds.
- the electric field density for the treatment is from 100 Volts per centimeter (V/cm) to 7,000 V/cm, while in other embodiments the density is 200 to 2000 V/cm as well as from 300 V/cm to 1000 V/cm.
- the number of pulses can vary. In certain embodiments the number of pulses is from 1 to 100 pulses. In one embodiment, as described herein, between about 10 pulses and about 100 pulses can be applied at about 2,000 V/cm to about 3,000 V/cm with a pulse width of about 10 ⁇ sec to about 50 ⁇ sec. After applying these pulses, a predetermined time delay of from about 1 seconds to about 10 minutes can optionally be commenced in order that intra-cellular contents and extra-cellular contents of the target tissue cells can mix. This procedure can be repeated, as necessary, until a conductivity change is measured in the tissue.
- about 1 pulse to about 300 pulses of about 2,000 V/cm to about 3,000 V/cm can be applied with a pulse width of about 70 ⁇ sec to about 100 ⁇ sec to widely ablate the tissue.
- This last step can be repeated until a desired number of ablation pulses is delivered to the tissue, for example, in the range of about 10 pulses to about 300 pulses, more particularly, about 100 pulses.
- groups of 1 to 100 pulses are also called pulse-trains
- the gap of time between groups of pulses can be from about 0.5 second to about 10 seconds.
- Therapeutic energy delivery devices disclosed herein are designed for tissue destruction in general, such as resection, excision, coagulation, disruption, denaturation, and ablation, and are applicable in a variety of surgical procedures, including but not limited to open surgeries, minimally invasive surgeries (e.g., laparoscopic surgeries, endoscopic surgeries, surgeries through natural body orifices), thermal ablation surgeries, non-thermal surgeries, as well as other procedures known to one of ordinary skill in the art.
- the devices may be designed as disposables or for repeated uses.
- the electrodes can be adapted to administer electrical pulses as necessary in order to reversibly or irreversibly electroporate the cell membranes of infectious cells located along the outer surface of an implanted medical device within a treatment zone, thereby treating a patient and sterilizing the medical device.
- electrical pulses By varying parameters of voltage, the number of electrical pulses, and pulse duration, the electrical field will either produce irreversible or reversible electroporation of the infectious cells that cover the implanted medical device.
- the pulse generator of the present invention can be designed to deliver a range of different voltages, currents and duration of pulses as well as number of pulses.
- Typical ranges include but are not limited to a voltage level of between 100-3000 volts, a pulse duration of between 20-200 microseconds (more preferably 50-100 microseconds), and multiple sets of pulses (e.g. 2-5 sets) of about 2-25 pulses per set and between 10 and -500 total pulses.
- the pulse generator can administer a current in a range of from about 2,000 V/cm to about 6,000 V/cm.
- the pulse generator can provide pulses which are at a specific known duration and with a specific amount of current.
- the pulse generator can be designed upon activation to provide 10 pulses for 100 microseconds each providing a current of 3,800 V/cm+/ ⁇ 50%+/ ⁇ 25%, +/ ⁇ 10%, +/ ⁇ 5%.
- Plastic and/or other types of metallic devices can be sterilized along the outer surface of the device, as electric field lines from the electrodes can travel along the outer surface of devices.
- the electroporation treatment zone is defined by mapping the electrical field that is created by the electrical pulses between two electrodes.
- a method of treating infectious cell growth 33 on an implanted medical device, such as a cartilaginous implant 35 , using IRE is disclosed.
- three (3) probes are illustrated in the method, any number of suitable probes can be used to deliver the electrical pulses.
- electrical pulses are administered within the irreversible parameter ranges, as described above, permanent pore formation occurs in the cellular membrane, resulting in cell death of the targeted infectious cells 33 .
- infectious cell growth 33 on an implanted medical device can be prevented altogether.
- electrical pulses may be administered within a reversible electroporation range. Temporary pores will form in the cellular membranes of infectious cells.
- the voltage pulse generator 10 can be configured to generate electrical pulses between electrodes 22 in an amount which is sufficient to induce irreversible electroporation of infectious cells that may be present on or near an implanted medical device without creating a clinically significant thermal effect to the surrounding tissue or critical structures.
- the electrical pulses can create permanent openings in infectious cells of smooth muscle cells, for example, thereby invoking cell death without creating a clinically significant thermal effect.
- the infectious cells 33 will remain in situ and can be subsequently removed by natural body processes. These infectious cells can be located anywhere along the implantable medical device. Research has also shown that growths of infectious cells can enhance implanted medical device-related bacteremia by providing an interface for adherence and colonization.
- biofilms which are impenetrable to systemic antibiotics leading to a cause of implanted medical device dysfunction, subsequent removal, and the attendant increases in morbidity and mortality.
- biofilms can also lead to chronic microbial infection, inflammation, and tissue necrosis.
- infections are frequently due to gram-positive bacteria, such as Staphylococcus epidermidis or Escherichia coli in the case of catheter-associated or other plastic-types of medical devices and Staphylococcus aureus in the case of metallic implants.
- bacteria could be present as well, such as, but not limited to, Streptococcus Mutans, Streptococcus Mitus, Streptococcus Salivarius , and Enterobacter Aerogenes .
- Initial infection is always linked to the ability of the bacteria to adhere to material surfaces. At first the bacterial adhesion is reversible, but then later becomes irreversible. Over time, the individual microorganisms and bacterial matrix formation can develop a high resistance to antibiotics.
- a series of electrical field lines can be generated.
- the strongest (defined as volts/cm) electrical field is nearest to the electrodes 22 and is depicted by gradient line 9 .
- the strength of the electrical field decreases.
- Outer gradient line 13 represents the outer perimeter of electric field gradient.
- any infectious cells 33 or other bio-film growth on the surface of the implantable medical device 35 within the outer perimeter 13 will undergo cell death by irreversible electroporation. Because the voltage pulse generation pattern from the generator does not generate damaging thermal effect, and because the voltage pulses only ablate living cells, the treatment does not damage blood, blood vessels or other non-cellular or non-living materials such as the implantable device itself.
- the pulse parameters that characterize the field gradient line can be adjusted to vary the treatment zone according to the location of the infectious cells growth and/or infectious cells to be destroyed.
- the electrodes can be positioned at any location necessary to destroy any such infectious cells 33 that have grown around or on the indwelling implanted medical device 35 .
- the electrodes 22 can be positioned at a proximal section of the implanted device for treating infectious cells that have grown around the implanted device, at a distal section of the implanted device, or surrounding the implanted medical device.
- the electrodes 22 can be positioned to destroy infectious cells 33 that have grown near the insertion site of the implanted device.
- infectious cell growth on the implanted device can be prevented altogether.
- the formation of infectious cells may occur as early as 24 hours after implanted medical device implantation.
- Application of electrical pulses applied to the implanted medical device at regular intervals post-implantation may be effective in preventing infectious cell growth during the implanted medical device implantation period.
- FIG. 37 illustrates the procedural steps associated with performing irreversible or reversible electroporation treatment using any of the probe devices described herein.
- electrode probes 22 as illustrated in FIG. 36A , are inserted into the patient's skin 27 such that the probes can be near or in contact with the infectious cell growth on the implanted medical device.
- the probes 22 are then positioned relative to the infectious cells' 33 location as previously described.
- the electrodes 22 can be deployed and positioned outside of the implanted medical device 35 as shown in FIGS. 36A and 36B . Electrical connectors from each probe are connected ( 801 ) to generator 10 using an extension cable.
- Electrodes 22 and the generator 10 This completes an electrical circuit between the electrodes 22 and the generator 10 . Electrical pulses are applied across the electrodes 22 in the desired pattern ( 802 ) to electroporate the smooth muscle cells of the infectious cells 17 . Electrical pulses are then applied across the electrodes 22 creating field gradient lines 9 and 13 , for example, as illustrated in FIG. 36B , sufficient to non-thermally electroporate the infectious cells. As illustrated in FIG. 37 , after treatment, the extension cable is disconnected from the electrical connector ( 805 ) and the probes are removed from the tissue. Non-thermal death of the infectious cells 33 will occur within the first twenty-four hours after electroporation treatment followed by a cellular breakdown of the infectious cells.
- the electroporation pulses can be synchronously matched to specifically repeatable phases of the cardiac cycle to protect cardiac cellular functioning. See, for example, U.S. Patent Application No. 61/181,727, filed May 28, 2009, entitled “Algorithm For Synchronizing Energy Delivery To The Cardiac Rhythm”, which is fully incorporated by reference herein.
- This feature is especially useful when the electroporation pulses are delivered in a location that is near the heart. This can be especially useful if a user is attempting to treat infection near an implanted medical device such as a pacemaker.
- FIG. 38 illustrates a treatment setup for a patient for synchronization of the delivery of electroporation pulses with a specific portion of the cardiac rhythm.
- Electrocardiogram (ECG) leads 17 , 19 , 21 are adapted to be attached to the patient for receiving electrical signals which are generated by the patient's cardiac cycle.
- the ECG leads transmit the ECG electrical signals to an electrocardiogram unit 29 .
- the electrocardiogram unit 29 can transmit this information to a synchronization device 25 which can include hardware or software to interpret ECG data. If the synchronization device 25 determines that it is safe to deliver electroporation pulses, it sends a control signal to a pulse generator 10 .
- the pulse generator 10 is adapted to connect to the electrical connector for delivering electroporation pulses.
- Each of the synchronization device 25 and pulse generator 10 can be implemented in a computer so that they can be programmed.
- the present invention affords several advantages. Infectious cell growths 33 are destroyed without having to remove the implanted medical device 35 from the patient.
- the treatment is minimally-invasive and highly efficacious. Because irreversible electroporation does not create thermal activity, the implanted medical device 35 is not damaged by the treatment. Infectious cells growths 33 are treated quickly, and the implanted medical devices 35 can be maintained according to a predetermined schedule to insure that they are routinely treated with IRE to remove the infected cells 33 .
- the irreversible electroporation device and method has been described herein for use with cartilaginous implanted medical devices, it should be understood that the irreversible electroporation device can be used with any type of implanted medical device 35 , such as, but not limited to, ports, catheters, stents, artificial cartilaginous implants, orthopedic prosthetics, pacemakers, PICCs, hip implants, tooth implants, heart valves, spinal implants, and other types of plastic and/or metallic devices, to name a few. While the embodiments shown use pulses that cause IRE, persons of ordinary skill in the art will appreciate that other types of pulses can be used for the destruction of the infectious cell growths 33 . In particular, ultrashort sub-microsecond pulses (pulses of less than 1 microsecond in duration) can be used to induce apoptosis that cause damage to the intracellular structures such as a cell nucleus.
- the method of IRE treatment described herein could be used to treat one or more parts of a patient's body that are infected due to some other infection, such as, for example, gangrene.
- Gangrene is particularly problematic in patients with poor blood flow, such as diabetic patients, particularly in certain parts of the body, such as the extremities (i.e., hands, feet, nose, ears, etc.).
- Gangrene is a type of necrotizing (flesh-destroying) bacterial infection.
- a physician prescribes antibiotics to a patient to treat gangrene.
- poor circulation can prevent certain drugs from reaching these extremities, thereby making patients more susceptible to infection in these areas.
- Gangrene often spreads so quickly that it can't be stopped by antibiotics alone.
- the gangrene can cause lesions in the skin.
- antibiotics may help slow the infection and clear small, unnoticed pockets of bacteria.
- a surgeon may still have to debride or cut away the infected flesh and a margin around it to prevent further spread. If debridement isn't enough, amputation is the next step.
- the patient is put in a hyperbaric chamber if one is available. This is a sealed metal tank pumped full of oxygen under high pressure. The pressure forces oxygen into the tissues, stopping the spread of anaerobic bacteria. All of these methods have pitfalls. For example, patients can build up a resistance to antibiotics, as described above.
- IRE methods of treatment as described above using any of the pulse parameters disclosed herein, could be used in such tissues to effectively kill gangrene tissue, allowing healthy tissue to regenerate, thereby eliminating the need for amputation.
- IRE could be used to treat infected cells present on the patient's tissue scaffold.
- a patient's own natural tissues could be used as a scaffold.
- the IRE electrical pulses can effectively de-cellularize the tissue scaffold in a desired target tissue zone of infectious cells 33 , while leaving the tissue scaffold intact.
- the patient's tissue can naturally re-cellularize onto the patient's natural tissue scaffold after IRE has been performed.
- This method allows vascular, neural, and other critical structures to remain intact and essentially unharmed.
- this method would still be a safe alternative to other forms of cellular ablation or decellularization such as physical, chemical, or enzymatic methods of decellularization.
- IRE infected tissue
- tissue or organ can provide a controlled, precise way to destroy cells of a tissue or organ, while leaving the underlying extracellular matrix intact, including the vascular and neural structures as well as other critical features intact.
- IRE can also prevent scar tissue formation as well as promote a beneficial immune response.
- the method could involve treating in vitro or in vivo, a tissue comprising infectious cells located on an underlying scaffold with electrical pulses of sufficient duration and power to kill infectious cells of the tissue, while leaving the extracellular matrix and other vascular and neural structures intact.
- the term “intact” means a state of being whereby an element is capable of performing its original function to a substantial extent.
- any of the IRE methods and parameters described herein can be used to deliver electrical pulses to the infectious cells present on the tissue scaffold. Any suitable frequency of pulsing that allows for irreversible electroporation without significant thermal damage to the tissue is acceptable.
- the electrodes 22 described herein can be placed into or near the vicinity of the tissue scaffold to cause irreversible electroporation of the infectious cells on or near the tissue scaffold.
- the electrical pulses irreversibly permeabilize the membranes of the infectious cells, thereby invoking cell death.
- the length of time of the electrical pulses, the voltage applied, and the resulting membrane permeability are all controlled within desired ranges.
- the debris left by the infectious cells may be left in situ and may be removed by natural processes, such as the body's own immune or circulation system.
- IRE could be used to ablate cysts in the abdomen.
- a cyst is an overgrowth of the epithelium, comprising specialized cells that reside on the surface of tissue, such as organs and glands. Once formed, they often become detached from the point of origin and circulate, although they may also become lodged between tissue structures and cause pressure. They generally appear as sacs or lumps surrounded by a thin membrane and consist of fluid or semi-solid material. While most cysts are benign, the development of an abdominal cyst may signal an underlying disease.
- abdominal cysts There are several types of abdominal cysts. One of the most common is an ovarian cyst, which forms on ovarian follicles. Even though most ovarian cysts are benign, they can cause pain and bleeding. Standard treatment to remove cysts involves surgical removal if they become too large.
- Mesenteric cysts are another type of abdominal cyst that may indicate impaired lymphatic functioning. These types of cysts develop in the mesentery, the area of the peritoneum that encompasses the gastrointestinal tract and extends from the duodenum to the rectum. In addition, these cysts may involve any of the organs of the retroperitoneum, such as the bladder and kidneys. Omental cysts generally occur in the anterior abdominal wall in the regions of the stomach and colon.
- cysts can usually be removed without having to resection the stomach or colon. While most abdominal cysts are not dangerous, they can sometimes grow from the size of a pea to a grapefruit over time and can sometimes present complications. Abdominal cysts can also cause pain, unexplained bleeding, bowl obstruction, and distension of the stomach or other organs, should be investigated without delay. Typical treatment modalities to remove cysts include surgical measure. However, surgery can be time-consuming, painful, and expensive.
- IRE treatment methods can be used as a minimally invasive and safe procedure to ablate and remove benign abdominal cysts as well as abdominal cancer cells.
- IRE methods can be more efficient, cheaper, and less painful compared to surgical procedures and would leave critical structures intact, such as vascular structures, etc. Even if the collateral structures are affected, using non-thermal IRE as a treatment method for removal of abdominal cysts would provide a safe treatment alternative to thermal or surgical removal methods that can be time-consuming, costly, and painful for the patient or the use of drugs that can have harmful side effects.
- Bone infections can be extremely difficult to treat.
- bone infections can be treated using surgical procedures.
- the bone can be accessed by variety of procedures, such as through the skin.
- the remaining bone defect(s) is treated with a large dose of antibiotics via a non-resorbable bone cement to eradicate any bacterial cells in the bone and bloodstream.
- subsequent surgery is required for removal and replacement with a bone graft or an absorbable mix of synthetic bone substitute.
- Bone rebuilding techniques can involve bone grafting or bone transport. Antibiotic treatment is then administered through an intravenous catheter.
- IRE can be used to treat bone infection.
- sufficient electrical pulse parameters can be selected, as described herein above, to irreversibly electroporate infected cells that are present within or along bone.
- the electrical probes described herein can be inserted into a target tissue surrounding an infected bone, and sufficient electrical pulse parameters could be selected to adequately irreversibly electroporate an infected bone.
- an outer layer of bone could be treated to remove infected cells.
- target bone tissue could include muscle and/or vessels which could be acutely necrosed.
- the critical cellular and/or vascular structures could grow back so that no long term harmful consequences would occur.
- IRE could also be used to sterilize implanted medical devices using any of methods comprising any of the electrical pulse parameters described herein.
- Implanted medical devices such as metallic devices could be sterilized using the device itself as a conductor.
- the metallic device could be comprised of stainless steel, cobalt-chromium-molybdenum alloys, pure titanium, or titanium alloys.
- the implanted medical device, functioning as a conductor could be placed between two electrodes, for example, thereby effectively functioning as another electrode.
- a plurality of electrodes could be used and placed surrounding the implanted medical device. A practitioner can position the electrodes a predetermined distance from the implant so that the implanted medical device can function like a return electrode.
- the electric field lines 9 through 13 could travel from each electrode to the outer surface of the implant, thereby allowing the implant to effectively become part of the sterilization.
- IRE IRE
- cryo RF, cryo, or other scar-prone surgical procedures.
- This method can be used proactively to ensure that deep-seated infection will not occur post-operatively. This would prevent tissues from being permanently scarred. This method is beneficial because after IRE is performed, healthy tissue will grow instead of scar tissue. The use of this procedure could also provide better long term results for patients and would eliminate the need to have patients endure multiple surgeries and lengthy healing times.
Abstract
Description
- This application is related to U.S. non-provisional application Ser. No. 12/488,070, filed Jun. 19, 2009; Ser. No. 12/751,826, filed Mar. 31, 2010; and Ser. No. 12/751,854, filed Mar. 31, 2010; and claims priority to U.S. provisional application No. 61/834,471 filed on Jun. 13, 2013; all of which are incorporated by reference herein.
- The present invention relates to methods of treating infections in mammals using irreversible electroporation (IRE) to destroy the pathogenic microorganisms comprising the infection and methods of sterilization of implanted medical devices using IRE.
- Infections are caused by parasitic microorganisms such as viruses, bacteria or fungi which invade the host and rapidly reproduce. The body's natural immune system is designed to combat most infections. Some infections may become chronic, particularly if the host has a compromised immune system. Uncontrolled infections may cause serious health problems including death. Infections are frequently associated with wounds and may also occur in the locale of implanted devices such as ports, catheters, stents, artificial cartilaginous implants, orthopedic prosthetics, pacemakers, PICCs, prosthetic knee or hip implants, tooth implants, heart valves, spinal implants, and other types of plastic and/or metallic devices, to name a few. These medical devices can become infected after implanted into a patient. Long-term implants can be particularly susceptible to infection. Infection of implanted medical devices can constitute one of the most serious complications after surgery. Removing these infected medical devices can require lengthy procedures to remove and replace the old infected devices with a new device. Such procedures can involve steps such as removing the infected implant through surgical procedure, and/or administering antibiotics, waiting for any infection to heal, and then performing another surgical procedure to re-insert a new medical implant into the patient. In the case of cartilaginous implants, this may have to be repeated several times and may require administering not only a new cartilage implant but also numerous doses of antibiotics in order to enable the infection and the patient's skin to heal and then to reinsert a new artificial cartilage implant. Thus, multiple surgeries can be required. This can greatly increase procedure time and costs and can cause much discomfort to the patient. Pharmaceuticals such as antimicrobial agents and antibiotics can be used to fight infections in such cases, but there are drawbacks to the use of these agents including allergic reactions, negative interactions with other drugs, and ineffective treatment due to an increase in resistant strains of these microorganisms. Sometimes a membrane can develop over infected areas, thereby creating an impassable barrier to antibiotics.
- Despite the many problems with infections of implantable medical devices, little has been done to address the cost, pain, and increased procedure time and to present effective solutions for sterilizing and/or treating infections that occur as a result of implanted medical devices. Most procedures involve removing infected devices and/or sterilizing medical devices through external application of bactericidal solutions or temperature extremes such as thermal heating or freezing, UV light, RF, microwave, or other radiation measures.
- Therefore, it is desirable to provide a cost-effective, painless, efficient method for treating infections by sterilizing infected implanted medical devices which methods can overcome the problems of traditional pharmaceutical treatment, such as, for example, resistance to systemic antibiotics. The methods provided herein use irreversible electroporation to sterilize implanted medical devices, thereby treating infection in patients, providing increased treatment efficacy, and eliminating or minimizing allergic reactions, which eliminates the chance of interactions with other drugs. This could also enhance patient quality of life, which would be very beneficial for patients having extreme arthritis, for example.
- What is provided herein is a method of using irreversible electroporation (IRE) to treat parts of the human body that have been subject to infection. This method avoids surgical methods that require removal surgery, a waiting period, then replacement of an infected medical device. This method can greatly improve outcomes, particularly for devices where infection may be catastrophic, i.e., a prosthetic knee or hip implant. It can also greatly improve costs and improve the longevity of implanted medical devices which are susceptible to infection, such as, for example, implantable ports. Such infection can be on or within a medical device that is implanted within a patient, as described above. Alternatively, a patient's tissue can be infected due to some other type of infection, for example, gangrene. IRE can be used to treat such infections and/or simultaneously sterilize an implanted medical device, as described herein to solve the above-mentioned problems.
- Electroporation is defined as a phenomenon that makes cell membranes permeable by exposing them to certain electric pulses. As a function of the electrical parameters, electroporation pulses can have two different effects on the permeability of the cell membrane. The permeabilization of the cell membrane can be reversible or irreversible as a function of the electrical parameters used. Reversible electroporation is the process by which the cellular membranes are made temporarily permeable. The cell membrane will reseal a certain time after the pulses cease, and the cell will survive. Reversible electroporation is most commonly used for the introduction of therapeutic or genetic material into the cell. Irreversible electroporation also creates pores in the cell membrane but these pores do not reseal, resulting in cell death.
- Irreversible electroporation has recently been discovered as a viable alternative for the ablation of undesired tissue. See, in particular, PCT Application No. PCT/US04/43477, filed Dec. 21, 2004. An important advantage of irreversible electroporation, as described in the above reference application, is that the undesired tissue is destroyed without creating a thermal effect. When tissue is ablated with thermal effects, not only are the cells destroyed, but the connective structure (tissue scaffold) and the structure of blood vessels are also destroyed, and the proteins are denatured. This thermal mode of damage detrimentally affects the tissue, that is, it destroys the vasculature structure and bile ducts, and produces collateral damage.
- Irreversible and reversible electroporation without thermal effect to ablate tissue offers many advantages. One advantage is that it does not result in thermal damage to target tissue or other tissue surrounding the target tissue. Another advantage is that it only ablates cells and does not damage blood vessels or other non-cellular or non-living materials such as implanted medical devices.
- Although the following examples discuss using the present invention and method to destroy various infectious cells, for example, such as implanted medical device-related bacteremia, that may substantially cover various implanted medical devices, persons of ordinary skill in the art will appreciate that the present devices and methods can be used to treat any undesirable cellular growth, including infectious cells, as well as to sterilize implanted medical devices.
- A method of treating an infection in patient that involves providing an ablation device, wherein the device comprises at least one electrode inserting the ablation device into a target tissue of the patient. The tissue at least partially surrounds an implanted medical device, and the outer surface of the medical device is at least partially covered by infectious cells. The method also involves positioning the at least one electrode in or near the implanted medical device and delivering electrical pulses to or near the implanted medical device sufficient to irreversibly electroporate the infectious cells.
-
FIG. 1 illustrates several components that can be used with the present invention to treat a patient using IRE or to sterilize an implanted medical device. -
FIG. 2 is a schematic diagram of a treatment control computer of the present invention. -
FIG. 3 is a screen shot of an “Information” screen of a treatment control module showing various input boxes. -
FIG. 4 is a screen shot of a “Probe Selection” screen of the treatment control module showing a side view and top view of the bipolar probe and an example of the general shape of the treatment zone that can be generated by such a probe type. The “treatment zone”, as defined herein, can comprise infected tissue cells. -
FIG. 5 is a screen shot of a “Probe Selection” screen of the treatment control module showing a side view and top view of the two probe array and an example of the general shape of the treatment zone that can be generated by a two probe array. -
FIG. 6 is a screen shot of a “Probe Selection” screen of the treatment control module showing a side view and top view of the three probe array and an example of the general shape of the treatment zone that can be generated by a three probe array. -
FIG. 7 is a screen shot of a “Probe Selection” screen of the treatment control module showing a side view and top view of the four probe array and an example of the general shape of the treatment zone that can be generated by a four probe array. -
FIG. 8 is a screen shot of a “Probe Selection” screen of the treatment control module showing a side view and top view of the five probe array and an example of the general shape of the treatment zone that can generated by a five probe array. -
FIG. 9 is a screen shot of a “Probe Selection” screen of the treatment control module showing a side view and top view of the six probe array and an example of the general shape of the treatment zone that can be generated by a six probe array. -
FIG. 10 is a screen shot of a “Probe Placement Process” screen of the treatment control module. -
FIG. 11 is a screen shot of a “Probe Placement Process” screen of the treatment control module showing a rotation feature of the treatment control module. -
FIG. 12 is a screen shot of a “Probe Placement Process” screen of the treatment control module showing an automatic measurement feature of the treatment control module. -
FIG. 13 is a screen shot of a “Probe Placement Process” screen of the treatment control module showing examples of treatment zones that can be created between the electrodes. -
FIG. 14 is a screen shot of a “Probe Placement Process” screen of the treatment control module showing an example of a combined treatment zone generated by a four probe array. -
FIG. 15 illustrates an example of a three probe array defining three individual treatment zones, which combine to form a combined treatment region. -
FIG. 16 is an example of a spreadsheet of the E-field values that are determined for x, y coordinates on the grid, as will be further described below in reference to Example 2. -
FIG. 17 illustrates an example of a multi-dimensional lookup table and a method of interpolating treatment zones. -
FIG. 18 is a screen shot of a “Probe Placement Process” screen of the treatment control module showing an automatic probe placement feature of the treatment control module. -
FIGS. 19-22 are screen shots of the treatment control module illustrating an alternative embodiment of an automatic probe placement feature of the treatment control module. -
FIGS. 23-25 are screen shots of a “Probe Placement Process” screen of the treatment control module showing several examples of how a user can edit and modify the treatment parameters. -
FIG. 26 is a screen shot of a “Probe Placement Process” screen of the treatment control module showing an example of a treatment zone that is created by a six probe array after the “Autoset Probes” button has been depressed by a user. -
FIG. 27 is a screen shot of a “Pulse Generation” screen of the treatment control module showing the status of the treatment parameters before the treatment procedure has been initiated by a user. -
FIG. 28 is a screen shot of a “Pulse Generation” screen of the treatment control module showing the status of the treatment parameters during the treatment procedure. -
FIG. 29 illustrates details of the generator shown inFIG. 1 , including elements for detecting an over-current condition. -
FIG. 30 is a screen shot of a “Pulse Generation” screen of the treatment control module showing the status of the treatment parameters after the treatment procedure. -
FIG. 31 is a screen shot of a “Pulse Generation” screen of the treatment control module showing a dialogue box that pops up if the “continue procedure” button is pressed in the example. -
FIG. 32 is a screen shot of a “Pulse Generation” screen of the treatment control module showing the status of the treatment parameters during the re-treatment procedure. -
FIGS. 33-34 are screen shots of a “Pulse Generation” screen of the treatment control module showing examples of result graphs. -
FIG. 35 is a screen shot of a “Probe Placement Process” screen of the treatment control module showing the probe placement grid after treatment has been delivered by the probes. -
FIGS. 36A and 36B illustrate a method of treating infected tissue and/or sterilizing an implanted medical device, such, as for, example, a cartilaginous implant. -
FIG. 37 is a flowchart depicting the method steps for infectious cell ablation using irreversible electroporation methods described herein. -
FIG. 38 illustrates a treatment setup for a patient for synchronization of the delivery of electroporation pulses with a specific portion of the cardiac rhythm. - Throughout the present teachings, any and all of the one, two, or more features and/or components disclosed or suggested herein, explicitly or implicitly, may be practiced and/or implemented in any combinations of two, three, or more thereof, whenever and wherever appropriate as understood by one of ordinary skill in the art. The various features and/or components disclosed herein are all illustrative for the underlying concepts, and thus are non-limiting to their actual descriptions. Any means for achieving substantially the same functions are considered as foreseeable alternatives and equivalents, and are thus fully described in writing and fully enabled. The various examples, illustrations, and embodiments described herein are by no means, in any degree or extent, limiting the broadest scopes of the claimed inventions presented herein or in any future applications claiming priority to the instant application.
- Disclosed herein are methods for treating infection in mammals using irreversible electroporation to destroy pathogenic microorganisms comprising the infection. In particular, the methods involve using a medical device to deliver electrical pulses to the treatment zone that comprises an implanted medical device and potentially infectious cells within a non-thermal irreversible electroporation range. A probe comprising at least one electrode is adapted to receive from a voltage generator a plurality of electrical pulses in an amount sufficient to cause destruction of cells comprising the infection. The number of pulses, pulse length, pulse amplitude can be used to irreversibly electroporate a target tissue. Also presented herein is a method for sterilizing an implanted medical device using irreversible electroporation.
- One embodiment of the present invention is illustrated in
FIGS. 1 through 35 . The components that can be used with the present invention are illustrated inFIG. 1 . One ormore probes 22 can deliver therapeutic energy and are powered by avoltage pulse generator 10 that generates high voltage pulses as therapeutic energy such as pulses capable of irreversibly electroporating the tissue cells. In the embodiment shown, thevoltage pulse generator 10 can include six separate receptacles for receiving up to sixindividual probes 22 which are adapted to be plugged into the respective receptacle. The receptacles are each labeled with a number in consecutive order. In other embodiments, thevoltage pulse generator 10 can have any number of receptacles for receiving more or less than six probes. - In the embodiment shown, each
probe 22 includes either a monopolar electrode or bipolar electrodes having two electrodes separated by an insulating sleeve. In one embodiment, if the probe includes a monopolar electrode, the amount of exposure of the active portion of the electrode can be adjusted by retracting or advancing an insulating sleeve relative to the electrode. See, for example, U.S. Pat. No. 7,344,533, which is incorporated by reference herein. Thegenerator 10 is connected to atreatment control computer 40 having input devices such askeyboard 12 and apointing device 14, and an output device such as adisplay device 11 for viewing an image of a target treatment area such as atarget tissue 300 surrounded by asafety margin 301. The therapeuticenergy delivery device 20 is used to treat atarget tissue 300 inside apatient 15. In one aspect, the target tissue can comprise infectious cells and/or an implanted medical device comprising infectious cells. Animaging device 30 includes amonitor 31 for viewing thetarget tissue 300 inside the patient 15 in real time. Examples ofimaging devices 30 include ultrasonic, CT, MRI and fluoroscopic devices as are known in the art. - The present invention includes computer software (treatment control module 54) which assists a user to plan for, execute, and review the results of a medical treatment procedure, as will be discussed in more detail below. For example, the
treatment control module 54 assists a user to plan for a medical treatment procedure by enabling a user to more accurately position each of theprobes 22 of the therapeuticenergy delivery device 20 in relation to thetarget tissue 300 in a way that will generate the most effective treatment zone. Thetreatment control module 54 can display the anticipated treatment zone based on the position of the probes and the treatment parameters. Thetreatment control module 54 can display the progress of the treatment in real time and can display the results of the treatment procedure after it is completed. This information can be used to determine whether the treatment was successful and whether it is necessary to re-treat the patient. - For purposes of this application, the terms “code”, “software”, “program”, “application”, “software code”, “software module”, “module” and “software program” are used interchangeably to mean software instructions that are executable by a processor.
- The “user” can be a physician or other medical professional. The
treatment control module 54 executed by a processor outputs various data including text and graphical data to themonitor 11 associated with thegenerator 10. - Referring now to
FIG. 2 , thetreatment control computer 40 of the present invention manages planning of treatment for a patient. Thecomputer 40 is connected to thecommunication link 52 through an I/O interface 42 such as a USB (universal serial bus) interface, which receives information from and sends information over thecommunication link 52 to thevoltage generator 10. Thecomputer 40 includesmemory storage 44 such as RAM, processor (CPU) 46,program storage 48 such as ROM or EEPROM, anddata storage 50 such as a hard disk, all commonly connected to each other through abus 53. Theprogram storage 48 stores, among others, atreatment control module 54 which includes a user interface module that interacts with the user in planning for, executing and reviewing the result of a treatment. Any of the software program modules in theprogram storage 48 and data from thedata storage 50 can be transferred to thememory 44 as needed and is executed by theCPU 46. - In one embodiment, the
computer 40 is built into thevoltage generator 10. In another embodiment, thecomputer 40 is a separate unit which is connected to the voltage generator through the communications link 52. In a preferred embodiment, thecommunication link 52 is a USB link. - In one embodiment, the
imaging device 30 is a stand alone device which is not connected to thecomputer 40. In the embodiment as shown inFIG. 1 , thecomputer 40 is connected to theimaging device 30 through acommunications link 53. As shown, thecommunication link 53 is a USB link. In this embodiment, the computer can determine the size and orientation of thetarget tissue 300 by analyzing the data such as the image data received from theimaging device 30, and thecomputer 40 can display this information on themonitor 11. In this embodiment, the target tissue generated by theimaging device 30 can be directly displayed on thegrid 200 of themonitor 11 of the computer running thetreatment control module 54. This embodiment would provide an accurate representation of the target tissue on thegrid 200, and may eliminate the step of manually inputting the dimensions of the target tissue in order to create the target tissue on thegrid 200. This embodiment would also be useful to provide an accurate representation of the target tissue if the target tissue has an irregular shape. - The basic functionality of the computer software (treatment control module 54) will now be discussed in relation to the following example. It should be noted that the software can be used independently of the
generator 10. For example, the user can plan the treatment in a different computer as will be explained below and then save the treatment parameters to an external memory device, such as a USB flash drive (not shown). The data from the memory device relating to the treatment parameters can then be downloaded into thecomputer 40 to be used with thegenerator 10 for treatment. - After the
treatment control module 54 is initialized, it displays an “Information” screen with various input boxes as shown inFIG. 3 . A keyboard orother input device 12, together with a mouse or other pointing device 14 (seeFIG. 1 ) are used to input the data. Any data that is inputted into the input boxes can be saved into internal or external memory along with a record of the treatment as described below for future reference. The basic patient information can be inputted, such as a patient ID number ininput box 100, the name of the patient ininput box 101, and the age of the patient ininput box 102. The user can enter clinical data, such as the clinical indication of the treatment ininput box 114. The date of the procedure is automatically displayed at 111 or can be inputted by the user in another embodiment. The user can enter other case information such as the name of the physician ininput box 112 and any specific case notes ininput box 113. - The dimensions of the
target tissue 300 are determined from viewing it on themonitor 31 of the imaging device 30 (seeFIG. 1 ) such as an ultrasonic imaging device and using known methods to calculate the dimensions from the image generated from theimaging device 30. The dimensions of the target tissue 300 (length atinput box 103, width at input box 104, and depth at input box 105) are inputted into the program. A safety margin is selected atinput box 106 which will surround theentire target tissue 300 in three dimensions. According to the size of the safety margin that is selected, a target treatment region is automatically calculated and is displayed inboxes - In the embodiment shown in
FIG. 3 , the user has indicated that the target tissue that will be treated has a length of 2 cm, width of 1 cm and a depth of 1 cm. With a user specified margin of 1 cm (which is a default margin setting), the target treatment region has a length of 4 cm, width of 3 cm and a depth of 3 cm. - The user can select the “ECG synchronization” option by clicking the circle in the
box 110 in order to synchronize the pulses with an electrocardiogram (ECG) device, if such a device is being used during the procedure (FIG. 38 ). The other options available for treatment that are included inbox 110 can include an option for “90 PPM” (pulses per minute) or “240 PPM”. The user should select at least one of the three options provided inbox 110. After all of the necessary data has been inputted, the user clicks on the “Next” button with apointing device 14 to proceed to the next screen described below. - Further regarding the ECG synchronization option, if this circle is selected in
window 110, thetreatment control module 54 will test this functionality to verify that the system is working properly. Thetreatment control module 54 can automatically detect whether an error has occurred during the testing phase of the ECG feature. The detectable errors include, but are not limited to, “no signal” (such as no pulses for 3.5 seconds) and “noisy” (such as pulses occurring at a rate greater than 120 beats per minute for at least 3.5 seconds). - The
treatment control module 54 can synchronize energy release with cardiac rhythm by analyzing cardiac output such as electrocardiogram results (or other cardiac function output) and sending synchronization signals to a controller of thepulse generator 10. Thecontrol module 54 is also capable of generating internal flags such as a synchronization problem flag and a synchronization condition flag to indicate to users on a graphic user interface a synchronization status, so that energy pulse delivery can be synchronized with the cardiac rhythm for each beat (in real-time) or aborted as necessary for patient safety and treatment efficiency. - Specifically, the
control module 54 synchronizes energy pulses such as IRE (irreversible electroporation) pulses with a specific portion of the cardiac rhythm. The module uses the R-wave of the heartbeat and generates a control signal to thepulse generator 10 indicating that this portion of the heartbeat is optimal for release of IRE pulses. For clarity, the S wave would be an optimal time for delivery of an energy pulse, but due to the fact that the S wave ends nebulously in some cases, the R wave is used as an indicator to start timing of energy release. - More specifically, the synchronization feature of the
control module 54 allows for monitoring of heart signals so as to ensure that changes, maladies, and other alterations associated with the heartbeat are coordinated such that pulses from thepulse generator 10 are released at the proper time, and that if the heartbeat is out of its normal rhythm, that the release of energy is either altered or aborted. - Next, the user can select the type of therapeutic energy delivery device according to the number of probes that the user believes will be necessary to produce a treatment zone which will adequately cover the
target tissue 300 and anysafety margin 301. The selection is made by clicking the circle next to each type of device, as shown in the “Probe Selection” screen, illustrated inFIGS. 4-9 . - In one embodiment, a “Probes Selection Status”
box 199 identifies which of the receptacles, if any, on thegenerator 10 have been connected to a probe by displaying the phrase “Connected” or the like next to the corresponding probe number. In one embodiment, each receptacle includes an RFID device and a connector (not shown) for each probe which connects to the receptacle and includes a compatible RFID device, so that thetreatment control module 54 can detect whether or not an authorized probe has been connected to the receptacle on thegenerator 10 by detecting a connection of the compatible RFID devices. If an authorized probe is not connected to a receptacle on the generator, the phrase “Not Connected” or the like will appear next to the probe number. In addition, the colors of each probe shown in the “Probes Selection Status”box 199 can be used to indicate whether or not each receptacle on the generator is connected to a compatible probe. This feature allows the user to verify that the requisite number of probes is properly connected to thegenerator 10 before selecting a probe type for the treatment procedure. For example, if thetreatment control module 54 detects a problem with the probe connection status (e.g. selecting a three probe array when only two probes are connected to the generator), it can notify the user by displaying an error message. - The user can select which of the connected probes will be used to perform the treatment procedure, by clicking on the box next to the selected probes in the “Probes Selection Status”
box 199. By default thetreatment control module 54 will automatically select probes in ascending numerical order, as they are labeled. - Referring to
FIG. 4 ,circle 120 is used to select a bipolar probe.FIG. 4 illustrates aside view 121 andtop view 122 of the bipolar probe and an example of the general shape of the treatment zone that can be generated by such a probe type. Theside view 121 shows an example of the general shape of the treatment zone that can be generated by an arrangement of twoelectrodes 123 separated by an insulation sleeve. - Referring to
FIG. 5 ,circle 130 is used to select a two probe array.FIG. 5 illustrates aside view 131 andtop view 132 of the two probe array and an example of the general shape of the treatment zone that can be generated by a two probe array. In the illustrated example, the exposed portion of each of the electrodes as shown is 20 mm in length and the two probes are spaced from each other by 15 mm. - Referring to
FIG. 6 ,circle 140 is used to select a three probe array.FIG. 6 illustrates aside view 141 andtop view 142 of the three probe array and an example of the general shape of the treatment zone that can be generated by a three probe array. In the illustrated example, the exposed portion of each of the electrodes as shown is 20 mm in length and each pair of the three probes are equally spaced from each other by 15 mm, as measured at three places (PLCS), meaning that there are three pairs (pairs 1-2, 2-3 and 1-3) where the spacing is equal to 15 mm. - Referring to
FIG. 7 ,circle 150 is used to select a four probe array.FIG. 7 illustrates aside view 151 andtop view 152 of the four probe array and an example of the general shape of the treatment zone that can be generated by a four probe array. In the illustrated example, the exposed portion of each of the electrodes as shown is 20 mm in length and each pair of the four probes are equally spaced from each other by 15 mm, as measured at four places (PLCS) along the perimeter. - Referring to
FIG. 8 ,circle 160 is used to select a five probe array.FIG. 8 illustrates a side view 161 andtop view 162 of the five probe array and an example of the general shape of the treatment zone that can be generated by a five probe array. In the illustrated example, the exposed portion of each of the electrodes as shown is 20 mm in length and each pair of the five probes are equally spaced from each other by 15 mm, as measured at seven places (PLCS). - Referring to
FIG. 9 ,circle 170 is used to select a six probe array.FIG. 9 illustrates aside view 171 andtop view 172 of the six probe array and an example of the general shape of the treatment zone that can be generated by a six probe array. In the illustrated example, the exposed portion of each of the electrodes as shown is 20 mm in length and each pair of the six probes are equally spaced from each other by 15 mm, as measured at five places (PLCS) from the center probe. Each pair of the six probes are equally spaced from each other by 17 mm, as measured at 5 places (PLCS) along the perimeter. - Other probe type selection can include a “six
probe array 10 mm” and “sixprobe array 15 mm”, which refers to probe types utilizing a template which can be used to align a group of six needles in a fixed predetermined arrangement for treatment, wherein each pair of probes are equally spaced by 10 mm and 15 mm, respectively. - Other probe device types having seven or more probes can be used. The user can select a probe type having a number of
probes 22 which will work most effectively to treat the specific size and shape of thetarget tissue 300 together with asafety margin 301. - After the user has selected a probe type on the “Probe Selection” screen, the user clicks on the “Next” button with a
pointing device 14 to proceed to the “Probe Placement Process” screen described below. -
FIG. 10 illustrates a “Probe Placement Process” screen of one aspect of the invention. The screen illustrated byFIG. 10 shows atarget tissue 300 according to the dimensions which were inputted on the “Information” screen (seeFIG. 3 ) along with asafety margin 301, if any, that was previously inputted. In the example depicted inFIG. 10 , thetarget tissue 300 has a length of 2.0 cm and a width of 1.0 cm, and the device selected on the “Probe Selection” screen (seeFIGS. 4-9 ) is a four probe array. Thetarget tissue 300 is displayed near the center of anx-y grid 200 with the distance between two adjacent grid lines representing 1 mm. Each of the fourprobes grid 200 and each probe can be manually positioned within the grid by clicking and dragging the probe with thepointing device 14. Twofiducials grid 200 and are used as a point of reference or a measure as will be described below. - The amount of longitudinal exposure of the active electrode portion for each probe that has already been manually adjusted by the user as explained above can be manually inputted in
input box 210, which can be selected by the user according to the depth (z) of the target tissue. In this way, thetreatment control module 54 can generate an estimated treatment zone according to the treatment parameters, and locations and depths of the probes. In one embodiment, a second x-z grid is displayed on themonitor 11 of the computer running thetreatment control module 54. In one embodiment, thetreatment control module 54 can automatically calculate preferred values for the amount of longitudinal exposure of the active electrode portions based on the size and shape of the target tissue. The depth (z) of the electric field image can be calculated analytically or with interpolation and displayed on the x-z grid. Because the distribution of the electric field (i.e., expected treatment region) between two monopolar electrodes may “dip in” along the boundary line (see, for example, the peanut shaped treatment region inFIG. 13 where the width of the region is smaller in the middle) depending on the electrode location and the applied voltage, it is beneficial to have an x-z grid included on the monitor. For example, if this “dip” of the boundary line travels into, rather than surround, the target tissue region, then the targeted region may not be fully treated. As a default to ensure treatment of the entire target tissue region, the probe depth placement and the exposure length may be set unnecessarily higher to ensure erring on the safe side. However, this will potentially treat a much larger volume than needed, killing healthy surrounding tissue, which can be an issue when treating sensitive tissues such as the pancreas, brain, etc. By optimizing the treatment depth (z) together with the width (x) and height (y), this effect may be reduced, further enhancing procedural protocol and clinical outcome. - The probe dock status is indicated in
box 210, by indicating if the probes are “docked” or “undocked”. The “UnDock Probes” button allows the user to “unplug” the probes from the generator while the “Probe Placement Process” screen is displayed without causing error messages. In normal operation, the user plugs the probes into the generator on the “Probe Selection” screen, and then the probes are “authorized” as being compatible probes according to the RFID devices, as discussed above. When the user proceeds to the “Probe Placement Process” screen, the software requires that all the selected probes remain plugged into the generator, or else the software will display an error message (e.g. “Probe # 2 unplugged”, etc.), and will also force the user back to the “Probe Selection” screen. However, sometimes users may want to perform another scan of thetarget tissue 300 or perform some other procedure while leaving the probes inserted in the patient. But, if the procedure cannot be performed near the generator, the probes are unplugged from the generator. If the user selects the “UnDock Probes” button, this will allow the probes to be unplugged from the generator without causing an error message. Then, after the user has performed the other procedure that was required, the user can re-attach the probes to the generator, and then select “Dock Probes” ininput box 210. In this way, the user will not receive any error messages while the “Probe Placement Process” screen is displayed. - There is a default electric field density setting (Volts/cm) which is shown in
input box 211. In the example, the default setting is 1500 Volts/cm. This number represents the electric field density that the user believes is needed to effectively treat the cells, e.g., ablate the tissue cells. For example, 1500 Volts/cm is an electric field density that is needed to irreversibly electroporate the tissue cells. Based on the number selected ininput box 211, thetreatment control module 54 automatically adjusts the voltage (treatment energy level) applied between the electrodes, as shown incolumn 222. -
Box 280 allows a user to select between two different Volts/cm types, namely “Linear” or “Non-Linear Lookup”. - The default Volts/cm setting is “Linear”, in which case the Voltage that is applied between a given pair of electrodes, as shown in
column 222, is determined by the following formula: -
Voltage=xd, (1) -
- where x=the electric field density setting (Volts/cm) shown in
column 225, which is based on the value frombox 211, and - where d=the distance (cm) between the given pair of electrodes shown in
column 226.
Therefore, when “Linear” is selected, the Voltage that is applied between a given pair of electrodes is directly proportional to the Distance between the given electrode pair in a linear relationship.
- where x=the electric field density setting (Volts/cm) shown in
- If the user selects “Non-Linear Lookup” in
box 280, then the Voltage that is applied between the given pair of electrodes will be similar to the Voltage values for a “Linear” selection when a pair of electrodes are closely spaced together (e.g. within about 1 cm). However, as a pair of given electrodes are spaced farther from one another, a “Non-Linear Lookup” will produce lower Voltages between the given pair of electrodes as compared to the Voltage values for a “Linear” selection at any given distance. The “Non-Linear Lookup” feature is particularly useful for reducing “popping” during treatment. “Popping” refers to an audible popping noise that sometimes occurs, which is believed to be caused by a plasma discharge from high voltage gradients at the tip of the electrodes. The “Non-Linear Lookup” feature can also minimize any swelling of the tissue that might occur as a result of a treatment. The Voltage values used for the “Non-Linear Lookup” selection can be pre-determined based on animal experiments and other research. In one embodiment, different tissue types can each have their own “Non-Linear Lookup” table. In the example shown, the tissue being treated is prostate tissue. - The details of the treatment parameters are displayed in
window 270. The firing (switching) sequence between probes is listed automatically inwindow 270. In the example, the firing sequence involves six steps beginning with betweenprobes Column 220 displays which probe is the positive probe (according to a number assigned to each probe) for each step.Column 221 displays which probe is the negative probe (according to a number assigned to each probe) for each step.Column 222 displays the actual voltage generated between each probe during each step of the firing sequence. In the example, the maximum voltage that can be generated between probes is limited by the capabilities of thegenerator 10, which in the example is limited to a maximum of 3000 Volts.Column 223 displays the length of each pulse that is generated between probes during each respective step of the firing sequence. In the example, the pulse length is predetermined and is the same for each respective step, and is set at 100 microseconds.Column 224 displays the number of pulses that is generated during each respective step of the firing sequence. In the example, the number of pulses is predetermined and is the same for each respective step, and is set at 90 pulses which are applied in a set of 10 pulses at a time.Column 225 displays the setting for Volts/cm according to the value selected atinput box 211.Column 226 displays the actual distance between the electrodes (measured in cm), which is automatically calculated according to the placement of each probe in thegrid 200. -
FIG. 11 illustrates a rotation feature of thetreatment control module 54. The user can rotate the image oftarget tissue 300 on thegrid 200 about its center in order to approximate the actual orientation of thetarget tissue 300 within the body of the patient 15 (seeFIG. 1 ), as shown by theimaging device 30. To do so, the user can view the actual orientation of thetarget tissue 300 within the body of the patient 15 by viewing themonitor 31 of theimaging device 30 shown inFIG. 1 . While viewing, the user can rotate thetarget tissue 300 on thegrid 200 in order to match the orientation of thetarget tissue 300 shown on themonitor 31 of theimaging device 30. There are at least three ways to rotate thetarget tissue 300 on thegrid 200. The user can click on a tab 250 (to select the tab) with apointing device 14 and drag thetab 250 to a new location which will rotate thetarget tissue 300. The user can alternatively click on any part of thesafety margin 301 or thetarget tissue 300 and drag it to rotate thetarget tissue 300. Alternatively, the user can manually input the treatment zone rotation angle ininput box 251, which represents the degree of rotation of thetarget tissue 300 measured from the horizontal “x” axis on thegrid 200. -
FIG. 12 illustrates an automatic measurement feature of thetreatment control module 54. When the user clicks on a probe and drags it with thepointing device 14, thetreatment control module 54 automatically and continuously displays the distance (cm) from thatelectrode 201 to each of the other electrodes 202 (distance displayed in box 230), 203 (distance displayed in box 232), 204 (distance displayed in box 233) as the probe is being dragged. Thetreatment control module 54 also displays the distance (cm) from thatelectrode 201 to the closest point on the outer surface of the target tissue 300 (distance displayed in box 234). Thetreatment control module 54 also displays the distance (cm) from thatelectrode 201 to fiducial “A” 208 (distance displayed in box 235), fiducial “B” 209 (distance displayed in box 236). Thetreatment control module 54 also displays the distance (cm) from fiducial “A” 208 to fiducial “B” 209 with the distance being displayed inbox 237. This feature assists the user in placing the electrodes in preferred locations. This feature is especially beneficial if the imaging device 30 (seeFIG. 1 ) allows the calculation of measurements as is known in the art. -
FIG. 13 illustrates examples of the treatment zones that are automatically created between the electrodes by thetreatment control module 54. Thetreatment control module 54 automatically calculates the treatment zones which are created and displays the area of the treatment zone. In a preferred embodiment, themonitor 11 of thegenerator 10 is in color and the color of the treatment zones 306, 307, thetarget tissue 300, and thesafety margin 301 are all different to easily differentiate them from one another. In one embodiment, thetarget tissue 300 is yellow and thesafety margin 301 is blue. In addition, thetreatment control module 54 can be programmed to adjust the color of thetarget tissue 300 and/or the boundary line of thetarget tissue 300 if the treatment zones 306, 307 do not effectively cover the target tissue, which could otherwise result in a clinical failure. - In addition, the
treatment control module 54 can be programmed to display aboundary line 320 that surrounds the areas of the treatment zones 306, 307 in a highlighted manner so that the outer boundaries of the treatment zones are readily identifiable. In one embodiment, the boundary line is a black line having sufficient thickness to provide a sharp contrast against the displayed target tissue and the grid.FIG. 14 illustrates a combined treatment region that is created by a fourprobe array control module 54 displays aboundary line 320 to identify the outer boundary of the combined treatment zone. Thecontrol module 54 also displays aboundary line 320 to identify one or more inner boundaries of the combined treatment zone, if applicable. This allows the user to easily identify the presence of any incomplete treatment coverage areas of thetarget tissue 300. Theinner boundary line 320 is especially useful to identify incomplete treatment areas that may have not otherwise been readily detectable on the computer screen. Since even a few surviving infectious cells can be detrimental in terms of recurrence of infection, this feature is especially important when treating an area with an implanted medical device having infectious cells. - The treatment control module can be programmed to calculate and display the area of the combined treatment regions on the
grid 200 by one of the following three methods, although other methods can be used. - Each of the following methods determines a boundary line surrounding a treatment zone that is created between a pair of electrodes. By combining a plurality of treatment zones with each treatment zone being defined by a pair of electrodes, a combined treatment region can be displayed on the x-y grid.
FIG. 15 illustrates threeelectrodes individual treatment zones treatment region 315 which is shown with hatched lines. - As discussed above, the monitor can further include an x-z grid to illustrate the depth of the target tissue and the shape of treatment region. The shape of the treatment zone in the x-z grid will vary according to the selected amounts of electrode exposure for each probe and can be determined by one or more methods.
- In one embodiment, the treatment boundary line that is created between two points on the x-y grid can be rotated about an axis joining the two points in order to generate the treatment region boundary line on the x-z grid. In this embodiment, several points may be selected along the exposed length of the active electrode portion for each probe at various depths (z). A three-dimensional combined treatment region can then be generated by determining the boundary line on the x-y grid between each individual pair of points and then rotating the boundary line along the axis joining each pair of points. The resulting boundary lines can be combined to create a three dimensional image that is displayed on the monitor.
- The following is an alternate method for determining a boundary line on the x-z grid, thereby determining a three dimensional treatment region. This example describes a two probe array with the probes being inserted in a parallel relationship and with the probes having the same amount of exposed portions of the electrode. In this example, the exposed portions of each probe start at the same “uppermost” depth (z) and end at the same “lowermost” depth (z). First, a treatment zone boundary line is created in the x-y plane at the uppermost depth (z). Next, the treatment zone boundary line is repeatedly created stepwise for all subsequently lower depths (z), preferably evenly spaced, until the lowermost depth (z) is reached. The result is a 3-D volume (stacked set of treatment zone boundary lines) having a flat top surface and a flat bottom surface. Next, two new focus points are selected, with the first focus point positioned midway between the probe positions in the x-y grid and near the uppermost depth (z) of the exposed electrode. The second focus point is also positioned midway between the probe positions in the x-y grid, but near the lowermost depth (z) of the exposed electrode. Next, a treatment zone boundary line is created in the x-z grid using one of the methods described earlier. The actual placement of each focus point may be closer together, namely, not positioned in the uppermost and lowermost x-y planes defined by the exposed portions. The placement of each focus point should be selected so that the treatment zone boundary line that is created in the x-z grid closely matches the treatment zone boundary lines that were created in the uppermost and lowermost x-y grids. Next, the treatment zone boundary line that was created in the x-z grid according to the two focus points is rotated about the axis joining the two focus points. This creates the shapes for the upper and lower 3-D volumes which are added to the flat top surface and the flat bottom surface described above.
- The above methods can be applied by persons of ordinary skill in the art to create 3-D treatment zones between exposed portions of electrodes even when the probes are not parallel to each other and even when the amount of the exposed portion varies with each probe.
- Furthermore, there are situations where it is advantageous to show multiple boundary zones as a result of a therapy. For example, indicating which regimes undergo no change, reversible electroporation, irreversible electroporation, and conventional thermal damage is possible in accordance with the present invention. In addition, it is possible to output the entire distribution rather than just delineating boundaries. For example, the “Second Method” (as discussed below) can be used to determine the entire potential field or temperature distribution within the domain.
- It has been shown repeatedly in the literature that tissue properties are highly variable between tissue types, between individuals, and even within an individual. These changes may result from differences in body fat composition, hydration levels, and hormone cycles. Due to the large dependence of IRE (irreversible electroporation) treatments on tissue conductivity, it is imperative to have accurate values. Therefore, to obtain viable conductivity values prior to treatment, a low amplitude voltage pulse is used between the electrode conductors and the resultant impedance/conductance is measured as a way to determine pertinent tissue property data such as the predicted current. The value determined may then be implemented when assessing field strength and treatment protocol in real time. For example, the resulting impedance or predicted current can be used to set the default electric field density.
- As discussed in the background, one accurate numerical model based method for generating a treatment zone between a pair of treatment probes involves finite element analysis (FEA). For example, U.S. Patent Application Publication No. 2007/0043345, which is hereby incorporated by reference, discloses using FEA models to generate treatment zones between a pair of electrodes (the calculations were performed using MATLAB's finite element solver, Femlab v2.2 (The MathWorks, Inc. Natick, Mass.)).
- Most engineering problems can be solved by breaking the system into cells where each corner of the cell or mesh is a node. FEA is used to relate each node to each of the other nodes by applying sets of partial differential equations. This type of a system can be coded by scratch, but most people use one of many commercial FEA programs that automatically define the mesh and create the equations given the model geometry and boundary conditions. Some FEA programs only work in one area of engineering, for example, heat transfer and others are known as mulitphysics. These systems can convert electricity to heat and can be used for studying the relationships between different types of energy.
- Typically the FEA mesh is not homogeneous and areas of transition have increased mesh density. The time and resources (memory) required to solve the FEA problem are proportional to the number of nodes, so it is generally unwise to have a uniformly small mesh over the entire model. If possible, FEA users also try to limit the analysis to 2D problems and/or use planes of symmetry to limit the size of the model being considered because even a modest 2D model often requires 30 minutes to several hours to run. By comparison, a 3D Model usually takes several hours to several days to run. A complicated model like a weather system or a crash simulation may take a super computer several days to complete.
- Depending on the complexity of the FEA models that are required, the purchase price of the FEA modeling software can cost several thousand dollars for a low end system to $30 k for a non-linear mulitphysics system. The systems that model the weather are custom made and cost tens of millions of dollars.
- In one example, the steps which are required for generating a treatment zone between a pair of treatment probes using finite element analysis include: (1) creating the geometry of interest (e.g., a plane of tissue with two circular electrodes); (2) defining the materials involved (e.g., tissue, metal); (3) defining the boundary conditions (e.g., Initial voltage, Initial temperature); (4) defining the system load (e.g., change the voltage of the electrodes to 3,000V); (5) determining the type of solver that will be used; (6) determining whether to use a time response or steady state solution; (7) running the model and wait for the analysis to finish; and (8) graphing the results.
- As discussed above, using FEA is not at all practical for use in calculating and displaying a treatment zone that is created between a pair of treatment probes in accordance with the present invention because of the time required to run these types of analyses. For the present invention, the system should allow a user to experiment with probe placement and should calculate a new treatment zone in less than a few seconds. Accordingly, the FEA model is not appropriate for such use and it would be desirable to find an analytic solution (closed form solution), which can calculate the treatment zones with only simple equations, but which closely approximate the solutions from a numerical model analysis such as the finite element analysis. The closed loop solutions should preferably generate the treatment zone calculation in a fraction of a second so as to allows a physician/user to experiment with probe placement in real time.
- According to the present invention, there are several closed loop (analytical model analysis) methods for estimating and displaying a treatment zone between a pair of treatment probes, which produce similar results to what would have been derived by a numerical model analysis such as FEA, but without the expense and time of performing FEA. Analytical models are mathematical models that have a closed form solution, i.e., the solution to the equations used to describe changes in a system can be expressed as a mathematical analytic function. The following three methods represent non-limiting examples of such alternative closed loop solutions.
- In mathematics, a Cassini oval is a set (or locus) of points in the plane such that each point p on the oval bears a special relation to two other, fixed points q1 and q2: the product of the distance from p to q1 and the distance from p to q2 is constant. That is, if the function dist(x,y) is defined to be the distance from a point x to a point y, then all points p on a Cassini oval satisfy the equation:
-
dist(q 1 ,p)×dist(q 2 ,p)=b 2 (2) - where b is a constant.
- The points q1 and q2 are called the foci of the oval.
- Suppose q1 is the point (a,0), and q2 is the point (−a,0). Then the points on the curve satisfy the equation:
-
((x−a)2 +y 2)((x+a)2 +y 2)=b 4 (3) - The equivalent polar equation is:
-
r 4−2a 2 r 2 cos 2θ=b 4 −a 4 (4) - The shape of the oval depends on the ratio b/a. When b/a is greater than 1, the locus is a single, connected loop. When b/a is less than 1, the locus comprises two disconnected loops. When b/a is equal to 1, the locus is a lemniscate of Bernoulli.
- The Cassini equation provides a very efficient algorithm for plotting the boundary line of the treatment zone that was created between two probes on the
grid 200. By taking pairs of probes for each firing sequence, the first probe is set as q1 being the point (a,0) and the second probe is set as q2 being the point (−a,0). - The polar equation for the Cassini curve was used because it provides a more efficient equation for computation. The current algorithm can work equally as well by using the Cartesian equation of the Cassini curve. By solving for r2 from eq. (4) above, the following polar equation was developed:
-
r 2 =a 2 cos(2*theta)+/−sqrt(b 4 −a 4 sin2(2*theta)) (5) - where a=the distance from the origin (0,0) to each probe in cm; and
- where b is calculated from the following equation:
-
- where V=the Voltage (V) applied between the probes;
- where a=the same a from eq. (5); and
- where A=the electric field density (V/cm) that is required to ablate the desired type of tissue according to known scientific values.
- As can be seen from the mathematics involved in the equation, r can be up to four separate values for each given value for theta.
- If V=2495 Volts; a=0.7 cm; and A=650 V/cm;
- Then b2=1.376377
- and then a cassini curve can be plotted by using eq. (5) above by solving for r, for each degree of theta from 0 degrees to 360 degrees.
- A portion of the solutions for eq. (5) are shown in Table 1 below:
- where M=a2 cos(2*theta); and L=sqrt(b4−a4 sin2(2*theta))
-
TABLE 1 Theta r = r = r = r = (degrees) sqrt(M + L) −sqrt(M + L) sqrt(M − L) −sqrt(M − L) 0 1.366154 −1.36615 0 0 1 1.366006 −1.36601 0 0 2 1.365562 −1.36556 0 0 3 1.364822 −1.36482 0 0 4 1.363788 −1.36379 0 0 5 1.362461 −1.36246 0 0 6 1.360843 −1.36084 0 0 7 1.358936 −1.35894 0 0 8 1.356743 −1.35674 0 0 9 1.354267 −1.35427 0 0 10 1.351512 −1.35151 0 0 11 1.348481 −1.34848 0 0 12 1.34518 −1.34518 0 0 13 1.341611 −1.34161 0 0 14 1.337782 −1.33778 0 0 15 1.333697 −1.3337 0 0 - The above eq. (6) was developed according to the following analysis.
- The curve from the cassini oval equation was calibrated as best as possible to the 650 V/cm contour line using two 1-mm diameter electrodes with an electrode spacing between 0.5-5 cm and an arbitrary applied voltage.
- For this worksheet, q1 and q2 reference points (taken to be +/−electrodes) could be moved to locations along the x-axis to points of (±a,0). A voltage could then be selected, and an arbitrary scaling factor (“gain denominator”) would convert this voltage to the corresponding “b” used in eq. (4). The worksheet would then plot the resulting Cassini oval, which has a shape progression with applied voltage beginning as two circles around the electrodes that grow into irregular ellipses before converging into a single “peanut” shape that ultimately becomes an ellipse expanding from the original electrode locations.
- The Cassini oval creates a reasonable visualization that mimics the shape of numerical results for the field distribution. In order to understand which values or levels correspond to a desired electric field of interest, a calibration involving the b4 term was necessary to develop the relationship between the analytical Cassini oval and the numerical results. This was done through a backwards calibration process defined as follows:
- 1. A reference contour was selected to correlate the analytical and numerical solutions. This was chosen to be when b/a=1, forming a lemniscate of Bernoulli (the point where the two ellipses first connect, forming “∞”).
- 2. A reference electric field density value was selected to be 650 V/cm
- 3. Numerical models were developed to mimic the x-y output from the Cassini oval for scenarios where a=±0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.25, and 2.5 cm.
- 4. Models were solved using trial and error to determine which voltage yielded the electric field contour of 650 V/cm in the shape of a lemniscate of Bernoulli
- 5. The determined voltage was placed into the Cassini oval electronic worksheet for the same electrode geometry and the “gain denominator” was adjusted until the shape from the cassini oval matched that from the numerical solution.
- 6. The determined gain denominators for all values of “a” were collected and a calibration plot was made and fitted with a logarithmic trendline of:
-
Gain Denominator=595.28·ln(a)+2339;R 2=0.993 (7) - 7. The calibration trendline function shown above was incorporated back into the Cassini Oval spreadsheet. At this point, the worksheet was capable of outputting a field contour of 650 V/cm for any electrode separation distance (±a) and applied voltage (V).
- 8. The calibration function was then scaled to a desired electric field contour input. This allowed the analytical solution to solve for any electric field for any given a separation distance and voltage. Since the Laplace equation is linear, scaling should provide a good estimate for how other fields would look.
- Table 1 incorporates all the steps above to yield a single, calibrated Cassini Oval output that analytically predicts the electric field distribution; providing a quick and simple solution for the prediction of IRE (irreversible electroporation) treatment regions that may be adjusted in real-time. The inputs are the electrode location (as a given “±a” distance from the origin along the x-axis), the applied voltage to the energized electrode, and the desired electric field to visualize. The resulting output is a contour representing a threshold where the entire area within it has been subjected to an electric field≥the one selected; and thus treated by IRE. It is important to remember that the analytical solution was calibrated for an electric field contour of 650 V/cm, and thus yields an accurate approximation for this value. Other field strength contours of interest still yield reasonable results that mimic the overall shape of the electric field. Overall, the analytical solution provided yields consistently good predictions for electric field strengths, and thus, treatment regions of IRE that may be used during treatment planning or analysis.
- A similar algorithm for calibration has also been used for a bipolar electrode and the electric field contour has been mapped its length. For example,
FIG. 4 illustrates an exemplary bipolar electrode. - In one example, the diameter of the probe is 0.065 cm, and the lengths of the two electrodes are respectively 0.295 cm and 0.276 cm, separated by an insulation sleeve of 0.315 cm in length. Adapting this scenario to the cassini oval presents some challenges because the distribution is now resulting from the two exposed cylinder lengths, rather than two distinct loci of points. This was solved by calibrating individual electric field contours for the same applied voltage and developing two equations that adjust the separation distance (±a) and gain denominator (GD) according to the equations:
-
a=7*10−9 *E 3−2*10−5 *E 2+0.015*E+6.1619;R 2=0.9806 (8) -
GD=1.0121*E+1920;R 2=0.9928 (9) - where E is the electric field magnitude contour desired.
- These two equations may then be used to calibrate the cassini ovals into a satisfactory shape to mimic the electric field distribution, and thus treatment region accordingly.
- Another closed loop method determines the E-field values (electric field density) for any x and y position on the grid based on the position of the probes, the diameter of the probes, and the voltage applied between the probes. To obtain the potential, temperature or field distribution, one can determine the analytical solution for a configuration.
- Since the solution to the Laplace Equation is linear, analytical solutions can be scaled and super-imposed to determine the entire distribution. For example, if two electrodes are energized and two electrodes are set to ground, the solution can be determined by adding the solutions for the two-needle electrode configuration together.
- For example, for a two-needle electrode configuration, the solution is an infinite series. This can be approximated using the following equation:
-
where, -
d=√{square root over ((x 2 −x 1)2+(y 2 −y 1)2)} (11) -
| r − r 1 |=√{square root over ((x−x 1)2+(y−y 1)2)} (12) -
| r − r 2 |=√{square root over ((x−x 2)2+(y−y 2)2)} (13) - Vo=the applied Voltage (V) between the probes
- a=diameter of each of the probes in meters
- d=distance between the probes in meters
- (x1, y1)=the position of the first probe
- (x2, y2)=the position of the second probe
- The user can then select a contour line in V/cm (i.e. 650 V/cm) based on the type of tissue which is being treated. This contour line can be used to therefore plot a boundary line of the treatment zone between two probes.
- (x1, y1)=(−0.005 m, 0 m)
- (x2, y2)=(0.001 m, 0.003 m)
- Vo=1000V
- a=0.0010 m
- d=0.006708 m
- Using eqs. (10-13) above, the E-field values are determined for x, y coordinates on the grid, as shown in the spreadsheet at
FIG. 16 . - This method can also be used to determine the E-field values for devices having two plate electrodes or two concentric cylinders.
- As an alternate method of estimating the treatment zone in real time, a predetermined set of values that define the outer boundary of a plurality of predetermined treatment zones (determined by FEA, one of the above two methods or the like) can be stored in memory as a data table and interpolation can be used to generate an actual treatment zone for a particular treatment area (e.g., tumor area).
- Interpolation is commonly used to determine values that are between values in a look up table. For example if a value half way between 5 and 10 in the first row of the lookup table (see Table 3 below) needs to be determined, a single interpolation (average of 5 and 10) is done to obtain 7.5. If a value between 15, 20, 25, and 30 needs to be determined, a double interpolation is done. A first interpolation is done between 15 and 20 to obtain 17.5 and between 25 and 30 to obtain 27.5. Then, a second interpolation is done between 17.5 and 27.5 to obtain 22.5.
-
TABLE 3 1 5 7.5 10 11 15 17.5 20 22.5 21 25 27.5 30 - It is to be noted that the interpolation is not limited to finding the mid point between two points. Interpolation can be done on any point between two points. For example, interpolation can be done at 15% (i.e., 15% away from one point and 85% away from the other point) and 75% (i.e., 75% away from one point and 25% away from the other point).
- Numerical techniques, such as Finite Element Analysis (FEA) which was described above, Finite Difference Methods, or Boundary Element Methods can be used to generate shapes that take into account multiple variables (applied voltage, electrode separation, desired field boundary, tissue specific constants, and the like). These shapes can be stored in a multidimensional array (i.e., a multi-dimensional lookup table) in either polar or Cartesian coordinates. When a specific treatment situation occurs, an interpolation between the known shapes as represented by the lookup table can be used to generate an estimate of an estimated treatment zone.
- For example,
FIG. 17 illustrates a multi-dimensional lookup table and a method of interpolating treatment zones. The multi-dimensional lookup table includes for each predetermined treatment zone a table or array of points that represent a particular treatment zone. For example, the top left corner ofFIG. 17 illustrates a lookup table for a predetermined treatment zone for 1 cm radius tumor area at 1700 Volts/cm electric field density for a pair of electrodes. - To treat a 1.75 cm radius tumor area at 1700 Volts/cm electric field density, the contour of the treatment zone is estimated by interpolating between two nearby zones (i.e., one for 1.5 cm radius tumor area at 1700 Volts and one for 2.0 cm radius tumor area at 1700 Volts).
- To treat a 1.75 cm radius tumor area at 2150 Volts/cm electric field density, the contour of the treatment zone is estimated by double interpolation. First, the treatment zones for 1.75 cm, 2000 Volts and 0.175 cm at 2300 Volts are determined. Then, the treatment zone for 1.75 cm at 2150 Volts is determined based on the interpolation results (i.e., estimated zone for 1.75 cm at 2000 Volts and estimated zone for 1.75 cm at 2300 Volts).
- Now referring to
FIG. 18 , this figure illustrates an automatic probe placement feature of thetreatment control module 54. If the user clicks on the “Autoset Probes”button 240 with thepointing device 14, thetreatment control module 54 will automatically position theprobes target tissue 300.FIG. 18 illustrates the position of theprobes button 240 has been depressed with thepointing device 14. - The automatic placement feature of the
treatment control module 54 is further discussed below. This feature is carried out by the following algorithm. The algorithm functions to most efficiently place a given number of probes, which is based on the type of device which is selected inFIGS. 4-9 as discussed above (ranging from 2 to 6 probes,) in an optimal pattern to cover the defined treatment area (i.e., the combinedtarget tissue 300 and the safety margin 301). The algorithm assumes that the combinedtarget tissue 300 andsafety margin 301 form a generally elliptical shape. This elliptical shape is determined from the dimensions of the target tissue zone (length and width), together with the desired safety margin which were inputted by the user (seeFIG. 3 ). - The algorithm uses the following formulas to calculate the most efficient placement of each of the probes on the
grid 200. The algorithm calculates the (xi,yi) location of each probe i on thegrid 200, relative to (0,0) origin, using the following two formulas: -
x i=εj *a*cos(θi+φ) (14) -
y i=εj *b*sin(θi+φ), (15) - where, a=the major axis of the elliptical shape (cm) that is selected at
FIG. 3 ; - b=the minor axis of the elliptical shape (cm) that is selected at
FIG. 3 ; - and;
- φ=the rotational angle (degrees) of the ellipse as shown on treatment screen (see
input box 251 atFIG. 11 ) - θi=the angular offset (degrees) for each probe according to Table 2.1 below:
-
TABLE 2.1 Total number Angular Offsets (θi) for each probe, of probes referenced from zero degrees (positive in the device x-axis) of the grid 2 probes 0° and 180° 3 probes 90°, 210°, and 330° 4 probes 45°, 135°, 225°, and 315° 5 probes 90°, 162°, 234°, 306°, and 18° 6 probes 90°, 162°, 234°, 306°, and 18° PLUS the 6th probe at the center of the grid (0, 0) - εj=the ratio of (the probe placement radius) to (the total radius to the edges of the target tissue), according Table 2.2 below:
-
TABLE 2.2 Total number of probes Probe placement in the device ratios (εj) 2 probes ε2 = 0.70 3 probes ε3 = 0.70 4 probes ε4 = 0.65 5 probes ε5 = 0.65 6 probes ε6 = 0.65
The above algorithm is based on the following assumptions: -
- Treatment zone center is at (0,0) or will be translated to (0,0) for calculations.
- Treatment zone area may or may not be adequately covered depending on size and number of probes to be deployed.
- A fixed angular array of probe placements is used, with the exception of 6 probes in which the last probe is placed in the center of the target tissue at (0,0). (see Table 2.1)
- A predetermined firing sequence is used according to the total number of probes. (see Table 2.3 below)
- An array of εj for j=2, 3, . . . 6 is used to determine the ratio of the probe placement radius from the edges of the target tissue. (see Table 2.2) The εj numbers are determined empirically for best-fit. Alternatively, these values can be represented as functions rather than fixed numerical values for each number of probes.
- A default electric field density between probes is 1500 volts/cm which can be changed by the user. The actual voltage value between probes is adjusted based on the default electric field density. For example, if the default is set at 1500 volts/cm, the actual treatment voltage for a pair of probes that are 1.5 cm apart is 2250V.
-
TABLE 2.3 Total number Firing Sequence of Probe Treatment of probes Pairs, identified by polarity and in the device specific probe number 2 probes (1 treatment pair) (+) 1, (−) 2 3 probes (3 treatment pairs) (+) 1, (−) 2 (+) 2, (−) 3 (+) 3, (−) 1 4 probes (5 treatment pairs) (+) 1, (−) 2 (+) 2, (−) 3 (+) 3, (−) 4 (+) 4, (−) 1 (+) 2, (−) 4 5 probes (8 treatment pairs) (+) 1, (−) 2 (+) 2, (−) 3 (+) 3, (−) 4 (+) 4, (−) 5 (+) 5, (−) 1 (+) 2, (−) 5 (+) 1, (−) 3 (+) 4, (−) 1 6 probes (10 treatment pairs) (+) 1, (−) 2 (+) 2, (−) 3 (+) 3, (−) 4 (+) 4, (−) 5 (+) 5, (−) 1 (+) 1, (−) 6 (+) 6, (−) 2 (+) 3, (−) 6 (+) 6, (−) 4 (+) 5, (−) 6 - A device having 3 probes is used to treat a target tissue where:
- a=2.0 cm; b=1.0 cm; and φ=0 degrees
- Using Table 2.1, θ1=90°, θ2=210°, and θ3=330°
- Using Table 2.2, ε3=0.70
- Therefore, when using the “Autoset Probes” feature, and eqs. (14) and (15) above, the (x,y) locations on the grid for each probe are calculated as follows:
-
x 1=εj *a*cos(θi+φ)=0.70*2.0 cm*cos(90 degrees)=0 -
y 1=εj *b*sin(θi+φ)=0.70*1.0 cm*sin(90 degrees)=0.70cm Probe # 1 -
x 2=εj *a*cos(θi+φ)=0.70*2.0 cm*cos(210 degrees)=−1.21 cm -
y 2=εj *b*sin(θi+φ)=0.70*1.0 cm*sin(210 degrees)=−0.35cm Probe # 2 -
x 3=εj *a*cos(θi+φ)=0.70*2.0 cm*cos(330 degrees)=1.21 cm -
y 3=εj *b*sin(θi+φ)=0.70*1.0 cm*sin(330 degrees)=−0.35cm Probe # 3 - Using Table 2.3, the firing sequence and respective polarity of the three probes will proceed as follows:
- (3 treatment pairs)
-
- (+)
Probe # 1, (−)Probe # 2 - (+)
Probe # 2, (−)Probe # 3 - (+)
Probe # 3, (−)Probe # 1
- (+)
- In another embodiment, the automatic probe placement feature can be executed by the
treatment control module 54 to reposition the probes on thegrid 200 according to distance measurements which are taken from the actual position of the probes after they have been inserted into the patient. - The user is allowed to enter any or all specific distance measurements taken between any pairs of treatment probes, and may also specify which probes may be repositioned on the
grid 200 by thetreatment control module 54 and which may not. Thetreatment control module 54 then finds the minimal error in the positions of the probes that best match the positions seen on the imaging software by the user. - It is very difficult with several probes to place them exactly on the
treatment grid 200 at the proper distances that are measured on a CT or similar scan. Often times, two, three, or four probes should be moved or rotated as a group to maintain proper distances between the other probes on thetreatment grid 200. This can be a frustrating, time-consuming, and error-prone method of ensuring that the probe locations on thetreatment grid 200 mirror the actual probe locations in the patient's body. The positions and distances of the probes are critical in treatment planning and delivery. Furthermore, in one embodiment, the probes may only be placed at exact 1 mm locations on thetreatment grid 200 so that they can easily be moved to “snap” to thegrid 200, which makes the optimal placements of the individual probes even more difficult. - The main code of the software for this feature involves a “solver” algorithm which performs an iterative search based on the starting positions of the probes and the distances desired as input by the user. Some probes may be specified as “Locked” meaning that their positions are fixed relative to the
grid 200. The solver moves all probes in a 1 mm×1 mm array in all possible positions and calculates the root mean square (RMS) error of the distances between the new probe locations and the desired probe locations on thegrid 200. The probe positions within each probes' bounding 1 mm box that offer the minimum RMS error to the total solution are taken as the “next” iteration of the algorithm. The solver then takes this new location and re-iterates to find a new, better set of positions on thegrid 200. The iterations continue until no improvement in the RMS error of the solution is found, at which point the solver quits and returns the optimal new positions that were found. - This distance placement feature will be used by the user to directly input the probe distances and cause the optimal positions of the probes based on these distances to be displayed on the
treatment grid 200 with a minimum of effort and error. This will allow better treatment planning and better treatments. The distance placement feature works best when the user places the probes in “approximately” the correct starting positions on thegrid 200 before running the solver algorithm. - This distance placement feature is illustrated by way of an example which is shown in
FIGS. 19-22 .FIG. 19 illustrates fiveprobes grid 200 by a user to plan the treatment of the target tissue on the “Probe Placement Process” screen. Next, the user actually inserts the five probes into the patient according to the planned locations. However, it is very difficult to actually physically place the probes at the exact same respective locations shown on thegrid 200. For example, certain anatomical structures of the patient may prevent the optimal placement of the probes, e.g., the location of the target tissue with respect to the location of the patient's ribs, etc. After the user has placed the five probes in the patient, distance measurements are taken as shown inFIG. 20 . These measurements represent the actual position of the five probes in the patient. One way to measure the distances between probes is to use theimaging device 30 such as a ultrasonic imaging device which allows the user to select any two point on thedisplay device 31 to automatically measure the distance as is well-known in the art. - Next, the user clicks on a “Probe Distance Adjuster” button or the like on the screen.
FIG. 21 illustrates an example of a pop-upwindow 333 that appears which includes input boxes for entering the measurement distances taken by the user. As discussed above, the user can select which probes to “lock” on thegrid 200, which will fix the location of those probes relative to thegrid 200. In the present example, the user has “Locked” the position of the second probe (labelled #2) 202. After the measurement distances have been inputted into the pop-upwindow 333, the user clicks on the “OK” button to execute this automatic probe placement feature. - The
treatment control module 54 then automatically adjusts the placement of the probes on thegrid 200 which have not been “Locked” to best match the distance measurements taken.FIG. 22 shows the placement of the fiveprobes grid 200 after the program has been executed. - Referring back to the example shown in
FIG. 18 , the combinedtreatment region 315 does not fully cover thesafety margin 301 by using a four probe device in the example.FIG. 18 illustrates the four probe device after the “Autoset Probes” button has been depressed. It should be noted that at any time, the user may move any of the probes in thegrid 200. When a probe is moved on thegrid 200, thetreatment control module 54 automatically updates the voltage (treatment energy level) calculation incolumn 222 based on the distance between the probes and continuously displays the distance between the probe being moved and the other probes (seeFIG. 12 ). Thetreatment control module 54 also automatically recalculates the size andboundary line 320 of the treatment zones in real time when a probe is moved on thegrid 200. Also, when the maximum voltage is achieved (e.g. 3000 Volts), that number as well as its corresponding distance value are highlighted (in different color, for example, relative to the other voltage values and distance values) incolumn 222 to alert the user. -
FIG. 26 illustrates thesame target tissue 300 being treated by a six probe device after the “Autoset Probes” button has been depressed. The six probe device does a better job at covering theentire safety margin 305 surrounding thetarget tissue 300. With the six probe device, more rows of data appear inwindow 270 than compared with the four probe device discussed above because additional treatment pairs are executed. Because of the additional probes, the distance is smaller between respective probes to cover a similar ablation area. This is reflected incolumn 226 ofwindow 270. This is also reflected incolumn 222 ofwindow 270 which displays the voltage generated during each step of treatment. As discussed earlier, the example assumes that the maximum capability of thegenerator 10 is 3000 Volts. It is preferred to stay below the maximum capability of the generator if possible.Column 222 shows that with the six probe device the power delivered during each step is below 3000 Volts. - The
treatment control module 54 allows a user to manually edit some of the numbers inwindow 270 in order to tailor the treatment. To edit the numbers inwindow 270, the user first clicks on the “Edit”icon 281 with thepointing device 14, as shown inFIG. 18 . After clicking on the “Edit”icon 281, in one embodiment thetreatment control module 54 can change the colors of the particular boxes inwindow 270 which are able to be edited. For example, as shown inFIG. 23 , thetreatment control module 54 can display the boxes which are able to be edited (columns columns 222, 226) in a grey color. Once the user has determined which box(es) to edit, the data in an individual box can be edited by clicking on that particular box with thepointing device 14. After the box has been clicked with thepointing device 14, the value can be edited by either manually deleting and typing in new data with thekeyboard 12, or by adjusting the number up or down by clicking on the up arrow or down arrow that appears in the box with thepointing device 14. - In the example shown in
FIG. 23 , the Volts/cm between probes “1” and “2” has been adjusted down from 1500 Volts/cm to 1000 Volts/cm. If a change is made to the data inwindow 270 which would affect the shape of the combinedtreatment zones 305, then thetreatment control module 54 automatically adjusts the depiction of thetreatment zones 305 shown ingrid 200 to reflect this. In the example shown inFIG. 23 , the area of the projected combinedtreatment region 305 has been diminished between probes “1” and “2” as shown. The ability to edit the treatment parameters as described can be particularly useful to a user in certain situations. For example, a user can edit the treatment parameters in order to avoid areas that should be preserved, such as a location of a nerve or the like. Once the user has completed making any edits of the boxes inwindow 270, if any, the edits are saved to thetreatment control module 54 by clicking on the “Apply”icon 282 with thepointing device 14. - The
treatment control module 54 allows a user to manually add additional rows or delete rows from thewindow 270 in order to tailor the treatment. To add rows inwindow 270, the user first clicks on the “+”icon 283 with thepointing device 14, as shown inFIG. 24 . After clicking on the “+”icon 283, an additional row will appear at the bottom of the list inwindow 270, which will indicate an additional pair of probes in which treatment will occur. In the example shown inFIG. 24 , an additional row has been added which indicates that treatment will occur between probe “1” and probe “3”. Referring to thegrid 200, this additional treatment pair indicates the diagonal treatment across the target tissue. It should be noted that a diagonal treatment was already present between probe “2” and probe “4” as indicated inwindow 270. However, by adding an additional diagonal treatment, overlapping with the other treatment zones, in combination with other edits to the boxes inwindow 270, as described above, the user can tailor the shape of the combinedtreatment region 305. Whenever a row is added or deleted, thetreatment control module 54 automatically updates the anticipated combined treatment zone displayed ingrid 200. By comparing thegrid 200 inFIG. 23 to thegrid 200 inFIG. 24 , the effect of adding the additional treatment row between probe “1” and probe “4” can be visually understood and appreciated. To delete rows inwindow 270, the user first selects which row is to be deleted by clicking to the left of the selected row with thepointing device 14. Next, the user clicks on the “-”icon 284 with thepointing device 14, as shown inFIG. 24 , thereby deleting the selected row fromwindow 270. - As discussed earlier, the user can select between a “Linear” or “Non-linear Lookup” for determining how the
treatment control module 54 will calculate the actual voltage (column 222) that will be applied between each pair of probes.FIG. 25 illustrates the result when the “Non-linear Lookup” circle is selected inbox 280, when compared toFIG. 18 which illustrates the same number of probes, the same probe placement, and the same Default Setting (1500 V/cm), but instead when the “Linear” circle is selected inbox 280. - After the user is satisfied with the positioning of the probes of the device and the other settings according to the features discussed above, the user clicks on the “Next” button with a
pointing device 14 to proceed to the “Pulse Generation” screen described below. -
FIG. 27 illustrates the status of the treatment before the treatment has been initiated. The following steps describe how the treatment is administered once the user has reached the “Pulse Generation” screen illustrated byFIG. 27 . - In
FIG. 27 , thetreatment control module 54 asks the user to “Click ‘Deliver test pulse’ to start” inwindow 420 in order to start the test signal (pulse) sequence. After the user presses the “Deliver test pulse”button 421 with thepointing device 14, thecontrol module 54 charges thepulse generator 10 to the test pulse voltage. When thegenerator 10 is charged, thecontrol module 54 applies a test pulse for each probe pair through thegenerator 10. For a 4 probe treatment, for example, a test pulse is applied through pairs 1-2, 1-3, 2-3, 2-4, 3-4 and 4-1 as shown inFIG. 11 . - In one embodiment, this test pulse voltage is approximately 1/10 to ⅕ the maximum treatment voltage but no lower than 200 volts and no higher than 500 volts. (It should be noted that in a preferred embodiment, valid treatment voltages are between 500 to 3000 volts.) In the embodiment shown, a test pulse of 400 volts is used for each pair of electrodes. From the test pulse, the
treatment control module 54 then checks the current through a sensor 73 (seeFIG. 29 ) for each probe pair to determine whether a treatment current will be too low (e.g., below approximately 300 milliamps) or too high (e.g., approximately 45 amps or more). Based on the current, the resistance R or conductance (1/R) of the tissue is calculated by themodule 54. Then, the voltage to be used to actually treat the tissue (seecolumn 222 inFIG. 23 , for example) is divided by the resistance to obtain the treatment current draw to be used in the treatment. - If the treatment current draw is determined to be too low (e.g., below 300 milliamps), the system will give the user the option to “Proceed to Treatment” for each pair that was too low in current. If the current is determined to be too high (e.g., 45 amps or more of threshold maximum current draw), the
control module 54 will indicate an error in thedisplay device 11 and the user should change the treatment voltage and/or re-position the mis-aligned probes to reduce the current. - The
treatment control module 54 generally applies one test pulse for every pair listed in the treatment spreadsheet although more than one pulse can be applied to each pair. For example, if the user sets up treatment between pairs (1 to 2), (1 to 3) and (2 to 3) there will be three test pulses, one for each pair. There is no therapeutic value in the test pulse. The test pulse only checks the setup before full therapeutic treatment is applied. Each test pulse is intended to ensure that two conditions are met with each test pulse: first, that there is a valid connection between the selected treatment pairs, and second, that the current will not exceed the maximum output capability of the generator 10 (seeFIG. 1 ). - Another reason for the administration of a “test pulse” is to ensure that the patient is properly anesthetized. Prior to treatment, the patient is administered general anesthesia in combination with a paralytic agent. If the patient is not paralyzed with anesthesia, then a noticeable muscle contraction will occur during administration of the “test pulse”. Since the test pulse is at approximately 10% to 20% of the therapeutic level, any muscle contraction displayed by the patient is not as much as it would be if full energy was applied. The user should be trained to watch for muscle movement during the test pulse. In one embodiment, the
treatment control module 54 can display a window which asks the user to confirm that there is no muscle movement being displayed by the patient by selecting an answer with thepointing device 14. In this embodiment, thetreatment control module 54 will not continue to the next step unless the user presses a button with the pointing device to indicate that the patient did not display any muscle contraction during the test pulse. Irreversible electroporation (IRE) requires that a paralytic agent is given as well as the normal anesthesia. These agents tend to have a short half-life and it is easy for the patient to be under medicated at the time of treatment. If the patient is under-medicated, it is possible that the patient could be injured from the severe muscle contraction that would occur from a full power treatment without a muscle blockade. The energies delivered by IRE are similar to a defibrillation pulse and the muscle contraction would also be similar. - After these steps are completed, the system charges to the full therapeutic treatment voltage (as shown in window 430) and waits for instructions from the user to begin treatment. In a preferred embodiment, a user is required to press both foot pedals of a double foot pedal device (not shown) in order to activate treatment (the first pedal is used to arm the
generator 10, the second pedal is used to fire or start the treatment). This provides a type of safety check and prevents accidental activation of the treatment. For illustration purposes, the screen shown inFIG. 27 uses twobuttons button 422 with thepointing device 14 to arm the probes. Then, the user will click on the “Pulse”button 423 with thepointing device 14 to initiate the treatment. - As shown in
FIG. 28 , after the treatment has been initiated, thetreatment control module 54 controls thegenerator 10 and administers a series of pulses according to the predetermined instructions illustrated incolumns column 401 illustrates the number of pulses that have been delivered in real time until the total number of predetermined pulses has been delivered.Column 402 displays the status percentage of the treatment for each pair of electrodes. The treatment process runs until each step of the probe firing sequence has been accomplished. Audible beeps are generated during the treatment to track the operation of thegenerator 10.Window 430 displays the status of the charge of thegenerator 10 during operation.Window 286 displays the total “Pulse progress” of the treatment.Window 420 displays further details of the treatment progress. - The
treatment control module 54 can include a feature that prevents the generator from exceeding its maximum current limit by reading the current every ten pulses and reducing the voltage by a predetermined percentage (e.g., 5% or 10%) if it approaches the maximum limit of the generator. -
FIG. 29 illustrates one embodiment of a circuitry to detect an abnormality in the applied pulses such as a high current, low current, high voltage or low voltage condition. This circuitry is located within the generator 10 (seeFIG. 1 ). AUSB connection 52 carries instructions from theuser computer 40 to acontroller 71. The controller can be a computer similar to thecomputer 40 as shown inFIG. 2 . Thecontroller 71 can include a processor, ASIC (application-specific integrated circuit), microcontroller or wired logic. Thecontroller 71 then sends the instructions to apulse generation circuit 72. Thepulse generation circuit 72 generates the pulses and sends electrical energy to the probes. For clarity, only one pair of probes/electrodes are shown. However, thegenerator 10 can accommodate any number of probes/electrodes (e.g., 6 probes as shown inFIG. 4 ). In the embodiment shown, the pulses are applied one pair of electrodes at a time, and then switched to another pair. Thepulse generation circuit 72 includes a switch, preferably an electronic switch, which switches the probe pairs based on the instructions received from thecomputer 40. Asensor 73 such as a sensor can sense the current or voltage between each pair of the probes in real time and communicate such information to thecontroller 71, which in turn, communicates the information to thecomputer 40. If thesensor 73 detects an abnormal condition during treatment such as a high current or low current condition, then it will communicate with thecontroller 71 and thecomputer 40 which may cause the controller to send a signal to thepulse generation circuit 72 to discontinue the pulses for that particular pair of probes. - The
treatment control module 54 can further include a feature that tracks the treatment progress and provides the user with an option to automatically retreat for low or missing pulses, or over-current pulses (see discussion below). Also, if the generator stops prematurely for any reason, thetreatment control module 54 can restart at the same point where it terminated, and administer the missing treatment pulses as part of the same treatment. - In other embodiments, the
treatment control module 54 is able to detect certain errors during treatment, which include, but are not limited to, “charge failure”, “hardware failure”, “high current failure”, and “low current failure”. - The following discussion relates to an example of a “high current failure”. Referring to
FIG. 30 , a “high current” failure occurred during treatment between probe “1” and probe “2”. As can be seen incolumn 401, the total number of pulses that were delivered between probe “1” and probe “2” was 20 instead of 90. This is because a “high current” condition occurred sometime after the 20th pulse was delivered. Thetreatment control module 54 was able to react to this error by discontinuing the remainder of the pulses between probe “1” and probe “2”. - During treatment energy stored on capacitors acts like a constant voltage source. It is not an ideal source and there is some drift of the applied voltage but it is close. What tends to occur during IRE treatment is as the cells porate, the intracellular fluid moves to the extracellular space. Since the intra cellular fluid is more conductive than the bulk tissue the overall resistance of the system decreases. Given the approximately constant voltage source when resistance goes down current goes up (V=IR). During treatment the system constantly monitors the energy being delivered. If the voltage is too high or too low the therapy is aborted because the primary variable controlling poration is the voltage applied and the geometry the voltage is applied to. The system also monitors the current delivered and ensures that for patient safety reasons and for hardware reliability the maximum current capabilities of the system are not exceeded. Low currents are also detected as a sign of poor connection to the patient.
- Any time current flows the tissue will heat up. For IRE the system is trying to deliver as much energy as it can without significant thermal effects. If the current was allowed to run uncontrolled, then thermal damage could occur. Also the components in the system would fail at some point if the system allowed unlimited amounts of current to flow.
- After the
treatment control module 54 has completed treatment for all probe pairs,column 402 displays whether the treatment was successful for each step of the treatment process by indicating a checkmark, or other indicia, if the step was successful and a lightning bolt, or other indicia, if the step encountered an error. In the example shown inFIG. 30 , the treatment between probe “1” and probe “2” indicates a “High Current” error incolumn 402 as discussed above. Thetreatment control module 54 tracks which pairs of probes have failed and automatically asks the user whether to “Continue Procedure” (by pressing button 426) or “Stop Procedure” (by pressing button 427). In this example, then the user chooses one of the following three options. 1) Accept the treatment as is (by pressing button 427). For example, if 89 of 90 pulses were properly delivered that may be acceptable. 2) Use the automated reduce and reapply option in the treatment control module 54 (by pressing button 426). This will lower the voltage and the corresponding current and will provide some level of treatment. 3) Reposition the probes to be further apart. This will increase the resistance of the system. - If the user clicks on the “Continue Procedure”
button 426, then as shown inFIG. 31 , adialogue box 428 will automatically pop up, which asks the user whether to “Adjust voltages for high current segments?” The user answers by clicking “Yes”, “No”, or “Cancel”. If the user clicks on the “Yes” button, then thetreatment control module 54 will automatically reduce the treatment voltage by a predetermined percentage (e.g. 5% which can be set or changed by the user). If the user clicks on the “No” button, then thetreatment control module 54 will keep the treatment voltage the same. Next, thetreatment control module 54 will go back to the arm ready state. The user can then activate the treatment to re-treat only the missing pulses. This high-current detection and reapplication feature is particularly advantageous because (1) the software remembers which pairs have failed so that the user does not have to remember and (2) thetreatment control module 54 is able to accurately keep track of which pulses were unsuccessful so that only the missing pulses are re-administered. -
FIG. 32 illustrates the “Pulse Generation” screen during re-treatment for the example. Again thepulse progress bar 286 is displayed and thestatus column 402 is updated again in real time. After the re-treatment has completed, the user will verify that the status of each probe pair is complete by checkingcolumn 402. - At any time, the user can click on the “Result Graphs”
tab 500 to view the complete voltage (V) results of the treatment vs. time, and the complete current (A) results of the treatment vs. time.FIG. 33 illustrates such result graphs according to the results of the treatment from the example. - In the embodiment shown, a plurality of sets of pulses are applied, and more specifically 9 sets of 10 pulses per set are applied with each pulse having a pulse duration of 100 microseconds.
- In the illustrations of
FIGS. 33-34 , the inter pulse spacing is not to scale. The inter pulse spacing is calculated based on the pulses per minute (PPM) which was selected on the “Information” screen (seeFIG. 3 ). The time between sets of pulses is about 3.5 seconds and can be a function of how long the capacitors need to charge. In another embodiment, the time between sets of pulses is less than 3.5 seconds or is completely eliminated. - The user can click the chart to change the zoom level of the result graphs.
FIG. 34 illustrates the graph results after the user has clicked the chart to zoom in on the results. The user can further zoom in by clicking the voltage or current chart to show 10 pulses for a treatment probe pair. The graph results shown inFIGS. 33-34 are the results of a demonstration mode of thetreatment control module 54. It should be understood that during a real world treatment, the graph results would be less uniform. The shape of the pulses can also be used as an indicator of the degree of poration of the cells. -
FIG. 35 is a screen shot of a “Probe Placement Process” screen of the treatment control module showing theprobe placement grid 200 after treatment has been delivered by a four probe array. The treated area 339 is saved by themodule 54 in thememory 44 and is shown in a highlighted contrasting manner to the displayedtarget region 301 and thetreatment region 305 defined by the probes. InFIG. 35 , the treated area 339 is filled in with cross-hatched lines that are marked in any other way for distinguishing this area on thegrid 200. In one embodiment, the treated area 339 is displayed in a different color to more easily distinguish it. This feature allows a user to plan for additional treatment of thetarget tissue 300 which is surrounded by thesafety margin 301. This feature is especially useful when the target tissue (treatment target area) requires more than one round of treatment to effectively cover the entire area. - Although the present treatment method has been discussed in relation to irreversible electroporation (IRE), the principles of this invention can be applied to any other method where therapeutic energy is applied at more than one point. For example, other methods can include reversible electroporation, supraporation, RF ablation, cryo-ablation, microwave ablation, etc. “Supraporation” uses much higher voltages and currents, in comparison to electroporation, but with shorter pulse widths.
- In addition to the example parameters described above, specific electro-medical applications of this technology include reversible electroporation as well as irreversible electroporation. This could include reversible or irreversible damage to the external cell membranes or membranes of the organelles, or damage to individual cellular structures such as mitochondrion so as to affect cellular metabolism or homeostasis of voltage or ion levels. Example embodiments for reversible electroporation can involve 1-8 pulses with a field strength of 1-100 V/cm. Other embodiments altering cellular structures adversely involve generators having a voltage range of 100 kV-300 kV operating with nano-second pulses with a maximum field strength of 2,000 V/cm to and in excess of 20,000 V/cm between electrodes. Certain embodiments can involve between 1-15 pulses between 5 microseconds and 62,000 milliseconds, while others can involve pulses of 75 microseconds to 20,000 milliseconds. In certain embodiments the electric field density for the treatment is from 100 Volts per centimeter (V/cm) to 7,000 V/cm, while in other embodiments the density is 200 to 2000 V/cm as well as from 300 V/cm to 1000 V/cm. Yet additional embodiments have a maximum field strength density between electrodes of 250V/cm to 500V/cm. The number of pulses can vary. In certain embodiments the number of pulses is from 1 to 100 pulses. In one embodiment, as described herein, between about 10 pulses and about 100 pulses can be applied at about 2,000 V/cm to about 3,000 V/cm with a pulse width of about 10 μsec to about 50 μsec. After applying these pulses, a predetermined time delay of from about 1 seconds to about 10 minutes can optionally be commenced in order that intra-cellular contents and extra-cellular contents of the target tissue cells can mix. This procedure can be repeated, as necessary, until a conductivity change is measured in the tissue. Following this step, about 1 pulse to about 300 pulses of about 2,000 V/cm to about 3,000 V/cm can be applied with a pulse width of about 70 μsec to about 100 μsec to widely ablate the tissue. This last step can be repeated until a desired number of ablation pulses is delivered to the tissue, for example, in the range of about 10 pulses to about 300 pulses, more particularly, about 100 pulses. In other embodiments, groups of 1 to 100 pulses (here groups of pulses are also called pulse-trains) are applied in succession following a gap of time. In certain embodiments the gap of time between groups of pulses can be from about 0.5 second to about 10 seconds.
- Therapeutic energy delivery devices disclosed herein are designed for tissue destruction in general, such as resection, excision, coagulation, disruption, denaturation, and ablation, and are applicable in a variety of surgical procedures, including but not limited to open surgeries, minimally invasive surgeries (e.g., laparoscopic surgeries, endoscopic surgeries, surgeries through natural body orifices), thermal ablation surgeries, non-thermal surgeries, as well as other procedures known to one of ordinary skill in the art. The devices may be designed as disposables or for repeated uses.
- In yet another embodiment, the electrodes can be adapted to administer electrical pulses as necessary in order to reversibly or irreversibly electroporate the cell membranes of infectious cells located along the outer surface of an implanted medical device within a treatment zone, thereby treating a patient and sterilizing the medical device. By varying parameters of voltage, the number of electrical pulses, and pulse duration, the electrical field will either produce irreversible or reversible electroporation of the infectious cells that cover the implanted medical device. The pulse generator of the present invention can be designed to deliver a range of different voltages, currents and duration of pulses as well as number of pulses. Typical ranges include but are not limited to a voltage level of between 100-3000 volts, a pulse duration of between 20-200 microseconds (more preferably 50-100 microseconds), and multiple sets of pulses (e.g. 2-5 sets) of about 2-25 pulses per set and between 10 and -500 total pulses. The pulse generator can administer a current in a range of from about 2,000 V/cm to about 6,000 V/cm. The pulse generator can provide pulses which are at a specific known duration and with a specific amount of current. For example, the pulse generator can be designed upon activation to provide 10 pulses for 100 microseconds each providing a current of 3,800 V/cm+/−50%+/−25%, +/−10%, +/−5%. Plastic and/or other types of metallic devices can be sterilized along the outer surface of the device, as electric field lines from the electrodes can travel along the outer surface of devices. The electroporation treatment zone is defined by mapping the electrical field that is created by the electrical pulses between two electrodes.
- As illustrated in
FIGS. 36A and 36B , a method of treatinginfectious cell growth 33 on an implanted medical device, such as acartilaginous implant 35, using IRE is disclosed. Although three (3) probes are illustrated in the method, any number of suitable probes can be used to deliver the electrical pulses. When electrical pulses are administered within the irreversible parameter ranges, as described above, permanent pore formation occurs in the cellular membrane, resulting in cell death of the targetedinfectious cells 33. In another aspect, by proactively administering the electrical pulses according to a predetermined schedule,infectious cell growth 33 on an implanted medical device can be prevented altogether. Alternatively, electrical pulses may be administered within a reversible electroporation range. Temporary pores will form in the cellular membranes of infectious cells. - The
voltage pulse generator 10 can be configured to generate electrical pulses betweenelectrodes 22 in an amount which is sufficient to induce irreversible electroporation of infectious cells that may be present on or near an implanted medical device without creating a clinically significant thermal effect to the surrounding tissue or critical structures. Specifically, the electrical pulses can create permanent openings in infectious cells of smooth muscle cells, for example, thereby invoking cell death without creating a clinically significant thermal effect. Theinfectious cells 33 will remain in situ and can be subsequently removed by natural body processes. These infectious cells can be located anywhere along the implantable medical device. Research has also shown that growths of infectious cells can enhance implanted medical device-related bacteremia by providing an interface for adherence and colonization. These pathogens may then produce a “biofilm” which is impenetrable to systemic antibiotics leading to a cause of implanted medical device dysfunction, subsequent removal, and the attendant increases in morbidity and mortality. These biofilms can also lead to chronic microbial infection, inflammation, and tissue necrosis. These infections are frequently due to gram-positive bacteria, such as Staphylococcus epidermidis or Escherichia coli in the case of catheter-associated or other plastic-types of medical devices and Staphylococcus aureus in the case of metallic implants. However, other types of bacteria could be present as well, such as, but not limited to, Streptococcus Mutans, Streptococcus Mitus, Streptococcus Salivarius, and Enterobacter Aerogenes. Initial infection is always linked to the ability of the bacteria to adhere to material surfaces. At first the bacterial adhesion is reversible, but then later becomes irreversible. Over time, the individual microorganisms and bacterial matrix formation can develop a high resistance to antibiotics. - As illustrated in
FIG. 36B , as electrical pulses are delivered to the target implanted device, a series of electrical field lines can be generated. The strongest (defined as volts/cm) electrical field is nearest to theelectrodes 22 and is depicted by gradient line 9. As the distance away from theelectrodes 22 increases, the strength of the electrical field decreases.Outer gradient line 13 represents the outer perimeter of electric field gradient. As an example, anyinfectious cells 33 or other bio-film growth on the surface of the implantablemedical device 35 within theouter perimeter 13 will undergo cell death by irreversible electroporation. Because the voltage pulse generation pattern from the generator does not generate damaging thermal effect, and because the voltage pulses only ablate living cells, the treatment does not damage blood, blood vessels or other non-cellular or non-living materials such as the implantable device itself. - Referring again to
FIG. 36B , the pulse parameters that characterize the field gradient line can be adjusted to vary the treatment zone according to the location of the infectious cells growth and/or infectious cells to be destroyed. Furthermore, in some embodiments of the invention, the electrodes can be positioned at any location necessary to destroy any suchinfectious cells 33 that have grown around or on the indwelling implantedmedical device 35. For example, theelectrodes 22 can be positioned at a proximal section of the implanted device for treating infectious cells that have grown around the implanted device, at a distal section of the implanted device, or surrounding the implanted medical device. In addition, theelectrodes 22 can be positioned to destroyinfectious cells 33 that have grown near the insertion site of the implanted device. - In another aspect of the invention, by periodically administering the electrical pulses according to a predetermined schedule, infectious cell growth on the implanted device can be prevented altogether. As an example, the formation of infectious cells may occur as early as 24 hours after implanted medical device implantation. Application of electrical pulses applied to the implanted medical device at regular intervals post-implantation may be effective in preventing infectious cell growth during the implanted medical device implantation period.
-
FIG. 37 illustrates the procedural steps associated with performing irreversible or reversible electroporation treatment using any of the probe devices described herein. After theinfectious cell formation 33 has been detected and the location determined using ultrasound or fluoroscopic imaging, electrode probes 22, as illustrated inFIG. 36A , are inserted into the patient'sskin 27 such that the probes can be near or in contact with the infectious cell growth on the implanted medical device. Theprobes 22 are then positioned relative to the infectious cells' 33 location as previously described. Theelectrodes 22 can be deployed and positioned outside of the implantedmedical device 35 as shown inFIGS. 36A and 36B . Electrical connectors from each probe are connected (801) togenerator 10 using an extension cable. This completes an electrical circuit between theelectrodes 22 and thegenerator 10. Electrical pulses are applied across theelectrodes 22 in the desired pattern (802) to electroporate the smooth muscle cells of theinfectious cells 17. Electrical pulses are then applied across theelectrodes 22 creatingfield gradient lines 9 and 13, for example, as illustrated inFIG. 36B , sufficient to non-thermally electroporate the infectious cells. As illustrated inFIG. 37 , after treatment, the extension cable is disconnected from the electrical connector (805) and the probes are removed from the tissue. Non-thermal death of theinfectious cells 33 will occur within the first twenty-four hours after electroporation treatment followed by a cellular breakdown of the infectious cells. - In one embodiment, the electroporation pulses can be synchronously matched to specifically repeatable phases of the cardiac cycle to protect cardiac cellular functioning. See, for example, U.S. Patent Application No. 61/181,727, filed May 28, 2009, entitled “Algorithm For Synchronizing Energy Delivery To The Cardiac Rhythm”, which is fully incorporated by reference herein. This feature is especially useful when the electroporation pulses are delivered in a location that is near the heart. This can be especially useful if a user is attempting to treat infection near an implanted medical device such as a pacemaker.
FIG. 38 illustrates a treatment setup for a patient for synchronization of the delivery of electroporation pulses with a specific portion of the cardiac rhythm. Electrocardiogram (ECG) leads 17, 19, 21 are adapted to be attached to the patient for receiving electrical signals which are generated by the patient's cardiac cycle. The ECG leads transmit the ECG electrical signals to anelectrocardiogram unit 29. Theelectrocardiogram unit 29 can transmit this information to asynchronization device 25 which can include hardware or software to interpret ECG data. If thesynchronization device 25 determines that it is safe to deliver electroporation pulses, it sends a control signal to apulse generator 10. Thepulse generator 10 is adapted to connect to the electrical connector for delivering electroporation pulses. Each of thesynchronization device 25 andpulse generator 10 can be implemented in a computer so that they can be programmed. - The present invention affords several advantages.
Infectious cell growths 33 are destroyed without having to remove the implantedmedical device 35 from the patient. The treatment is minimally-invasive and highly efficacious. Because irreversible electroporation does not create thermal activity, the implantedmedical device 35 is not damaged by the treatment.Infectious cells growths 33 are treated quickly, and the implantedmedical devices 35 can be maintained according to a predetermined schedule to insure that they are routinely treated with IRE to remove theinfected cells 33. - Although the irreversible electroporation device and method has been described herein for use with cartilaginous implanted medical devices, it should be understood that the irreversible electroporation device can be used with any type of implanted
medical device 35, such as, but not limited to, ports, catheters, stents, artificial cartilaginous implants, orthopedic prosthetics, pacemakers, PICCs, hip implants, tooth implants, heart valves, spinal implants, and other types of plastic and/or metallic devices, to name a few. While the embodiments shown use pulses that cause IRE, persons of ordinary skill in the art will appreciate that other types of pulses can be used for the destruction of theinfectious cell growths 33. In particular, ultrashort sub-microsecond pulses (pulses of less than 1 microsecond in duration) can be used to induce apoptosis that cause damage to the intracellular structures such as a cell nucleus. - In yet another embodiment, the method of IRE treatment described herein could be used to treat one or more parts of a patient's body that are infected due to some other infection, such as, for example, gangrene. Gangrene is particularly problematic in patients with poor blood flow, such as diabetic patients, particularly in certain parts of the body, such as the extremities (i.e., hands, feet, nose, ears, etc.). Gangrene is a type of necrotizing (flesh-destroying) bacterial infection. Typically, a physician prescribes antibiotics to a patient to treat gangrene. However, poor circulation can prevent certain drugs from reaching these extremities, thereby making patients more susceptible to infection in these areas. Gangrene often spreads so quickly that it can't be stopped by antibiotics alone. In some cases, the gangrene can cause lesions in the skin. At most, antibiotics may help slow the infection and clear small, unnoticed pockets of bacteria. A surgeon may still have to debride or cut away the infected flesh and a margin around it to prevent further spread. If debridement isn't enough, amputation is the next step. During this procedure the patient is put in a hyperbaric chamber if one is available. This is a sealed metal tank pumped full of oxygen under high pressure. The pressure forces oxygen into the tissues, stopping the spread of anaerobic bacteria. All of these methods have pitfalls. For example, patients can build up a resistance to antibiotics, as described above. Surgery to excise infected flesh can be expensive, time-consuming, and most importantly, painful for the patient. As an alternative, IRE methods of treatment, as described above using any of the pulse parameters disclosed herein, could be used in such tissues to effectively kill gangrene tissue, allowing healthy tissue to regenerate, thereby eliminating the need for amputation.
- In yet another aspect, IRE could be used to treat infected cells present on the patient's tissue scaffold. A patient's own natural tissues could be used as a scaffold. The IRE electrical pulses can effectively de-cellularize the tissue scaffold in a desired target tissue zone of
infectious cells 33, while leaving the tissue scaffold intact. After IRE is performed on or near the tissue scaffold, then the patient's tissue can naturally re-cellularize onto the patient's natural tissue scaffold after IRE has been performed. This method allows vascular, neural, and other critical structures to remain intact and essentially unharmed. However, even if the IRE pulses target collateral structures, this method would still be a safe alternative to other forms of cellular ablation or decellularization such as physical, chemical, or enzymatic methods of decellularization. Such treatments can be very harsh and can degrade the tissue scaffold as well as the vasculature and neural structures. Furthermore, such methods are often insufficient by themselves to achieve decellularization alone, and often have to be combined with each other to achieve the desired result. These methods can also compromise the structure of the extracellular matrix (ECM). - In contrast, the use of IRE to decellularize infected tissue can provide a controlled, precise way to destroy cells of a tissue or organ, while leaving the underlying extracellular matrix intact, including the vascular and neural structures as well as other critical features intact. IRE can also prevent scar tissue formation as well as promote a beneficial immune response. The method could involve treating in vitro or in vivo, a tissue comprising infectious cells located on an underlying scaffold with electrical pulses of sufficient duration and power to kill infectious cells of the tissue, while leaving the extracellular matrix and other vascular and neural structures intact. As used herein, the term “intact” means a state of being whereby an element is capable of performing its original function to a substantial extent.
- In one aspect, any of the IRE methods and parameters described herein can be used to deliver electrical pulses to the infectious cells present on the tissue scaffold. Any suitable frequency of pulsing that allows for irreversible electroporation without significant thermal damage to the tissue is acceptable. In one embodiment, the
electrodes 22 described herein can be placed into or near the vicinity of the tissue scaffold to cause irreversible electroporation of the infectious cells on or near the tissue scaffold. The electrical pulses irreversibly permeabilize the membranes of the infectious cells, thereby invoking cell death. The length of time of the electrical pulses, the voltage applied, and the resulting membrane permeability are all controlled within desired ranges. The debris left by the infectious cells may be left in situ and may be removed by natural processes, such as the body's own immune or circulation system. - In another exemplary embodiment, IRE could be used to ablate cysts in the abdomen. A cyst is an overgrowth of the epithelium, comprising specialized cells that reside on the surface of tissue, such as organs and glands. Once formed, they often become detached from the point of origin and circulate, although they may also become lodged between tissue structures and cause pressure. They generally appear as sacs or lumps surrounded by a thin membrane and consist of fluid or semi-solid material. While most cysts are benign, the development of an abdominal cyst may signal an underlying disease.
- There are several types of abdominal cysts. One of the most common is an ovarian cyst, which forms on ovarian follicles. Even though most ovarian cysts are benign, they can cause pain and bleeding. Standard treatment to remove cysts involves surgical removal if they become too large. Mesenteric cysts are another type of abdominal cyst that may indicate impaired lymphatic functioning. These types of cysts develop in the mesentery, the area of the peritoneum that encompasses the gastrointestinal tract and extends from the duodenum to the rectum. In addition, these cysts may involve any of the organs of the retroperitoneum, such as the bladder and kidneys. Omental cysts generally occur in the anterior abdominal wall in the regions of the stomach and colon. These types of cysts can usually be removed without having to resection the stomach or colon. While most abdominal cysts are not dangerous, they can sometimes grow from the size of a pea to a grapefruit over time and can sometimes present complications. Abdominal cysts can also cause pain, unexplained bleeding, bowl obstruction, and distension of the stomach or other organs, should be investigated without delay. Typical treatment modalities to remove cysts include surgical measure. However, surgery can be time-consuming, painful, and expensive.
- In one aspect, IRE treatment methods, as described herein, can be used as a minimally invasive and safe procedure to ablate and remove benign abdominal cysts as well as abdominal cancer cells. IRE methods can be more efficient, cheaper, and less painful compared to surgical procedures and would leave critical structures intact, such as vascular structures, etc. Even if the collateral structures are affected, using non-thermal IRE as a treatment method for removal of abdominal cysts would provide a safe treatment alternative to thermal or surgical removal methods that can be time-consuming, costly, and painful for the patient or the use of drugs that can have harmful side effects.
- Another example of infected tissue that can be treated using IRE is infected bone, or osteomyelitis. Bone infections can be extremely difficult to treat. Typically, bone infections can be treated using surgical procedures. The bone can be accessed by variety of procedures, such as through the skin. After the bone is surgically cleaned out, the remaining bone defect(s) is treated with a large dose of antibiotics via a non-resorbable bone cement to eradicate any bacterial cells in the bone and bloodstream. After this, subsequent surgery is required for removal and replacement with a bone graft or an absorbable mix of synthetic bone substitute. After all of these bone cleaning and replacements, the bone is typically not strong enough to bear weight. Bone rebuilding techniques can involve bone grafting or bone transport. Antibiotic treatment is then administered through an intravenous catheter. These treatment procedures have the attendant disadvantages mentioned above.
- Instead of using the above-described extensive, painful, and expensive procedures, IRE can be used to treat bone infection. In one aspect, sufficient electrical pulse parameters can be selected, as described herein above, to irreversibly electroporate infected cells that are present within or along bone. In one aspect, the electrical probes described herein can be inserted into a target tissue surrounding an infected bone, and sufficient electrical pulse parameters could be selected to adequately irreversibly electroporate an infected bone. In one embodiment, an outer layer of bone could be treated to remove infected cells. When infected tissue of a bone is irreversibly electroporated, such target bone tissue could include muscle and/or vessels which could be acutely necrosed. However, in time, the critical cellular and/or vascular structures could grow back so that no long term harmful consequences would occur.
- IRE could also be used to sterilize implanted medical devices using any of methods comprising any of the electrical pulse parameters described herein. Implanted medical devices such as metallic devices could be sterilized using the device itself as a conductor. In one aspect, the metallic device could be comprised of stainless steel, cobalt-chromium-molybdenum alloys, pure titanium, or titanium alloys. The implanted medical device, functioning as a conductor, could be placed between two electrodes, for example, thereby effectively functioning as another electrode. In another embodiment, a plurality of electrodes could be used and placed surrounding the implanted medical device. A practitioner can position the electrodes a predetermined distance from the implant so that the implanted medical device can function like a return electrode. When IRE is performed, the electric field lines 9 through 13 could travel from each electrode to the outer surface of the implant, thereby allowing the implant to effectively become part of the sterilization.
- In summary, the use of IRE to sterilize such medical devices and/or treat infected tissue can be an effective alternative to RF, cryo, or other scar-prone surgical procedures. This method can be used proactively to ensure that deep-seated infection will not occur post-operatively. This would prevent tissues from being permanently scarred. This method is beneficial because after IRE is performed, healthy tissue will grow instead of scar tissue. The use of this procedure could also provide better long term results for patients and would eliminate the need to have patients endure multiple surgeries and lengthy healing times.
- The above disclosure is intended to be illustrative and not exhaustive. This description will suggest many modifications, variations, and alternatives may be made by ordinary skill in this art without departing from the scope of the invention. Those familiar with the art may recognize other equivalents to the specific embodiments described herein. Accordingly, the scope of the invention is not limited to the foregoing specification.
Claims (7)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/864,421 US20180116710A1 (en) | 2013-06-13 | 2018-01-08 | Methods of Sterilization and Treating Infection Using Irreversible Electroporation |
US17/073,039 US11957405B2 (en) | 2020-10-16 | Methods of sterilization and treating infection using irreversible electroporation |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361834471P | 2013-06-13 | 2013-06-13 | |
US14/302,678 US9895189B2 (en) | 2009-06-19 | 2014-06-12 | Methods of sterilization and treating infection using irreversible electroporation |
US15/864,421 US20180116710A1 (en) | 2013-06-13 | 2018-01-08 | Methods of Sterilization and Treating Infection Using Irreversible Electroporation |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/302,678 Continuation US9895189B2 (en) | 2009-06-19 | 2014-06-12 | Methods of sterilization and treating infection using irreversible electroporation |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/073,039 Continuation US11957405B2 (en) | 2020-10-16 | Methods of sterilization and treating infection using irreversible electroporation |
Publications (1)
Publication Number | Publication Date |
---|---|
US20180116710A1 true US20180116710A1 (en) | 2018-05-03 |
Family
ID=52111502
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/302,678 Active 2035-09-13 US9895189B2 (en) | 2009-06-19 | 2014-06-12 | Methods of sterilization and treating infection using irreversible electroporation |
US15/864,421 Abandoned US20180116710A1 (en) | 2013-06-13 | 2018-01-08 | Methods of Sterilization and Treating Infection Using Irreversible Electroporation |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/302,678 Active 2035-09-13 US9895189B2 (en) | 2009-06-19 | 2014-06-12 | Methods of sterilization and treating infection using irreversible electroporation |
Country Status (1)
Country | Link |
---|---|
US (2) | US9895189B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023034771A1 (en) * | 2021-08-30 | 2023-03-09 | Nanovis, LLC | Devices and methods for treating infected tissue |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9283051B2 (en) | 2008-04-29 | 2016-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating a treatment volume for administering electrical-energy based therapies |
US9867652B2 (en) | 2008-04-29 | 2018-01-16 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds |
EP2280741A4 (en) | 2008-04-29 | 2012-06-13 | Virginia Tech Intell Prop | Irreversible electroporation to create tissue scaffolds |
US9198733B2 (en) | 2008-04-29 | 2015-12-01 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for electroporation-based therapies |
US10245098B2 (en) | 2008-04-29 | 2019-04-02 | Virginia Tech Intellectual Properties, Inc. | Acute blood-brain barrier disruption using electrical energy based therapy |
US10702326B2 (en) | 2011-07-15 | 2020-07-07 | Virginia Tech Intellectual Properties, Inc. | Device and method for electroporation based treatment of stenosis of a tubular body part |
US11272979B2 (en) | 2008-04-29 | 2022-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
US10117707B2 (en) | 2008-04-29 | 2018-11-06 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
US11254926B2 (en) | 2008-04-29 | 2022-02-22 | Virginia Tech Intellectual Properties, Inc. | Devices and methods for high frequency electroporation |
US8992517B2 (en) | 2008-04-29 | 2015-03-31 | Virginia Tech Intellectual Properties Inc. | Irreversible electroporation to treat aberrant cell masses |
US10272178B2 (en) | 2008-04-29 | 2019-04-30 | Virginia Tech Intellectual Properties Inc. | Methods for blood-brain barrier disruption using electrical energy |
US10238447B2 (en) | 2008-04-29 | 2019-03-26 | Virginia Tech Intellectual Properties, Inc. | System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress |
US11382681B2 (en) | 2009-04-09 | 2022-07-12 | Virginia Tech Intellectual Properties, Inc. | Device and methods for delivery of high frequency electrical pulses for non-thermal ablation |
US11638603B2 (en) | 2009-04-09 | 2023-05-02 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
MX357449B (en) | 2009-05-11 | 2018-07-10 | Triagenics Llc | Therapeutic tooth bud ablation. |
WO2014143014A1 (en) | 2013-03-15 | 2014-09-18 | Triagenics, Llc | Therapeutic tooth bud ablation |
US10022202B2 (en) | 2013-03-15 | 2018-07-17 | Triagenics, Llc | Therapeutic tooth bud ablation |
US8903488B2 (en) | 2009-05-28 | 2014-12-02 | Angiodynamics, Inc. | System and method for synchronizing energy delivery to the cardiac rhythm |
WO2012051433A2 (en) | 2010-10-13 | 2012-04-19 | Angiodynamics, Inc. | System and method for electrically ablating tissue of a patient |
WO2012088149A2 (en) | 2010-12-20 | 2012-06-28 | Virginia Tech Intellectual Properties, Inc. | High-frequency electroporation for cancer therapy |
US9078665B2 (en) | 2011-09-28 | 2015-07-14 | Angiodynamics, Inc. | Multiple treatment zone ablation probe |
US10105122B2 (en) * | 2012-08-22 | 2018-10-23 | Samsung Medison Co., Ltd. | Ultrasound diagnosis device, display device displaying ultrasound image, and method of operating ultrasound diagnosis device |
US9438264B1 (en) | 2015-09-10 | 2016-09-06 | Realtek Semiconductor Corp. | High-speed capacitive digital-to-analog converter and method thereof |
EP3137160B1 (en) * | 2014-05-02 | 2023-04-19 | Koninklijke Philips N.V. | A device for inactivating bacteria |
WO2015175570A1 (en) | 2014-05-12 | 2015-11-19 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
US10643371B2 (en) * | 2014-08-11 | 2020-05-05 | Covidien Lp | Treatment procedure planning system and method |
US10694972B2 (en) | 2014-12-15 | 2020-06-30 | Virginia Tech Intellectual Properties, Inc. | Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment |
AU2017289267B2 (en) | 2016-06-27 | 2021-08-12 | Galvanize Therapeutics, Inc. | Generator and a catheter with an electrode and a method for treating a lung passageway |
US10905492B2 (en) | 2016-11-17 | 2021-02-02 | Angiodynamics, Inc. | Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode |
US11607537B2 (en) | 2017-12-05 | 2023-03-21 | Virginia Tech Intellectual Properties, Inc. | Method for treating neurological disorders, including tumors, with electroporation |
US11925405B2 (en) | 2018-03-13 | 2024-03-12 | Virginia Tech Intellectual Properties, Inc. | Treatment planning system for immunotherapy enhancement via non-thermal ablation |
US11311329B2 (en) | 2018-03-13 | 2022-04-26 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for immunotherapy based treatments using non-thermal ablation techniques |
US20190290903A1 (en) * | 2018-03-23 | 2019-09-26 | The Board Of Regents Of The University Of Oklahoma | System and Method of Electric-Induced Acoustic Tomography for Electrotherapy Monitoring |
CN109157280A (en) * | 2018-08-10 | 2019-01-08 | 重庆大学 | Irreversible electroporated tissue ablation effect dynamic realtime assessment equipment |
US11756681B2 (en) | 2019-05-07 | 2023-09-12 | Medtronic, Inc. | Evaluation of post implantation patient status and medical device performance |
EP3979938A4 (en) | 2019-06-06 | 2023-06-28 | TriAgenics, Inc. | Ablation probe systems |
US20210344880A1 (en) * | 2020-04-30 | 2021-11-04 | Medtronic, Inc. | Post operative implantation site monitoring |
JP2023532549A (en) * | 2020-07-02 | 2023-07-28 | ガーウッド メディカル デバイシズ,リミティド ライアビリティ カンパニー | A Method for Optimizing Treatment of Infected Metallic Implants by Measuring Charge Transfer |
Family Cites Families (816)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1653819A (en) | 1926-08-07 | 1927-12-27 | Northcott Ephraim | Electrotherapeutical apparatus |
US3746004A (en) | 1971-06-14 | 1973-07-17 | B Jankelson | Disposable electrodes for electrical stimulation of muscles and nerves of the head |
US3730238A (en) | 1971-09-21 | 1973-05-01 | R Butler | Friction type screwdriver |
US3871359A (en) | 1973-06-25 | 1975-03-18 | Interscience Technology Corp | Impedance measuring system |
US4037341A (en) | 1973-08-13 | 1977-07-26 | Johns-Manville Corporation | Luminaire for lighting a sign and method |
US4016886A (en) | 1974-11-26 | 1977-04-12 | The United States Of America As Represented By The United States Energy Research And Development Administration | Method for localizing heating in tumor tissue |
DE2705734C3 (en) | 1977-02-11 | 1982-04-22 | Akzo Gmbh, 5600 Wuppertal | Dialysis membrane for hemodialysis |
US4407943A (en) | 1976-12-16 | 1983-10-04 | Millipore Corporation | Immobilized antibody or antigen for immunoassay |
CH617590A5 (en) | 1977-05-27 | 1980-06-13 | Carba Ag | |
US4299217A (en) | 1977-06-03 | 1981-11-10 | Terumo Corporation | Intravascular catheter |
DE2800039C2 (en) | 1978-01-02 | 1984-06-20 | Horst Dr.Med. 6700 Ludwigshafen Kief | Acupuncture device |
US4216860A (en) | 1978-12-11 | 1980-08-12 | Electro-Catheter Corporation | Medical device container and method of manufacture |
US4469098A (en) | 1978-12-18 | 1984-09-04 | Davi Samantha K | Apparatus for and method of utilizing energy to excise pathological tissue |
US4336881A (en) | 1979-06-14 | 1982-06-29 | Diachem, Inc. | Aqueous acid concentrate for hemodialysis dialysate |
US4278092A (en) | 1979-07-05 | 1981-07-14 | American Hospital Supply Corporation | Peritoneal catheter |
US4406827A (en) | 1979-09-04 | 1983-09-27 | Minnesota Mining And Manufacturing Company | Cohesive nonsticky electrically conductive gel composition |
GB2068735B (en) | 1980-01-16 | 1983-08-10 | Kubota Y | Device for determining location of the tip of catheter and pathological condition in the thorax |
US4756838A (en) | 1980-02-21 | 1988-07-12 | Veltman Preston Leonard | Preparation of dry dialysate products |
CA1148819A (en) | 1980-05-08 | 1983-06-28 | Gabor Zellerman | Peritoneal catheter |
US4311148A (en) | 1980-05-19 | 1982-01-19 | Mitchell V. Kaminski, Jr. | Micro-jejunostomy feeding tube |
US4489535A (en) | 1980-10-02 | 1984-12-25 | Veltman Preston Leonard | Materials and method for preparing dialysis solutions containing bicarbonate ions |
US4447235A (en) | 1981-05-07 | 1984-05-08 | John M. Clarke | Thoracentesis device |
US4416276A (en) | 1981-10-26 | 1983-11-22 | Valleylab, Inc. | Adaptive, return electrode monitoring system |
US5385544A (en) | 1992-08-12 | 1995-01-31 | Vidamed, Inc. | BPH ablation method and apparatus |
US5370675A (en) | 1992-08-12 | 1994-12-06 | Vidamed, Inc. | Medical probe device and method |
CA1244889A (en) | 1983-01-24 | 1988-11-15 | Kureha Chemical Ind Co Ltd | Device for hyperthermia |
US4580572A (en) | 1983-06-01 | 1986-04-08 | Bio-Stimu Trend Corp. | Garment apparatus for delivering or receiving electric impulses |
US4512765A (en) | 1983-06-09 | 1985-04-23 | Rudolph Muto | Selective tracheal bronchial catheter |
US4672969A (en) | 1983-10-06 | 1987-06-16 | Sonomo Corporation | Laser healing method |
GB8408529D0 (en) | 1984-04-03 | 1984-05-16 | Health Lab Service Board | Concentration of biological particles |
US4636199A (en) | 1984-07-09 | 1987-01-13 | Victor Lyle D | Device for inserting a catheter within the intercostal space |
CA1245931A (en) | 1984-09-21 | 1988-12-06 | Sophia Pesotchinsky | Positionable tissue interfacing device for the management of percutaneous conduits |
US4772269A (en) | 1985-05-01 | 1988-09-20 | Curators Of The University Of Missouri | Peritoneal dialysis catheter |
US4687471A (en) | 1985-05-01 | 1987-08-18 | Curators Of The University Of Missouri | Peritoneal dialysis catheter |
USD294519S (en) | 1985-07-29 | 1988-03-01 | Peter LaHaye | Instrument for tattooing |
NL8502382A (en) | 1985-08-30 | 1987-03-16 | Martinus Jacobus Antonius Joha | CATHETER SUITABLE FOR MULTIPLE PURPOSES. |
US4976709A (en) | 1988-12-15 | 1990-12-11 | Sand Bruce J | Method for collagen treatment |
US4946793A (en) | 1986-05-09 | 1990-08-07 | Electropore, Inc. | Impedance matching for instrumentation which electrically alters vesicle membranes |
JPS6346171A (en) | 1986-06-06 | 1988-02-27 | 旭光学工業株式会社 | Support of medical device stayed in living body |
US4716896A (en) | 1986-08-01 | 1988-01-05 | Ackrad Laboratories | Bronchial catheter |
US4840172A (en) | 1986-09-04 | 1989-06-20 | Augustine Scott D | Device for positioning an endotracheal tube |
US4723549A (en) | 1986-09-18 | 1988-02-09 | Wholey Mark H | Method and apparatus for dilating blood vessels |
US4987895A (en) | 1986-10-06 | 1991-01-29 | Heimlich Henry J | Tracheal tube |
US4886502A (en) | 1986-12-09 | 1989-12-12 | Thermedics, Inc. | Peritoneal access catheter |
US4813929A (en) | 1987-02-19 | 1989-03-21 | Neal Semrad | Chest tube device and method of inserting device |
US5098843A (en) | 1987-06-04 | 1992-03-24 | Calvin Noel M | Apparatus for the high efficiency transformation of living cells |
US4836204A (en) | 1987-07-06 | 1989-06-06 | Landymore Roderick W | Method for effecting closure of a perforation in the septum of the heart |
US4863426A (en) | 1987-08-18 | 1989-09-05 | Ferragamo Michael C | Percutaneous venous catheter |
US4819637A (en) | 1987-09-01 | 1989-04-11 | Interventional Therapeutics Corporation | System for artificial vessel embolization and devices for use therewith |
US4822470A (en) | 1987-10-09 | 1989-04-18 | Baylor College Of Medicine | Method of and apparatus for cell poration and cell fusion using radiofrequency electrical pulses |
US5389069A (en) | 1988-01-21 | 1995-02-14 | Massachusetts Institute Of Technology | Method and apparatus for in vivo electroporation of remote cells and tissue |
US5749847A (en) | 1988-01-21 | 1998-05-12 | Massachusetts Institute Of Technology | Delivery of nucleotides into organisms by electroporation |
EP0398960B1 (en) | 1988-01-21 | 1995-12-06 | Massachusetts Institute Of Technology | Transport of molecules across tissue using electroporation |
US4886496A (en) | 1988-02-04 | 1989-12-12 | Conoscenti Craig S | Bronchoscopic balloon tipped catheter and method of making the same |
DE3812754C1 (en) | 1988-04-16 | 1989-04-27 | Rudolf Schoen | |
US5186800A (en) | 1988-04-18 | 1993-02-16 | Bio-Rad Laboratories, Inc. | Electroporation of prokaryotic cells |
DE8805477U1 (en) | 1988-04-26 | 1988-07-07 | Muti, Arturo, Dr., 4000 Duesseldorf, De | |
US4919148A (en) | 1988-06-13 | 1990-04-24 | Muccio Philip E | Apparatus and method for transcutaneous electrical stimulation |
EP0346513A1 (en) | 1988-06-15 | 1989-12-20 | Etama Ag | Assembly for electrotherapy |
US4921484A (en) | 1988-07-25 | 1990-05-01 | Cordis Corporation | Mesh balloon catheter device |
US4885003A (en) | 1988-07-25 | 1989-12-05 | Cordis Corporation | Double mesh balloon catheter device |
US4920978A (en) | 1988-08-31 | 1990-05-01 | Triangle Research And Development Corporation | Method and apparatus for the endoscopic treatment of deep tumors using RF hyperthermia |
US4889634A (en) | 1988-10-04 | 1989-12-26 | Gynex, Inc. | Dialysate solution containing hydroxypropyl-beta-cyclodextrin and method of using same |
US5564417A (en) | 1991-01-24 | 1996-10-15 | Non-Invasive Technology, Inc. | Pathlength corrected oximeter and the like |
ES2012944A6 (en) | 1989-01-09 | 1990-04-16 | Tomas Justribo Jose Ramon | A device for the administration of medication by iontopheresis for local - regional treatment. |
US5290263A (en) | 1989-02-02 | 1994-03-01 | Regents Of The University Of Minnesota | Bidirectional check valve catheter |
CS275292B2 (en) | 1989-02-22 | 1992-02-19 | Cvut Fakulta Elektrotechnick | Private rehabilitation apparatus with ion transcutaneous acceleration |
US5071558A (en) | 1989-08-11 | 1991-12-10 | Nikkiso Co., Ltd. | Sodium bicarbonate dialysate |
US4986810A (en) | 1989-09-01 | 1991-01-22 | Neal Semrad | Toggle catheter |
CA2025907A1 (en) | 1989-09-21 | 1991-03-22 | Franklin D. Collins | Method of transporting compositions across the blood brain barrier |
US5137517A (en) | 1989-11-28 | 1992-08-11 | Scimed Life Systems, Inc. | Device and method for gripping medical shaft |
DE3943412A1 (en) | 1989-12-30 | 1991-07-11 | Braun Melsungen Ag | TRANSCUTANE IMPLANT CATHETER |
US5209723A (en) | 1990-01-08 | 1993-05-11 | The Curators Of The University Of Missouri | Multiple lumen catheter for hemodialysis |
US5405320A (en) | 1990-01-08 | 1995-04-11 | The Curators Of The University Of Missouri | Multiple lumen catheter for hemodialysis |
DE4000893A1 (en) | 1990-01-15 | 1991-07-18 | Bosch Gmbh Robert | Multichannel appts. for electro-simulation - provides several current circuits for patient with electrodes applying pulse signals |
US5391144A (en) | 1990-02-02 | 1995-02-21 | Olympus Optical Co., Ltd. | Ultrasonic treatment apparatus |
US5031775A (en) | 1990-02-14 | 1991-07-16 | Angeion Corporation | Medical instrument holder |
USD329496S (en) | 1990-02-20 | 1992-09-15 | Celia Clarke | Needle depth gauge |
US5053013A (en) | 1990-03-01 | 1991-10-01 | The Regents Of The University Of Michigan | Implantable infusion device |
US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
US5122137A (en) | 1990-04-27 | 1992-06-16 | Boston Scientific Corporation | Temperature controlled rf coagulation |
US5134070A (en) | 1990-06-04 | 1992-07-28 | Casnig Dael R | Method and device for cell cultivation on electrodes |
US5193537A (en) | 1990-06-12 | 1993-03-16 | Zmd Corporation | Method and apparatus for transcutaneous electrical cardiac pacing |
US5190541A (en) | 1990-10-17 | 1993-03-02 | Boston Scientific Corporation | Surgical instrument and method |
US5052391A (en) | 1990-10-22 | 1991-10-01 | R.F.P., Inc. | High frequency high intensity transcutaneous electrical nerve stimulator and method of treatment |
US5186715A (en) | 1990-12-06 | 1993-02-16 | E-Z-Em, Inc. | Biliary drainage method |
US6394973B1 (en) | 1990-12-14 | 2002-05-28 | Robert L. Cucin | Power-assisted liposuction instrument with cauterizing cannula assembly |
US5439444A (en) | 1991-01-28 | 1995-08-08 | Corpak, Inc. | Pre-formed member for percutaneous catheter |
US5308325A (en) | 1991-01-28 | 1994-05-03 | Corpak, Inc. | Retention balloon for percutaneous catheter |
US5192312A (en) | 1991-03-05 | 1993-03-09 | Colorado State University Research Foundation | Treated tissue for implantation and methods of treatment and use |
US5188592A (en) | 1991-06-24 | 1993-02-23 | Hakki Sam I | Dynamic pressurized catheter with simultaneous oxygen delivery and suction |
US5540737A (en) | 1991-06-26 | 1996-07-30 | Massachusetts Institute Of Technology | Minimally invasive monopole phased array hyperthermia applicators and method for treating breast carcinomas |
US5990095A (en) | 1991-07-03 | 1999-11-23 | Hyal Pharmaceutical Corporation | Use of hyaluronic acid and forms to prevent arterial restenosis |
US5383917A (en) | 1991-07-05 | 1995-01-24 | Jawahar M. Desai | Device and method for multi-phase radio-frequency ablation |
US5215530A (en) | 1991-07-11 | 1993-06-01 | City Of Hope | Sleeved extension and anchoring system for percutaneous catheters |
DE9109006U1 (en) | 1991-07-22 | 1991-10-10 | Schmitz-Rode, Thomas, Dipl.-Ing. Dr.Med., 5100 Aachen, De | |
US5173158A (en) | 1991-07-22 | 1992-12-22 | Schmukler Robert E | Apparatus and methods for electroporation and electrofusion |
US5328451A (en) | 1991-08-15 | 1994-07-12 | Board Of Regents, The University Of Texas System | Iontophoretic device and method for killing bacteria and other microbes |
US5141499A (en) | 1991-10-09 | 1992-08-25 | Zappacosta Anthony R | Peritoneal dialysis catheter |
US5425752A (en) | 1991-11-25 | 1995-06-20 | Vu'nguyen; Dung D. | Method of direct electrical myostimulation using acupuncture needles |
US6004438A (en) * | 1991-12-31 | 1999-12-21 | 3M Innovative Properties Company | Biofilm reduction sterilizer |
USD343687S (en) | 1992-01-06 | 1994-01-25 | Becton, Dickinson And Company | Biopsy procedure tray |
US6142992A (en) | 1993-05-10 | 2000-11-07 | Arthrocare Corporation | Power supply for limiting power in electrosurgery |
US6210402B1 (en) | 1995-11-22 | 2001-04-03 | Arthrocare Corporation | Methods for electrosurgical dermatological treatment |
US6500173B2 (en) | 1992-01-07 | 2002-12-31 | Ronald A. Underwood | Methods for electrosurgical spine surgery |
US5697882A (en) | 1992-01-07 | 1997-12-16 | Arthrocare Corporation | System and method for electrosurgical cutting and ablation |
US6277112B1 (en) | 1996-07-16 | 2001-08-21 | Arthrocare Corporation | Methods for electrosurgical spine surgery |
US5224933A (en) | 1992-03-23 | 1993-07-06 | C. R. Bard, Inc. | Catheter purge device |
US5586982A (en) | 1992-04-10 | 1996-12-24 | Abela; George S. | Cell transfection apparatus and method |
US5281213A (en) | 1992-04-16 | 1994-01-25 | Implemed, Inc. | Catheter for ice mapping and ablation |
US5562720A (en) | 1992-05-01 | 1996-10-08 | Vesta Medical, Inc. | Bipolar/monopolar endometrial ablation device and method |
US5277201A (en) | 1992-05-01 | 1994-01-11 | Vesta Medical, Inc. | Endometrial ablation apparatus and method |
US6132419A (en) | 1992-05-22 | 2000-10-17 | Genetronics, Inc. | Electroporetic gene and drug therapy |
US5318563A (en) | 1992-06-04 | 1994-06-07 | Valley Forge Scientific Corporation | Bipolar RF generator |
US5222997A (en) | 1992-07-24 | 1993-06-29 | Montgomery David S | Parallel holder device |
US5484400A (en) | 1992-08-12 | 1996-01-16 | Vidamed, Inc. | Dual channel RF delivery system |
US5273525A (en) | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
US5242415A (en) | 1992-08-14 | 1993-09-07 | L-Vad Technology, Inc. | Percutaneous access device |
US5279564A (en) | 1992-09-11 | 1994-01-18 | Edward Weck Incorporated | Cannula retention device |
US5227730A (en) | 1992-09-14 | 1993-07-13 | Kdc Technology Corp. | Microwave needle dielectric sensors |
US5634899A (en) | 1993-08-20 | 1997-06-03 | Cortrak Medical, Inc. | Simultaneous cardiac pacing and local drug delivery method |
US5318543A (en) | 1992-10-08 | 1994-06-07 | Abbott Laboratories | Laparoscopic jejunostomy instrumentation kit |
WO1994009838A1 (en) | 1992-11-04 | 1994-05-11 | Denver Biomaterials, Inc. | Apparatus for removal of pleural effusion fluid |
US5807306A (en) | 1992-11-09 | 1998-09-15 | Cortrak Medical, Inc. | Polymer matrix drug delivery apparatus |
US5620479A (en) | 1992-11-13 | 1997-04-15 | The Regents Of The University Of California | Method and apparatus for thermal therapy of tumors |
GB9226376D0 (en) | 1992-12-18 | 1993-02-10 | British Tech Group | Tomography |
DE4242926C2 (en) | 1992-12-18 | 1994-12-15 | Fresenius Ag | Dialysis solution for peritoneal dialysis |
JP3146332B2 (en) | 1992-12-24 | 2001-03-12 | 允 石崎 | CAPD catheter |
CN1119418A (en) | 1993-02-02 | 1996-03-27 | 怀达医疗公司 | Transurethral needle ablation device and method |
USD351661S (en) | 1993-02-16 | 1994-10-18 | Ultradent Products, Inc. | Combined organizer and tray for an endodontic dental kit |
US5792187A (en) | 1993-02-22 | 1998-08-11 | Angeion Corporation | Neuro-stimulation to control pain during cardioversion defibrillation |
US5403311A (en) | 1993-03-29 | 1995-04-04 | Boston Scientific Corporation | Electro-coagulation and ablation and other electrotherapeutic treatments of body tissue |
FR2703253B1 (en) | 1993-03-30 | 1995-06-23 | Centre Nat Rech Scient | APPLICATOR OF ELECTRIC PULSES FOR TREATING BIOLOGICAL TISSUES. |
US5439440A (en) | 1993-04-01 | 1995-08-08 | Genetronics, Inc. | Electroporation system with voltage control feedback for clinical applications |
US5702359A (en) | 1995-06-06 | 1997-12-30 | Genetronics, Inc. | Needle electrodes for mediated delivery of drugs and genes |
US5462522A (en) | 1993-04-19 | 1995-10-31 | Olympus Optical Co., Ltd. | Ultrasonic therapeutic apparatus |
US5308338A (en) | 1993-04-22 | 1994-05-03 | Helfrich G Baird | Catheter or the like with medication injector to prevent infection |
US5417687A (en) | 1993-04-30 | 1995-05-23 | Medical Scientific, Inc. | Bipolar electrosurgical trocar |
US6832996B2 (en) | 1995-06-07 | 2004-12-21 | Arthrocare Corporation | Electrosurgical systems and methods for treating tissue |
US5464437A (en) | 1993-07-08 | 1995-11-07 | Urologix, Inc. | Benign prostatic hyperplasia treatment catheter with urethral cooling |
US5921982A (en) | 1993-07-30 | 1999-07-13 | Lesh; Michael D. | Systems and methods for ablating body tissue |
US5533999A (en) | 1993-08-23 | 1996-07-09 | Refractec, Inc. | Method and apparatus for modifications of visual acuity by thermal means |
US5807395A (en) | 1993-08-27 | 1998-09-15 | Medtronic, Inc. | Method and apparatus for RF ablation and hyperthermia |
US5536267A (en) | 1993-11-08 | 1996-07-16 | Zomed International | Multiple electrode ablation apparatus |
US5728143A (en) | 1995-08-15 | 1998-03-17 | Rita Medical Systems, Inc. | Multiple antenna ablation apparatus and method |
US5458597A (en) | 1993-11-08 | 1995-10-17 | Zomed International | Device for treating cancer and non-malignant tumors and methods |
US5683384A (en) | 1993-11-08 | 1997-11-04 | Zomed | Multiple antenna ablation apparatus |
US6958062B1 (en) | 1993-11-08 | 2005-10-25 | Rita Medical Systems, Inc. | Multiple antenna ablation apparatus and method |
US5334167A (en) | 1993-11-19 | 1994-08-02 | Cocanower David A | Modified nasogastric tube for use in enteral feeding |
US5487385A (en) | 1993-12-03 | 1996-01-30 | Avitall; Boaz | Atrial mapping and ablation catheter system |
US6530922B2 (en) | 1993-12-15 | 2003-03-11 | Sherwood Services Ag | Cluster ablation electrode system |
US6241725B1 (en) | 1993-12-15 | 2001-06-05 | Sherwood Services Ag | High frequency thermal ablation of cancerous tumors and functional targets with image data assistance |
US5462521A (en) | 1993-12-21 | 1995-10-31 | Angeion Corporation | Fluid cooled and perfused tip for a catheter |
US5707332A (en) | 1994-01-21 | 1998-01-13 | The Trustees Of Columbia University In The City Of New York | Apparatus and method to reduce restenosis after arterial intervention |
WO1995020348A1 (en) | 1994-01-28 | 1995-08-03 | Ep Technologies, Inc. | Matching electrical characteristics and propagation velocities to locate ablation sites |
US5391158A (en) | 1994-02-24 | 1995-02-21 | Peters; Michael J. | Nasogastric tube |
DE69532976T2 (en) | 1994-03-14 | 2005-05-04 | Cryolife, Inc. | METHOD OF MANUFACTURING TISSUE FOR IMPLANTATION |
US5458625A (en) | 1994-05-04 | 1995-10-17 | Kendall; Donald E. | Transcutaneous nerve stimulation device and method for using same |
US5836905A (en) | 1994-06-20 | 1998-11-17 | Lemelson; Jerome H. | Apparatus and methods for gene therapy |
US6405732B1 (en) | 1994-06-24 | 2002-06-18 | Curon Medical, Inc. | Method to treat gastric reflux via the detection and ablation of gastro-esophageal nerves and receptors |
US6056744A (en) | 1994-06-24 | 2000-05-02 | Conway Stuart Medical, Inc. | Sphincter treatment apparatus |
US6009877A (en) | 1994-06-24 | 2000-01-04 | Edwards; Stuart D. | Method for treating a sphincter |
US5509902A (en) | 1994-07-25 | 1996-04-23 | Raulerson; J. Daniel | Subcutaneous catheter stabilizing devices and methods for securing a catheter using the same |
US20080167649A1 (en) | 1994-08-12 | 2008-07-10 | Angiodynamics, Inc. | Ablation apparatus and method |
US5810742A (en) | 1994-10-24 | 1998-09-22 | Transcan Research & Development Co., Ltd. | Tissue characterization based on impedance images and on impedance measurements |
US5588960A (en) | 1994-12-01 | 1996-12-31 | Vidamed, Inc. | Transurethral needle delivery device with cystoscope and method for treatment of urinary incontinence |
WO1996022121A1 (en) | 1995-01-17 | 1996-07-25 | Christoph Hehrlein | Balloon catheter used to prevent re-stenosis after angioplasty and process for producing a balloon catheter |
DE69635311T2 (en) | 1995-01-30 | 2007-04-19 | Boston Scientific Corp., Natick | ELECTROCHIRUGIC TISSUE REMOVAL |
US6106524A (en) | 1995-03-03 | 2000-08-22 | Neothermia Corporation | Methods and apparatus for therapeutic cauterization of predetermined volumes of biological tissue |
US5630426A (en) | 1995-03-03 | 1997-05-20 | Neovision Corporation | Apparatus and method for characterization and treatment of tumors |
US5616126A (en) | 1995-03-03 | 1997-04-01 | Malekmehr; Farshad | Low residual bladder catheter |
US6503248B1 (en) | 2000-10-30 | 2003-01-07 | Seedling Enterprises, Llc | Cooled, non-sticking electrosurgical devices |
US5720921A (en) | 1995-03-10 | 1998-02-24 | Entremed, Inc. | Flow electroporation chamber and method |
US5647871A (en) | 1995-03-10 | 1997-07-15 | Microsurge, Inc. | Electrosurgery with cooled electrodes |
US6575967B1 (en) | 1995-03-24 | 2003-06-10 | The Board Of Regents Of The University Of Nebraska | Method and systems for volumetric tissue ablation |
US5810762A (en) | 1995-04-10 | 1998-09-22 | Genetronics, Inc. | Electroporation system with voltage control feedback for clinical applications |
US6575969B1 (en) | 1995-05-04 | 2003-06-10 | Sherwood Services Ag | Cool-tip radiofrequency thermosurgery electrode system for tumor ablation |
AU5727096A (en) | 1995-05-04 | 1996-11-21 | Eric R. Cosman | Cool-tip electrode thermosurgery system |
US6994689B1 (en) | 1995-06-05 | 2006-02-07 | Medtronic Vascular, Inc. | Occlusion of a vessel |
US6041252A (en) | 1995-06-07 | 2000-03-21 | Ichor Medical Systems Inc. | Drug delivery system and method |
US20060024359A1 (en) | 1995-06-07 | 2006-02-02 | Walker Jeffrey P | Drug delivery system and method |
US7393351B2 (en) | 1995-06-07 | 2008-07-01 | Arthrocare Corporation | Apparatus and methods for treating cervical inter-vertebral discs |
US6607529B1 (en) | 1995-06-19 | 2003-08-19 | Medtronic Vidamed, Inc. | Electrosurgical device |
US5697905A (en) | 1995-06-19 | 1997-12-16 | Leo T. d'Ambrosio | Triple-lumen intra-aortic catheter |
US5919142A (en) | 1995-06-22 | 1999-07-06 | Btg International Limited | Electrical impedance tomography method and apparatus |
US5588424A (en) | 1995-06-28 | 1996-12-31 | The Cleveland Clinic Foundation | Bronchial blocker endotracheal apparatus |
USD450391S1 (en) | 1995-07-07 | 2001-11-13 | Arrow International, Inc. | Medical instrument tray |
USD376652S (en) | 1995-07-07 | 1996-12-17 | Hunt Ilyssa A | Medical instrument tray |
USD380272S (en) | 1995-07-07 | 1997-06-24 | Becton, Dickinson And Company | Skin preparation tray |
US5983131A (en) | 1995-08-11 | 1999-11-09 | Massachusetts Institute Of Technology | Apparatus and method for electroporation of tissue |
US5863290A (en) | 1995-08-15 | 1999-01-26 | Rita Medical Systems | Multiple antenna ablation apparatus and method |
US6235023B1 (en) | 1995-08-15 | 2001-05-22 | Rita Medical Systems, Inc. | Cell necrosis apparatus |
US6059780A (en) | 1995-08-15 | 2000-05-09 | Rita Medical Systems, Inc. | Multiple antenna ablation apparatus and method with cooling element |
US5782827A (en) | 1995-08-15 | 1998-07-21 | Rita Medical Systems, Inc. | Multiple antenna ablation apparatus and method with multiple sensor feedback |
US5672173A (en) | 1995-08-15 | 1997-09-30 | Rita Medical Systems, Inc. | Multiple antenna ablation apparatus and method |
US5672174A (en) | 1995-08-15 | 1997-09-30 | Rita Medical Systems, Inc. | Multiple antenna ablation apparatus and method |
US5810804A (en) | 1995-08-15 | 1998-09-22 | Rita Medical Systems | Multiple antenna ablation apparatus and method with cooling element |
US6330478B1 (en) | 1995-08-15 | 2001-12-11 | Rita Medical Systems, Inc. | Cell necrosis apparatus |
US5735847A (en) | 1995-08-15 | 1998-04-07 | Zomed International, Inc. | Multiple antenna ablation apparatus and method with cooling element |
US6090105A (en) | 1995-08-15 | 2000-07-18 | Rita Medical Systems, Inc. | Multiple electrode ablation apparatus and method |
US5800484A (en) | 1995-08-15 | 1998-09-01 | Rita Medical Systems, Inc. | Multiple antenna ablation apparatus with expanded electrodes |
US5913855A (en) | 1995-08-15 | 1999-06-22 | Rita Medical Systems, Inc. | Multiple antenna ablation apparatus and method |
US6689127B1 (en) | 1995-08-15 | 2004-02-10 | Rita Medical Systems | Multiple antenna ablation apparatus and method with multiple sensor feedback |
AU7385596A (en) | 1995-10-02 | 1997-04-28 | Duke University | Dopamine transporter knockout mice |
US6198970B1 (en) | 1995-10-27 | 2001-03-06 | Esd Limited Liability Company | Method and apparatus for treating oropharyngeal respiratory and oral motor neuromuscular disorders with electrical stimulation |
US5807272A (en) | 1995-10-31 | 1998-09-15 | Worcester Polytechnic Institute | Impedance spectroscopy system for ischemia monitoring and detection |
US5700252A (en) | 1995-11-01 | 1997-12-23 | Klingenstein; Ralph James | Lumen-seeking nasogastric tube and method |
EP0776678A1 (en) | 1995-11-30 | 1997-06-04 | Hewlett-Packard Company | System for administering transcutaneous cardiac pacing with transcutaneous electrical nerve stimuli |
US6010613A (en) | 1995-12-08 | 2000-01-04 | Cyto Pulse Sciences, Inc. | Method of treating materials with pulsed electrical fields |
US5718246A (en) | 1996-01-03 | 1998-02-17 | Preferential, Inc. | Preferential induction of electrically mediated cell death from applied pulses |
US6090106A (en) | 1996-01-09 | 2000-07-18 | Gyrus Medical Limited | Electrosurgical instrument |
US6682501B1 (en) | 1996-02-23 | 2004-01-27 | Gyrus Ent, L.L.C. | Submucosal tonsillectomy apparatus and method |
US5830184A (en) | 1996-03-06 | 1998-11-03 | Medical Components, Inc. | Composite catheter stabilizing devices, methods of making the same and catheter extracting device |
US5645855A (en) | 1996-03-13 | 1997-07-08 | Ridge Scientific Enterprises, Inc. | Adhesive compositions including polyvinylpyrrolidone acrylic acid polymers, and polyamines |
US6016452A (en) | 1996-03-19 | 2000-01-18 | Kasevich; Raymond S. | Dynamic heating method and radio frequency thermal treatment |
US5778894A (en) | 1996-04-18 | 1998-07-14 | Elizabeth Arden Co. | Method for reducing human body cellulite by treatment with pulsed electromagnetic energy |
US6419673B1 (en) | 1996-05-06 | 2002-07-16 | Stuart Edwards | Ablation of rectal and other internal body structures |
US5690620A (en) | 1996-05-14 | 1997-11-25 | Knott; Michael Mcfarland | Anatomically conforming nasogastric tube with normally-curved tip and method for using same |
US5904648A (en) | 1996-06-18 | 1999-05-18 | Cook Incorporated | Guided endobronchial blocker catheter |
US5944710A (en) | 1996-06-24 | 1999-08-31 | Genetronics, Inc. | Electroporation-mediated intravascular delivery |
US20020040204A1 (en) | 1996-06-24 | 2002-04-04 | Dev Nagendu B. | Electroporation-enhanced inhibition of vascular neointimal hyperplasia |
SE509241C2 (en) | 1996-07-18 | 1998-12-21 | Radinvent Ab | Devices for electrodynamic radiation therapy of tumor diseases |
US6102885A (en) | 1996-08-08 | 2000-08-15 | Bass; Lawrence S. | Device for suction-assisted lipectomy and method of using same |
US6106521A (en) | 1996-08-16 | 2000-08-22 | United States Surgical Corporation | Apparatus for thermal treatment of tissue |
WO1998010745A1 (en) | 1996-09-11 | 1998-03-19 | Aksys, Ltd. | Batch quantity dialysate chemical formulations |
US5954740A (en) | 1996-09-23 | 1999-09-21 | Boston Scientific Corporation | Catheter balloon having raised radial segments |
US6004339A (en) | 1996-11-13 | 1999-12-21 | Angiodynamics Incorporated | Balloon catheter with multiple distensibilities |
JP2002516582A (en) | 1996-11-27 | 2002-06-04 | クック バスキュラー インコーポレーティッド. | Sheath for radio frequency dilator |
US8182473B2 (en) | 1999-01-08 | 2012-05-22 | Palomar Medical Technologies | Cooling system for a photocosmetic device |
US5991697A (en) | 1996-12-31 | 1999-11-23 | The Regents Of The University Of California | Method and apparatus for optical Doppler tomographic imaging of fluid flow velocity in highly scattering media |
US6029090A (en) | 1997-01-27 | 2000-02-22 | Herbst; Ewa | Multi-functional electrical stimulation system |
US6109270A (en) | 1997-02-04 | 2000-08-29 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Multimodality instrument for tissue characterization |
US7027869B2 (en) | 1998-01-07 | 2006-04-11 | Asthmatx, Inc. | Method for treating an asthma attack |
US6283988B1 (en) | 1997-04-07 | 2001-09-04 | Broncus Technologies, Inc. | Bronchial stenter having expandable electrodes |
US6411852B1 (en) | 1997-04-07 | 2002-06-25 | Broncus Technologies, Inc. | Modification of airways by application of energy |
US6634363B1 (en) | 1997-04-07 | 2003-10-21 | Broncus Technologies, Inc. | Methods of treating lungs having reversible obstructive pulmonary disease |
US5972026A (en) | 1997-04-07 | 1999-10-26 | Broncus Technologies, Inc. | Bronchial stenter having diametrically adjustable electrodes |
US6488673B1 (en) | 1997-04-07 | 2002-12-03 | Broncus Technologies, Inc. | Method of increasing gas exchange of a lung |
US6273907B1 (en) | 1997-04-07 | 2001-08-14 | Broncus Technologies, Inc. | Bronchial stenter |
US5873849A (en) | 1997-04-24 | 1999-02-23 | Ichor Medical Systems, Inc. | Electrodes and electrode arrays for generating electroporation inducing electrical fields |
US6132397A (en) | 1997-05-01 | 2000-10-17 | Chase Medical Inc. | Integral aortic arch infusion clamp catheter |
US5868708A (en) | 1997-05-07 | 1999-02-09 | Applied Medical Resources Corporation | Balloon catheter apparatus and method |
US5954745A (en) | 1997-05-16 | 1999-09-21 | Gertler; Jonathan | Catheter-filter set having a compliant seal |
US6085115A (en) | 1997-05-22 | 2000-07-04 | Massachusetts Institite Of Technology | Biopotential measurement including electroporation of tissue surface |
US6312426B1 (en) | 1997-05-30 | 2001-11-06 | Sherwood Services Ag | Method and system for performing plate type radiofrequency ablation |
US5978704A (en) | 1997-06-03 | 1999-11-02 | Uab Research Foundation | Method and apparatus for treating cardiac arrhythmia |
US5957919A (en) | 1997-07-02 | 1999-09-28 | Laufer; Michael D. | Bleb reducer |
US6096037A (en) | 1997-07-29 | 2000-08-01 | Medtronic, Inc. | Tissue sealing electrosurgery device and methods of sealing tissue |
WO1999004710A1 (en) | 1997-07-25 | 1999-02-04 | Cosman Eric R | Cluster ablation electrode system |
US6216034B1 (en) | 1997-08-01 | 2001-04-10 | Genetronics, Inc. | Method of programming an array of needle electrodes for electroporation therapy of tissue |
US6055453A (en) | 1997-08-01 | 2000-04-25 | Genetronics, Inc. | Apparatus for addressing needle array electrodes for electroporation therapy |
EP1009452A4 (en) | 1997-08-07 | 2004-03-31 | Ajay Gupta | Dialysis solutions containing water soluble vitamins and nutrients |
AU9472998A (en) | 1997-09-04 | 1999-03-22 | Science Research Laboratory, Inc. | Cell separation using electric fields |
AU1187899A (en) | 1997-10-09 | 1999-05-03 | Camran Nezhat | Methods and systems for organ resection |
US6071281A (en) | 1998-05-05 | 2000-06-06 | Ep Technologies, Inc. | Surgical method and apparatus for positioning a diagnostic or therapeutic element within the body and remote power control unit for use with same |
US5999847A (en) | 1997-10-21 | 1999-12-07 | Elstrom; John A. | Apparatus and method for delivery of surgical and therapeutic agents |
AU1114699A (en) | 1997-10-24 | 1999-05-17 | Children's Medical Center Corporation | Methods for promoting cell transfection (in vivo) |
USD442697S1 (en) | 1997-10-27 | 2001-05-22 | Mohammed Ali Hajianpour | Accessory tray for hip replacement surgery |
US5984896A (en) | 1997-10-28 | 1999-11-16 | Ojp #73, Inc. | Fixated catheter |
FR2770409B1 (en) | 1997-10-31 | 2000-06-23 | Soprane Sa | UNIVERSAL CATHETER |
TW368420B (en) | 1997-11-04 | 1999-09-01 | Genetronics Inc | Apparatus and method for transdermal molecular delivery by applying sufficient amplitude of electric field to induce migration of molecules through pores in the stratum corneum |
US6775569B2 (en) | 1997-11-05 | 2004-08-10 | Hisamitsu Pharmaceutical Co., Inc. | Electroporation device for in vivo delivery of therapeutic agents |
US6280441B1 (en) | 1997-12-15 | 2001-08-28 | Sherwood Services Ag | Apparatus and method for RF lesioning |
US6208893B1 (en) | 1998-01-27 | 2001-03-27 | Genetronics, Inc. | Electroporation apparatus with connective electrode template |
US6009347A (en) | 1998-01-27 | 1999-12-28 | Genetronics, Inc. | Electroporation apparatus with connective electrode template |
US6045551A (en) | 1998-02-06 | 2000-04-04 | Bonutti; Peter M. | Bone suture |
US6440127B2 (en) | 1998-02-11 | 2002-08-27 | Cosman Company, Inc. | Method for performing intraurethral radio-frequency urethral enlargement |
US5947284A (en) | 1998-02-13 | 1999-09-07 | United States Surgical Corporation | Package with guide for flexible medical instruments |
US6122599A (en) | 1998-02-13 | 2000-09-19 | Mehta; Shailesh | Apparatus and method for analyzing particles |
US8906010B2 (en) | 1998-02-19 | 2014-12-09 | Mederi Therapeutics, Inc. | Graphical user interface for association with an electrode structure deployed in contact with a tissue region |
AUPP229498A0 (en) | 1998-03-11 | 1998-04-09 | Oldfield Family Holdings Pty Limited | Endotracheal tube for selective bronchial occlusion |
US6068121A (en) | 1998-03-11 | 2000-05-30 | Schneider (Usa) Inc. | Universal catheter tray |
WO1999046361A1 (en) | 1998-03-12 | 1999-09-16 | Center For Advanced Science And Technology Incubation, Ltd. | Techniques for piercing specific site of cell |
GB9807303D0 (en) | 1998-04-03 | 1998-06-03 | Gyrus Medical Ltd | An electrode assembly for an electrosurgical instrument |
US7892229B2 (en) | 2003-01-18 | 2011-02-22 | Tsunami Medtech, Llc | Medical instruments and techniques for treating pulmonary disorders |
SE513814C2 (en) | 1998-03-31 | 2000-11-06 | Aditus Medical Ab | Device for the treatment of diseases with electric fields |
US6219577B1 (en) | 1998-04-14 | 2001-04-17 | Global Vascular Concepts, Inc. | Iontophoresis, electroporation and combination catheters for local drug delivery to arteries and other body tissues |
US6450989B2 (en) | 1998-04-27 | 2002-09-17 | Artemis Medical, Inc. | Dilating and support apparatus with disease inhibitors and methods for use |
US6312425B1 (en) | 1998-05-05 | 2001-11-06 | Cardiac Pacemakers, Inc. | RF ablation catheter tip electrode with multiple thermal sensors |
US6558378B2 (en) | 1998-05-05 | 2003-05-06 | Cardiac Pacemakers, Inc. | RF ablation system and method having automatic temperature control |
US6050994A (en) | 1998-05-05 | 2000-04-18 | Cardiac Pacemakers, Inc. | RF ablation apparatus and method using controllable duty cycle with alternate phasing |
US6059778A (en) | 1998-05-05 | 2000-05-09 | Cardiac Pacemakers, Inc. | RF ablation apparatus and method using unipolar and bipolar techniques |
US6171305B1 (en) | 1998-05-05 | 2001-01-09 | Cardiac Pacemakers, Inc. | RF ablation apparatus and method having high output impedance drivers |
US6493589B1 (en) | 1998-05-07 | 2002-12-10 | Medtronic, Inc. | Methods and apparatus for treatment of pulmonary conditions |
US6159163A (en) | 1998-05-07 | 2000-12-12 | Cedars-Sinai Medical Center | System for attenuating pain during bone marrow aspiration and method |
US6327505B1 (en) | 1998-05-07 | 2001-12-04 | Medtronic, Inc. | Method and apparatus for rf intraluminal reduction and occlusion |
CA2331532A1 (en) | 1998-05-08 | 1999-11-18 | Genetronics, Inc. | Electrically induced vessel vasodilation |
USD430015S (en) | 1998-06-11 | 2000-08-29 | Pharmacia & Upjohn Ab | Blister pack for a syringe |
JP2000005180A (en) | 1998-06-25 | 2000-01-11 | Olympus Optical Co Ltd | Acoustic impedance measuring device |
EP2428250A1 (en) | 1998-07-13 | 2012-03-14 | Genetronics, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
US6972013B1 (en) | 1998-07-13 | 2005-12-06 | Genetronics, Inc. | Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation |
US6212433B1 (en) | 1998-07-28 | 2001-04-03 | Radiotherapeutics Corporation | Method for treating tumors near the surface of an organ |
US6074374A (en) | 1998-07-31 | 2000-06-13 | Angiodynamics, Inc. | Catheter with lumen occluding means |
US6139545A (en) | 1998-09-09 | 2000-10-31 | Vidaderm | Systems and methods for ablating discrete motor nerve regions |
ATE241933T1 (en) | 1998-09-30 | 2003-06-15 | Cygnus Therapeutic Systems | METHOD AND DEVICE FOR PREDICTING PHYSIOLOGICAL MEASUREMENT VALUES |
AU6216199A (en) | 1998-10-08 | 2000-04-26 | Astrazeneca Ab | Microfabricated cell injector |
US6012885A (en) | 1998-10-09 | 2000-01-11 | Dzn, Incorporated | Cargo chock |
US7012061B1 (en) | 1998-10-19 | 2006-03-14 | New York University | Method for increasing the permeability of the blood brain barrier |
US6150148A (en) | 1998-10-21 | 2000-11-21 | Genetronics, Inc. | Electroporation apparatus for control of temperature during the process |
US6328735B1 (en) | 1998-10-30 | 2001-12-11 | E.P., Limited | Thermal ablation system |
US6611706B2 (en) | 1998-11-09 | 2003-08-26 | Transpharma Ltd. | Monopolar and bipolar current application for transdermal drug delivery and analyte extraction |
DE69924750T2 (en) | 1998-11-16 | 2006-03-02 | United States Surgical Corp., Norwalk | DEVICE FOR THE THERMAL TREATMENT OF TISSUE |
US6090016A (en) | 1998-11-18 | 2000-07-18 | Kuo; Hai Pin | Collapsible treader with enhanced stability |
US6351674B2 (en) | 1998-11-23 | 2002-02-26 | Synaptic Corporation | Method for inducing electroanesthesia using high frequency, high intensity transcutaneous electrical nerve stimulation |
FR2786397B1 (en) | 1998-11-30 | 2003-01-10 | Synt Em | PEPTIDE VECTORS OF SUBSTANCES THROUGH THE HEMATOENCEPHALIC BARRIER FOR USE IN DIAGNOSIS OR THERAPY OF CNS DISEASE |
US7449019B2 (en) | 1999-01-25 | 2008-11-11 | Smith & Nephew, Inc. | Intervertebral decompression |
US6113593A (en) | 1999-02-01 | 2000-09-05 | Tu; Lily Chen | Ablation apparatus having temperature and force sensing capabilities |
US6233490B1 (en) | 1999-02-09 | 2001-05-15 | Kai Technologies, Inc. | Microwave antennas for medical hyperthermia, thermotherapy and diagnosis |
US6193715B1 (en) | 1999-03-19 | 2001-02-27 | Medical Scientific, Inc. | Device for converting a mechanical cutting device to an electrosurgical cutting device |
US6678558B1 (en) | 1999-03-25 | 2004-01-13 | Genetronics, Inc. | Method and apparatus for reducing electroporation-mediated muscle reaction and pain response |
US6261831B1 (en) | 1999-03-26 | 2001-07-17 | The United States Of America As Represented By The Secretary Of The Air Force | Ultra-wide band RF-enhanced chemotherapy for cancer treatmeat |
US7412285B2 (en) | 1999-04-09 | 2008-08-12 | Oncostim, Inc. | Method and device for treating cancer with electrical therapy in conjunction with chemotherapeutic agents and radiation therapy |
US6738663B2 (en) | 1999-04-09 | 2004-05-18 | Oncostim, A Minnesota Corporation | Implantable device and method for the electrical treatment of cancer |
US6627421B1 (en) | 1999-04-13 | 2003-09-30 | Imarx Therapeutics, Inc. | Methods and systems for applying multi-mode energy to biological samples |
US6463331B1 (en) | 1999-04-19 | 2002-10-08 | Novasys Medical, Inc. | Application of energy and substances in the treatment of uro-genital disorders |
US6684097B1 (en) | 1999-04-22 | 2004-01-27 | University Of Miami | Intraoperative monitoring of temperature-induced tissue changes with a high-resolution digital x-ray system during thermotherapy |
US7171264B1 (en) | 1999-05-10 | 2007-01-30 | Genetronics, Inc. | Intradermal delivery of active agents by needle-free injection and electroporation |
US6643535B2 (en) | 1999-05-26 | 2003-11-04 | Endocare, Inc. | System for providing computer guided ablation of tissue |
US6478793B1 (en) | 1999-06-11 | 2002-11-12 | Sherwood Services Ag | Ablation treatment of bone metastases |
US6116330A (en) | 1999-06-23 | 2000-09-12 | The University Of Dayton | Heat storage system utilizing phase change materials government rights |
US6403348B1 (en) | 1999-07-21 | 2002-06-11 | The Regents Of The University Of California | Controlled electroporation and mass transfer across cell membranes |
US7053063B2 (en) | 1999-07-21 | 2006-05-30 | The Regents Of The University Of California | Controlled electroporation and mass transfer across cell membranes in tissue |
US6387671B1 (en) | 1999-07-21 | 2002-05-14 | The Regents Of The University Of California | Electrical impedance tomography to control electroporation |
US6300108B1 (en) | 1999-07-21 | 2001-10-09 | The Regents Of The University Of California | Controlled electroporation and mass transfer across cell membranes |
US6927049B2 (en) | 1999-07-21 | 2005-08-09 | The Regents Of The University Of California | Cell viability detection using electrical measurements |
DE60026313D1 (en) | 1999-07-23 | 2006-04-27 | Uutech Ltd | SENSITIZATION OF RED BLOOD BODIES AGAINST ULTRASOUND BY IMPACT OF AN ELECTRIC FIELD |
US6326177B1 (en) | 1999-08-04 | 2001-12-04 | Eastern Virginia Medical School Of The Medical College Of Hampton Roads | Method and apparatus for intracellular electro-manipulation |
US20020010491A1 (en) | 1999-08-04 | 2002-01-24 | Schoenbach Karl H. | Method and apparatus for intracellular electro-manipulation |
WO2001010314A2 (en) | 1999-08-05 | 2001-02-15 | Broncus Technologies, Inc. | Methods and devices for creating collateral channels in the lungs |
US20030078499A1 (en) | 1999-08-12 | 2003-04-24 | Eppstein Jonathan A. | Microporation of tissue for delivery of bioactive agents |
US6293951B1 (en) | 1999-08-24 | 2001-09-25 | Spiration, Inc. | Lung reduction device, system, and method |
US6328689B1 (en) | 2000-03-23 | 2001-12-11 | Spiration, Inc., | Lung constriction apparatus and method |
US7113821B1 (en) | 1999-08-25 | 2006-09-26 | Johnson & Johnson Consumer Companies, Inc. | Tissue electroperforation for enhanced drug delivery |
US6613211B1 (en) | 1999-08-27 | 2003-09-02 | Aclara Biosciences, Inc. | Capillary electrokinesis based cellular assays |
SE517346C2 (en) | 1999-09-15 | 2002-05-28 | Delaval Holding Ab | Milking device with washing and rinsing of different parts and with interval control |
US6287293B1 (en) | 1999-09-28 | 2001-09-11 | C. R. Bard, Inc. | Method and apparatus for locating the injection point of an implanted medical device |
JP4676042B2 (en) | 1999-10-01 | 2011-04-27 | 帝國製薬株式会社 | Topical analgesic / anti-inflammatory patch containing felbinac |
US6287304B1 (en) | 1999-10-15 | 2001-09-11 | Neothermia Corporation | Interstitial cauterization of tissue volumes with electrosurgically deployed electrodes |
US6514248B1 (en) | 1999-10-15 | 2003-02-04 | Neothermia Corporation | Accurate cutting about and into tissue volumes with electrosurgically deployed electrodes |
USD445198S1 (en) | 1999-10-27 | 2001-07-17 | J F Medical L.L.C. | Equipment storage tray |
USD437941S1 (en) | 1999-10-27 | 2001-02-20 | J F Medical L.L.C. | Equipment storage tray |
US6258249B1 (en) * | 1999-11-10 | 2001-07-10 | Sulzer Carbomedics Inc. | Sterilization of surgical sites |
US6613046B1 (en) | 1999-11-22 | 2003-09-02 | Scimed Life Systems, Inc. | Loop structures for supporting diagnostic and therapeutic elements in contact with body tissue |
US6493592B1 (en) | 1999-12-01 | 2002-12-10 | Vertis Neuroscience, Inc. | Percutaneous electrical therapy system with electrode position maintenance |
US6479064B1 (en) | 1999-12-29 | 2002-11-12 | Children's Medical Center Corporation | Culturing different cell populations on a decellularized natural biostructure for organ reconstruction |
US6699242B2 (en) | 2000-02-03 | 2004-03-02 | Baylor College Of Medicine | Methods and devices for intraosseous nerve ablation |
US6714816B1 (en) | 2000-02-22 | 2004-03-30 | University Of South Florida | Electroporation and electrophoresis system and method for achieving molecular penetration into cells in vivo |
US7465566B2 (en) | 2000-02-23 | 2008-12-16 | The Trustees Of The University Of Pennsylvania | Regulation of genes via application of specific and selective electrical and electromagnetic signals |
US6679264B1 (en) | 2000-03-04 | 2004-01-20 | Emphasys Medical, Inc. | Methods and devices for use in performing pulmonary procedures |
US8048070B2 (en) | 2000-03-06 | 2011-11-01 | Salient Surgical Technologies, Inc. | Fluid-assisted medical devices, systems and methods |
US6770070B1 (en) | 2000-03-17 | 2004-08-03 | Rita Medical Systems, Inc. | Lung treatment apparatus and method |
US6537198B1 (en) | 2000-03-21 | 2003-03-25 | Myocor, Inc. | Splint assembly for improving cardiac function in hearts, and method for implanting the splint assembly |
USD443360S1 (en) | 2000-03-22 | 2001-06-05 | Dexterity Surgical Inc. | Distal end of obturator for a trocar |
WO2001074251A2 (en) | 2000-03-31 | 2001-10-11 | Rita Medical Systems Inc. | Tissue biopsy and treatment apparatus and method |
IT1320186B1 (en) | 2000-04-21 | 2003-11-26 | Igea Srl | ELECTRO-PORTATION DEVICE AND METHOD IN WHICH THE IMPULSE OF THE PULSE OR PULSES IS ESTABLISHED AUTOMATICALLY IN |
US6488680B1 (en) | 2000-04-27 | 2002-12-03 | Medtronic, Inc. | Variable length electrodes for delivery of irrigated ablation |
JP4926359B2 (en) | 2000-05-03 | 2012-05-09 | シー・アール・バード・インコーポレーテッド | Apparatus and method for mapping and cauterization in electrophysiological procedures |
US20010044596A1 (en) | 2000-05-10 | 2001-11-22 | Ali Jaafar | Apparatus and method for treatment of vascular restenosis by electroporation |
EP1284663A4 (en) | 2000-05-18 | 2007-04-18 | Emphasys Medical Inc | Bronchiopulmonary occlusion devices and lung volume reduction methods |
US7520877B2 (en) | 2000-06-07 | 2009-04-21 | Wisconsin Alumni Research Foundation | Radiofrequency ablation system using multiple prong probes |
US20020022864A1 (en) | 2000-06-07 | 2002-02-21 | Mahvi David M. | Multipolar electrode system for radiofrequency ablation |
US8486065B2 (en) | 2000-06-07 | 2013-07-16 | Wisconsin Alumni Research Foundation | Radio-frequency ablation system and method using multiple electrodes |
KR100375657B1 (en) | 2000-06-21 | 2003-03-15 | 주식회사 몸앤맘 | Apparatus and method for eliminating a fat mass in human body |
JP3296812B2 (en) | 2000-06-26 | 2002-07-02 | 三洋電機株式会社 | Water treatment method, water treatment apparatus and hydroponic cultivation system using the same |
US6638277B2 (en) | 2000-07-06 | 2003-10-28 | Scimed Life Systems, Inc. | Tumor ablation needle with independently activated and independently traversing tines |
US20020095197A1 (en) | 2000-07-11 | 2002-07-18 | Lardo Albert C. | Application of photochemotherapy for the treatment of cardiac arrhythmias |
US6669691B1 (en) | 2000-07-18 | 2003-12-30 | Scimed Life Systems, Inc. | Epicardial myocardial revascularization and denervation methods and apparatus |
CA2416581A1 (en) | 2000-07-25 | 2002-04-25 | Rita Medical Systems, Inc. | Apparatus for detecting and treating tumors using localized impedance measurement |
JP2004504897A (en) | 2000-07-27 | 2004-02-19 | メドトロニック・インコーポレーテッド | Atrial cardioverter |
US6962814B2 (en) | 2000-08-16 | 2005-11-08 | Duke University | Decellularized tissue engineered constructs and tissues |
US6795728B2 (en) | 2001-08-17 | 2004-09-21 | Minnesota Medical Physics, Llc | Apparatus and method for reducing subcutaneous fat deposits by electroporation |
US6892099B2 (en) | 2001-02-08 | 2005-05-10 | Minnesota Medical Physics, Llc | Apparatus and method for reducing subcutaneous fat deposits, virtual face lift and body sculpturing by electroporation |
US8251986B2 (en) | 2000-08-17 | 2012-08-28 | Angiodynamics, Inc. | Method of destroying tissue cells by eletroporation |
US6697670B2 (en) | 2001-08-17 | 2004-02-24 | Minnesota Medical Physics, Llc | Apparatus and method for reducing subcutaneous fat deposits by electroporation with improved comfort of patients |
US6482221B1 (en) | 2000-08-21 | 2002-11-19 | Counter Clockwise, Inc. | Manipulatable delivery catheter for occlusive devices (II) |
EP1582166B1 (en) | 2000-09-07 | 2007-06-27 | Sherwood Services AG | Apparatus for the treatment of the intervertebral disc |
US20020147462A1 (en) | 2000-09-11 | 2002-10-10 | Closure Medical Corporation | Bronchial occlusion method and apparatus |
US20020119437A1 (en) | 2000-09-20 | 2002-08-29 | Grooms Jamie M. | Method of preparing and processing transplant tissue |
US6702808B1 (en) | 2000-09-28 | 2004-03-09 | Syneron Medical Ltd. | Device and method for treating skin |
US6589174B1 (en) | 2000-10-20 | 2003-07-08 | Sunnybrook & Women's College Health Sciences Centre | Technique and apparatus for ultrasound therapy |
US20020133324A1 (en) | 2000-11-03 | 2002-09-19 | Weaver James C. | Functional simulation method |
US6821274B2 (en) | 2001-03-07 | 2004-11-23 | Gendel Ltd. | Ultrasound therapy for selective cell ablation |
US7549987B2 (en) | 2000-12-09 | 2009-06-23 | Tsunami Medtech, Llc | Thermotherapy device |
WO2002064193A2 (en) | 2000-12-14 | 2002-08-22 | Georgia Tech Research Corporation | Microneedle devices and production thereof |
EP1363700A4 (en) | 2001-01-11 | 2005-11-09 | Rita Medical Systems Inc | Bone-treatment instrument and method |
US20030055220A1 (en) | 2001-01-12 | 2003-03-20 | Pierre Legrain | Protein-protein interactions between Shigella flexneri polypeptides and mammalian polypeptides |
WO2002066096A2 (en) | 2001-02-16 | 2002-08-29 | Cordis Corporation | Balloon catheter stent delivery system with ridges |
US20020112729A1 (en) | 2001-02-21 | 2002-08-22 | Spiration, Inc. | Intra-bronchial obstructing device that controls biological interaction with the patient |
US7029916B2 (en) | 2001-02-21 | 2006-04-18 | Maxcyte, Inc. | Apparatus and method for flow electroporation of biological samples |
US6533784B2 (en) | 2001-02-24 | 2003-03-18 | Csaba Truckai | Electrosurgical working end for transecting and sealing tissue |
AU2002250170B2 (en) | 2001-02-28 | 2006-08-10 | Rex Medical, L.P. | Apparatus for Delivering Ablation Fluid to Treat Lesions |
US7008421B2 (en) | 2002-08-21 | 2006-03-07 | Resect Medical, Inc. | Apparatus and method for tissue resection |
US7087040B2 (en) | 2001-02-28 | 2006-08-08 | Rex Medical, L.P. | Apparatus for delivering ablation fluid to treat lesions |
US7011094B2 (en) | 2001-03-02 | 2006-03-14 | Emphasys Medical, Inc. | Bronchial flow control devices and methods of use |
US7798147B2 (en) | 2001-03-02 | 2010-09-21 | Pulmonx Corporation | Bronchial flow control devices with membrane seal |
US20050043726A1 (en) | 2001-03-07 | 2005-02-24 | Mchale Anthony Patrick | Device II |
GB0107669D0 (en) | 2001-03-27 | 2001-05-16 | Habib Nagy A | Improvements relating to liver surgery |
US20020177847A1 (en) | 2001-03-30 | 2002-11-28 | Long Gary L. | Endoscopic ablation system with flexible coupling |
US6497704B2 (en) | 2001-04-04 | 2002-12-24 | Moshe Ein-Gal | Electrosurgical apparatus |
US6666858B2 (en) | 2001-04-12 | 2003-12-23 | Scimed Life Systems, Inc. | Cryo balloon for atrial ablation |
EP1377680B1 (en) | 2001-04-12 | 2011-10-05 | Imperial Innovations Limited | Diagnosis and treatment of breast cancer based upon scn5a |
US6989010B2 (en) | 2001-04-26 | 2006-01-24 | Medtronic, Inc. | Ablation system and method of use |
WO2002087692A1 (en) | 2001-04-26 | 2002-11-07 | The Procter & Gamble Company | A method and apparatus for the treatment of cosmetic skin conditioins |
US7250048B2 (en) | 2001-04-26 | 2007-07-31 | Medtronic, Inc. | Ablation system and method of use |
CN100518685C (en) | 2001-05-10 | 2009-07-29 | 脉管动力股份有限公司 | RF tissue ablation apparatus and method |
US6623638B2 (en) | 2001-06-01 | 2003-09-23 | Baxter International Inc. | Hemodialyzer having improved dialysate perfusion |
ITTO20010534A1 (en) | 2001-06-04 | 2002-12-04 | Igea Srl | ELECTROPORATION DEVICE AND METHOD THAT REDUCES MUSCLE CONTRACTION AND SENSATION OF PAIN. |
US6520183B2 (en) | 2001-06-11 | 2003-02-18 | Memorial Sloan-Kettering Cancer Center | Double endobronchial catheter for one lung isolation anesthesia and surgery |
US7127284B2 (en) | 2001-06-11 | 2006-10-24 | Mercator Medsystems, Inc. | Electroporation microneedle and methods for its use |
US20020188242A1 (en) | 2001-06-12 | 2002-12-12 | Allan Wu | Method and invention for the treatment of diseases and disorders of the cervix |
US6832111B2 (en) | 2001-07-06 | 2004-12-14 | Hosheng Tu | Device for tumor diagnosis and methods thereof |
US6491706B1 (en) | 2001-07-10 | 2002-12-10 | Spiration, Inc. | Constriction device including fixation structure |
US6860847B2 (en) | 2001-07-10 | 2005-03-01 | Spiration, Inc. | Constriction device viewable under X ray fluoroscopy |
US6638253B2 (en) | 2001-07-17 | 2003-10-28 | Eugene Michael Breznock | Method and apparatus for chest drainage |
US6994706B2 (en) | 2001-08-13 | 2006-02-07 | Minnesota Medical Physics, Llc | Apparatus and method for treatment of benign prostatic hyperplasia |
US7130697B2 (en) | 2002-08-13 | 2006-10-31 | Minnesota Medical Physics Llc | Apparatus and method for the treatment of benign prostatic hyperplasia |
USRE42016E1 (en) | 2001-08-13 | 2010-12-28 | Angiodynamics, Inc. | Apparatus and method for the treatment of benign prostatic hyperplasia |
JP3987312B2 (en) | 2001-08-31 | 2007-10-10 | 株式会社東芝 | Semiconductor device manufacturing apparatus and manufacturing method, and semiconductor manufacturing apparatus cleaning method |
US20030050648A1 (en) | 2001-09-11 | 2003-03-13 | Spiration, Inc. | Removable lung reduction devices, systems, and methods |
US6743228B2 (en) | 2001-09-12 | 2004-06-01 | Manoa Medical, Inc. | Devices and methods for tissue severing and removal |
US6761716B2 (en) | 2001-09-18 | 2004-07-13 | Cardiac Pacemakers, Inc. | System and method for assessing electrode-tissue contact and lesion quality during RF ablation by measurement of conduction time |
CN100450456C (en) | 2001-09-28 | 2009-01-14 | 锐达医疗系统公司 | Impedance controlled tissue ablation apparatus and method |
US20040243107A1 (en) | 2001-10-01 | 2004-12-02 | Macoviak John A | Methods and devices for treating atrial fibrilation |
US7208014B2 (en) | 2001-10-01 | 2007-04-24 | Spinecore, Inc. | Intervertebral spacer device utilizing a belleville washer having radially extending grooves |
CA2458595C (en) | 2001-10-11 | 2007-12-04 | Peter M. Wilson | Bronchial flow control devices and methods of use |
FR2830767B1 (en) | 2001-10-12 | 2004-03-12 | Optis France Sa | DEVICE FOR DELIVERING DRUGS BY IONTOPHORESIS OR INTROCULAR ELECTROPORATION |
JP4460807B2 (en) | 2001-10-16 | 2010-05-12 | 大研医器株式会社 | Expansion aid for medical device with cuff and broncho-occlusion device provided with the same |
US6589161B2 (en) | 2001-10-18 | 2003-07-08 | Spiration, Inc. | Constriction device including tear resistant structures |
US7979117B2 (en) | 2001-10-24 | 2011-07-12 | Power Paper Ltd. | Device and method for controlled delivery of active substance into the skin |
US6592594B2 (en) | 2001-10-25 | 2003-07-15 | Spiration, Inc. | Bronchial obstruction device deployment system and method |
US6807444B2 (en) | 2001-11-05 | 2004-10-19 | Hosheng Tu | Apparatus and methods for monitoring tissue impedance |
WO2003041779A1 (en) | 2001-11-14 | 2003-05-22 | Emphasys Medical, Inc. | Active pump bronchial implant and methods of use thereof |
EP1448247B1 (en) | 2001-11-16 | 2011-02-16 | Children's Medical Center Corporation | Creation of tissue engineered female reproductive organs |
US7488313B2 (en) | 2001-11-29 | 2009-02-10 | Boston Scientific Scimed, Inc. | Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment |
AU2002360540A1 (en) | 2001-12-04 | 2003-06-17 | University Of Southern California | Method for intracellular modifications within living cells using pulsed electric fields |
US7184820B2 (en) | 2002-01-25 | 2007-02-27 | Subqiview, Inc. | Tissue monitoring system for intravascular infusion |
US20050267407A1 (en) | 2002-02-01 | 2005-12-01 | Vascular Designs, Inc. | Multi-function catheter and use thereof |
US7813798B2 (en) | 2002-02-14 | 2010-10-12 | Pacesetter, Inc. | Systems and methods for preventing, detecting, and terminating pacemaker mediated tachycardia in biventricular implantable cardiac stimulation systems |
US20030154988A1 (en) | 2002-02-21 | 2003-08-21 | Spiration, Inc. | Intra-bronchial device that provides a medicant intra-bronchially to the patient |
USD480816S1 (en) | 2002-02-28 | 2003-10-14 | Kimberly-Clark Worldwide, Inc. | Surgical kit for percutaneous endoscopic gastrostomy procedures |
USD471641S1 (en) | 2002-02-28 | 2003-03-11 | Kimberly-Clark Worldwide, Inc. | Surgical kit tray |
USD471640S1 (en) | 2002-02-28 | 2003-03-11 | Kimberly-Clark Worldwide, Inc. | Surgical kit for percutaneous endoscopic gastrostomy procedures |
US20070156136A1 (en) | 2002-03-05 | 2007-07-05 | Neil Godara | Methods of treating the sacroiliac region of a patient's body |
US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
AU2003220124A1 (en) | 2002-03-08 | 2003-09-22 | Emphasys Medical, Inc. | Methods and devices for inducing collapse in lung regions fed by collateral pathways |
AU2003225735A1 (en) | 2002-03-11 | 2003-09-29 | Altea Therapeutics Corporation | Transdermal drug delivery patch system, method of making same and method of using same |
US20030216769A1 (en) | 2002-05-17 | 2003-11-20 | Dillard David H. | Removable anchored lung volume reduction devices and methods |
US6960189B2 (en) | 2002-03-29 | 2005-11-01 | Gore Enterprise Holdings | Proximal catheter assembly allowing for natural and suction-assisted aspiration |
US6912417B1 (en) | 2002-04-05 | 2005-06-28 | Ichor Medical Systmes, Inc. | Method and apparatus for delivery of therapeutic agents |
US6978174B2 (en) | 2002-04-08 | 2005-12-20 | Ardian, Inc. | Methods and devices for renal nerve blocking |
US8131371B2 (en) | 2002-04-08 | 2012-03-06 | Ardian, Inc. | Methods and apparatus for monopolar renal neuromodulation |
US20070129761A1 (en) | 2002-04-08 | 2007-06-07 | Ardian, Inc. | Methods for treating heart arrhythmia |
US7617005B2 (en) | 2002-04-08 | 2009-11-10 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
US8347891B2 (en) | 2002-04-08 | 2013-01-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen |
US7756583B2 (en) | 2002-04-08 | 2010-07-13 | Ardian, Inc. | Methods and apparatus for intravascularly-induced neuromodulation |
US20110207758A1 (en) | 2003-04-08 | 2011-08-25 | Medtronic Vascular, Inc. | Methods for Therapeutic Renal Denervation |
US7620451B2 (en) | 2005-12-29 | 2009-11-17 | Ardian, Inc. | Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach |
US8145316B2 (en) | 2002-04-08 | 2012-03-27 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
US8175711B2 (en) | 2002-04-08 | 2012-05-08 | Ardian, Inc. | Methods for treating a condition or disease associated with cardio-renal function |
US7162303B2 (en) | 2002-04-08 | 2007-01-09 | Ardian, Inc. | Renal nerve stimulation method and apparatus for treatment of patients |
US8145317B2 (en) | 2002-04-08 | 2012-03-27 | Ardian, Inc. | Methods for renal neuromodulation |
US20080213331A1 (en) | 2002-04-08 | 2008-09-04 | Ardian, Inc. | Methods and devices for renal nerve blocking |
US20070135875A1 (en) | 2002-04-08 | 2007-06-14 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
US7853333B2 (en) | 2002-04-08 | 2010-12-14 | Ardian, Inc. | Methods and apparatus for multi-vessel renal neuromodulation |
US7653438B2 (en) | 2002-04-08 | 2010-01-26 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
US8150519B2 (en) | 2002-04-08 | 2012-04-03 | Ardian, Inc. | Methods and apparatus for bilateral renal neuromodulation |
US20030195385A1 (en) | 2002-04-16 | 2003-10-16 | Spiration, Inc. | Removable anchored lung volume reduction devices and methods |
US6752767B2 (en) | 2002-04-16 | 2004-06-22 | Vivant Medical, Inc. | Localization element with energized tip |
US6801804B2 (en) | 2002-05-03 | 2004-10-05 | Aciont, Inc. | Device and method for monitoring and controlling electrical resistance at a tissue site undergoing iontophoresis |
US6780178B2 (en) | 2002-05-03 | 2004-08-24 | The Board Of Trustees Of The Leland Stanford Junior University | Method and apparatus for plasma-mediated thermo-electrical ablation |
US20040009459A1 (en) | 2002-05-06 | 2004-01-15 | Anderson James H. | Simulation system for medical procedures |
WO2003092520A1 (en) | 2002-05-06 | 2003-11-13 | Sherwood Services Ag | Blood detector for controlling anesu and method therefor |
US20030212412A1 (en) | 2002-05-09 | 2003-11-13 | Spiration, Inc. | Intra-bronchial obstructing device that permits mucus transport |
ATE412447T1 (en) | 2002-05-23 | 2008-11-15 | Gendel Ltd | ABLATION DEVICE |
US20040089306A1 (en) | 2002-05-28 | 2004-05-13 | Ronald Hundertmark | Devices and methods for removing bronchial isolation devices implanted in the lung |
US7063698B2 (en) | 2002-06-14 | 2006-06-20 | Ncontact Surgical, Inc. | Vacuum coagulation probes |
CA2491003A1 (en) | 2002-06-27 | 2004-01-08 | Shaike Schatzberger | Method and apparatus for positioning a surgical instrument |
US6881213B2 (en) | 2002-06-28 | 2005-04-19 | Ethicon, Inc. | Device and method to expand treatment array |
US20040059263A1 (en) | 2002-09-24 | 2004-03-25 | Spiration, Inc. | Device and method for measuring the diameter of an air passageway |
AU2003256798A1 (en) | 2002-07-26 | 2004-02-16 | Emphasys Medical, Inc. | Bronchial flow control devices with membrane seal |
US7427280B2 (en) | 2002-09-06 | 2008-09-23 | Medtronic, Inc. | Method, system and device for treating disorders of the pelvic floor by delivering drugs to various nerves or tissues |
US7400931B2 (en) | 2002-09-18 | 2008-07-15 | Cardiac Pacemakers, Inc. | Devices and methods to stimulate therapeutic angiogenesis for ischemia and heart failure |
US6695861B1 (en) | 2002-09-20 | 2004-02-24 | Interrad Medical, Inc. | Sutureless retention device |
US20040068228A1 (en) | 2002-10-04 | 2004-04-08 | Jon Cunningham | Device and method for stabilizing catheters |
US7455675B2 (en) | 2002-11-06 | 2008-11-25 | Angiodynamics, Inc. | Device and method for withdrawing a tubular body part |
WO2004045679A1 (en) | 2002-11-21 | 2004-06-03 | Kowa Co., Ltd. | Peritoneal dialysis method |
US7914529B2 (en) | 2002-11-26 | 2011-03-29 | Thermal Corp. | Cooling element for electrosurgery |
US7195628B2 (en) | 2002-12-11 | 2007-03-27 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Atrial fibrillation therapy with pulmonary vein support |
US6926713B2 (en) | 2002-12-11 | 2005-08-09 | Boston Scientific Scimed, Inc. | Angle indexer for medical devices |
US20040267340A1 (en) | 2002-12-12 | 2004-12-30 | Wit Ip Corporation | Modular thermal treatment systems with single-use disposable catheter assemblies and related methods |
JP4226893B2 (en) | 2002-12-25 | 2009-02-18 | アスモ株式会社 | Actuator |
US6972014B2 (en) | 2003-01-04 | 2005-12-06 | Endocare, Inc. | Open system heat exchange catheters and methods of use |
EP1583562B1 (en) | 2003-01-06 | 2011-06-15 | Angiochem Inc. | Angiopep-1, related compounds, and uses thereof |
US6847848B2 (en) | 2003-01-07 | 2005-01-25 | Mmtc, Inc | Inflatable balloon catheter structural designs and methods for treating diseased tissue of a patient |
US7162300B2 (en) | 2003-01-13 | 2007-01-09 | Medtronic, Inc. | Synchronized atrial anti-tachy pacing system and method |
DE10302310A1 (en) | 2003-01-20 | 2004-07-29 | Freitag, Lutz, Dr. | Patient lung reduction method, e.g. for treating pulmonary emphysema, whereby a bronchial catheter is inserted into an over-swollen lung area and the supplying bronchopulmonary closed in synchronism with patient breathing |
US7331949B2 (en) | 2003-02-27 | 2008-02-19 | Margaret Grahn Marisi | Urinary catheter with check valve |
US20040176855A1 (en) | 2003-03-07 | 2004-09-09 | Acell, Inc. | Decellularized liver for repair of tissue and treatment of organ deficiency |
US20040210248A1 (en) | 2003-03-12 | 2004-10-21 | Spiration, Inc. | Apparatus, method and assembly for delivery of intra-bronchial devices |
US20070055142A1 (en) | 2003-03-14 | 2007-03-08 | Webler William E | Method and apparatus for image guided position tracking during percutaneous procedures |
US7211083B2 (en) | 2003-03-17 | 2007-05-01 | Minnesota Medical Physics, Llc | Apparatus and method for hair removal by electroporation |
US20050020965A1 (en) | 2003-03-20 | 2005-01-27 | Scimed Life Systems, Inc. | Devices and methods for delivering agents to tissue region while preventing leakage |
JP4565810B2 (en) | 2003-03-31 | 2010-10-20 | 三洋電機株式会社 | Laminated battery |
US7100616B2 (en) | 2003-04-08 | 2006-09-05 | Spiration, Inc. | Bronchoscopic lung volume reduction method |
EP1619995A2 (en) | 2003-04-22 | 2006-02-01 | Ekos Corporation | Ultrasound enhanced central venous catheter |
US7036510B2 (en) | 2003-04-28 | 2006-05-02 | Cook Critical Care Incorporated | Percutaneous tracheostomy balloon apparatus |
US6916310B2 (en) | 2003-05-30 | 2005-07-12 | Codman & Shurtleff, Inc. | Percutaneous access device |
USD489973S1 (en) | 2003-06-02 | 2004-05-18 | Vascular Solutions, Inc. | Medical device package |
US7632291B2 (en) | 2003-06-13 | 2009-12-15 | Trivascular2, Inc. | Inflatable implant |
USD495807S1 (en) | 2003-06-23 | 2004-09-07 | Codman & Shurtleff, Inc. | Tray |
JP4231743B2 (en) | 2003-07-07 | 2009-03-04 | オリンパス株式会社 | Biological tissue resection device |
US20050013870A1 (en) | 2003-07-17 | 2005-01-20 | Toby Freyman | Decellularized extracellular matrix of conditioned body tissues and uses thereof |
EP1648555B1 (en) | 2003-07-18 | 2015-09-02 | Eastern Virginia Medical School | Method for introducing an Agent into a Cell |
WO2005011476A2 (en) | 2003-07-29 | 2005-02-10 | Endoscopic Technologies, Inc. | Tissue positioner |
US7533671B2 (en) | 2003-08-08 | 2009-05-19 | Spiration, Inc. | Bronchoscopic repair of air leaks in a lung |
DE202004021942U1 (en) | 2003-09-12 | 2013-05-13 | Vessix Vascular, Inc. | Selectable eccentric remodeling and / or ablation of atherosclerotic material |
US7341558B2 (en) | 2003-09-19 | 2008-03-11 | Medcanica, Llc | Pericardial retractor |
JPWO2005039416A1 (en) | 2003-10-23 | 2007-11-22 | 株式会社日立メディコ | Image processing device for treatment support |
US7232437B2 (en) | 2003-10-30 | 2007-06-19 | Medical Cv, Inc. | Assessment of lesion transmurality |
US7437194B2 (en) | 2003-10-31 | 2008-10-14 | Medtronic, Inc. | Stimulating the prostate gland |
EP1682196A2 (en) | 2003-11-10 | 2006-07-26 | Angiotech International Ag | Medical implants and anti-scarring agents |
US6958064B2 (en) | 2003-11-14 | 2005-10-25 | Boston Scientific Scimed, Inc. | Systems and methods for performing simultaneous ablation |
EP1684655A2 (en) | 2003-11-18 | 2006-08-02 | SciMed Life Systems, Inc. | System and method for tissue ablation |
US8298222B2 (en) | 2003-12-24 | 2012-10-30 | The Regents Of The University Of California | Electroporation to deliver chemotherapeutics and enhance tumor regression |
ES2543832T3 (en) | 2003-12-24 | 2015-08-24 | The Regents Of The University Of California | Tissue ablation with irreversible electroporation |
US20050171522A1 (en) | 2004-01-30 | 2005-08-04 | Christopherson Mark A. | Transurethral needle ablation system with needle position indicator |
US7647112B2 (en) | 2004-02-11 | 2010-01-12 | Ethicon, Inc. | System and method for selectively stimulating different body parts |
WO2005087137A1 (en) | 2004-03-08 | 2005-09-22 | Emphasys Medical, Inc. | Implanted bronchial isolation devices and methods |
US7703459B2 (en) | 2004-03-09 | 2010-04-27 | Usgi Medical, Inc. | Apparatus and methods for mapping out endoluminal gastrointestinal surgery |
DE102004013762B4 (en) | 2004-03-20 | 2006-08-03 | Forschungszentrum Karlsruhe Gmbh | Process for better and gentle release of valuable ingredients from grapes and a must obtained from them |
US7565208B2 (en) | 2004-03-25 | 2009-07-21 | Boston Scientific Scimed, Inc. | Catheter with sensor tips, tool and device and methods of use of same |
JP4443278B2 (en) | 2004-03-26 | 2010-03-31 | テルモ株式会社 | Catheter with expansion body |
USD549332S1 (en) | 2004-04-09 | 2007-08-21 | Olympus Corporation | Endoscope |
WO2005099367A2 (en) | 2004-04-16 | 2005-10-27 | Critical Care Innovations, Inc. | Systems and methods for improving image-guided tissue ablation |
NL1026190C2 (en) | 2004-05-13 | 2005-11-15 | Peter Tjong Joe Wai | Bronchus blocker and ventilation system with bronchus blocker and ventilation tube. |
US20050261672A1 (en) | 2004-05-18 | 2005-11-24 | Mark Deem | Systems and methods for selective denervation of heart dysrhythmias |
US7549984B2 (en) | 2004-06-16 | 2009-06-23 | Pneumrx, Inc. | Method of compressing a portion of a lung |
US20060074413A1 (en) | 2004-06-28 | 2006-04-06 | Kamran Behzadian | Method and apparatus for substantial and uniform ablation about a linear bipolar array of electrodes |
US7544301B2 (en) | 2004-08-19 | 2009-06-09 | Hhd Llc | Citrate-based dialysate chemical formulations |
US7553309B2 (en) | 2004-10-08 | 2009-06-30 | Covidien Ag | Electrosurgical system employing multiple electrodes and method thereof |
US20060079845A1 (en) | 2004-10-08 | 2006-04-13 | Eben Howard And Pamela A. Howard | Movable inflatable anchor for medical devices |
US7282049B2 (en) | 2004-10-08 | 2007-10-16 | Sherwood Services Ag | Electrosurgical system employing multiple electrodes and method thereof |
US7776035B2 (en) | 2004-10-08 | 2010-08-17 | Covidien Ag | Cool-tip combined electrode introducer |
US20060079838A1 (en) | 2004-10-08 | 2006-04-13 | Walker Steven C | Movable Balloon anchor for medical devices |
US7261710B2 (en) | 2004-10-13 | 2007-08-28 | Medtronic, Inc. | Transurethral needle ablation system |
US7229438B2 (en) | 2004-10-14 | 2007-06-12 | Boston Scientific Scimed, Inc. | Ablation probe with distal inverted electrode array |
US7959577B2 (en) | 2007-09-06 | 2011-06-14 | Baxano, Inc. | Method, system, and apparatus for neural localization |
US20060089635A1 (en) | 2004-10-22 | 2006-04-27 | Scimed Life Systems, Inc. | Methods and apparatus for focused bipolar tissue ablation using an insulated shaft |
US20070083239A1 (en) | 2005-09-23 | 2007-04-12 | Denise Demarais | Methods and apparatus for inducing, monitoring and controlling renal neuromodulation |
US7937143B2 (en) | 2004-11-02 | 2011-05-03 | Ardian, Inc. | Methods and apparatus for inducing controlled renal neuromodulation |
WO2006052940A2 (en) | 2004-11-05 | 2006-05-18 | Asthmatx, Inc. | Medical device with procedure improvement features |
US7451765B2 (en) | 2004-11-18 | 2008-11-18 | Mark Adler | Intra-bronchial apparatus for aspiration and insufflation of lung regions distal to placement or cross communication and deployment and placement system therefor |
US7641989B2 (en) | 2004-12-13 | 2010-01-05 | Hitachi Global Storage Technologies Netherlands B.V. | Perpendicular magnetic recording medium for high density recording and manufacturing of the same |
WO2006078863A2 (en) | 2005-01-18 | 2006-07-27 | Daniel Steven A | Device and method for thermal ablation of biological tissue using spherical ablation patterns |
US8496006B2 (en) | 2005-01-20 | 2013-07-30 | Pulmonx Corporation | Methods and devices for passive residual lung volume reduction and functional lung volume expansion |
US20060173490A1 (en) | 2005-02-01 | 2006-08-03 | Boston Scientific Scimed, Inc. | Filter system and method |
GB0502384D0 (en) | 2005-02-04 | 2005-03-16 | Instrumedical Ltd | Electro-surgical needle apparatus |
WO2006086516A2 (en) | 2005-02-09 | 2006-08-17 | Angiodynamics, Inc. | Reinforced balloon for a catheter |
US7699838B2 (en) | 2005-02-16 | 2010-04-20 | Case Western Reserve University | System and methods for image-guided thermal treatment of tissue |
US7892228B2 (en) | 2005-02-25 | 2011-02-22 | Boston Scientific Scimed, Inc. | Dual mode lesion formation apparatus, systems and methods |
AU2006218484B2 (en) | 2005-03-03 | 2009-04-02 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Method and apparatus for locating the fossa ovalis, creating a virtual fossa ovalis and performing transseptal puncture |
GB0504988D0 (en) | 2005-03-10 | 2005-04-20 | Emcision Ltd | Device and method for the treatment of diseased tissue such as tumors |
US20120226271A1 (en) | 2005-03-25 | 2012-09-06 | Peter Callas | Vacuum Ablation Apparatus and Method |
WO2006105121A2 (en) | 2005-03-28 | 2006-10-05 | Minnow Medical, Llc | Intraluminal electrical tissue characterization and tuned rf energy for selective treatment of atheroma and other target tissues |
US7542800B2 (en) | 2005-04-05 | 2009-06-02 | Cardiac Pacemakers, Inc. | Method and apparatus for synchronizing neural stimulation to cardiac cycles |
BRPI0610079B8 (en) | 2005-04-22 | 2021-06-22 | Becton Dickinson Co | pre-packaged medical device, packaging tray and method |
EP2305188B1 (en) | 2005-04-27 | 2015-06-03 | ZOLL Circulation, Inc. | Apparatus for providing enhanced heat transfer from a body |
US20060264752A1 (en) | 2005-04-27 | 2006-11-23 | The Regents Of The University Of California | Electroporation controlled with real time imaging |
DE602006012469D1 (en) | 2005-04-29 | 2010-04-08 | Stryker Corp | BIPOLAR MEDICAL ELECTRODE ARRANGEMENT WITH CANNULA AND REMOVABLE CONNECTOR ELECTRODE |
USD575402S1 (en) | 2005-05-23 | 2008-08-19 | Sandor Marilyn C | Disposable prophylaxis |
US8672990B2 (en) | 2005-05-27 | 2014-03-18 | Boston Scientific Scimed, Inc. | Fiber mesh controlled expansion balloon catheter |
US20060293725A1 (en) | 2005-06-24 | 2006-12-28 | Boris Rubinsky | Methods and systems for treating fatty tissue sites using electroporation |
US20060293731A1 (en) | 2005-06-24 | 2006-12-28 | Boris Rubinsky | Methods and systems for treating tumors using electroporation |
US20060293730A1 (en) | 2005-06-24 | 2006-12-28 | Boris Rubinsky | Methods and systems for treating restenosis sites using electroporation |
US8114070B2 (en) | 2005-06-24 | 2012-02-14 | Angiodynamics, Inc. | Methods and systems for treating BPH using electroporation |
EP1913578B1 (en) | 2005-06-30 | 2012-08-01 | LG Electronics Inc. | Method and apparatus for decoding an audio signal |
GB2434314B (en) | 2006-01-03 | 2011-06-15 | Microsulis Ltd | Microwave applicator with dipole antenna |
US8080009B2 (en) | 2005-07-01 | 2011-12-20 | Halt Medical Inc. | Radio frequency ablation device for the destruction of tissue masses |
US8512330B2 (en) | 2005-07-01 | 2013-08-20 | Halt Medical Inc. | Ablation method |
US20070010805A1 (en) | 2005-07-08 | 2007-01-11 | Fedewa Russell J | Method and apparatus for the treatment of tissue |
JP5826450B2 (en) | 2005-07-22 | 2015-12-02 | ザ ファウンドリー, エルエルシー | Systems and methods for delivery of therapeutic agents |
US20070021803A1 (en) | 2005-07-22 | 2007-01-25 | The Foundry Inc. | Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction |
JP2009507068A (en) | 2005-09-06 | 2009-02-19 | メディター ファーマスーティカルズ リミテッド | Prevention of hypotension and stabilization of blood pressure in hemodialysis patients |
JP2009506873A (en) | 2005-09-07 | 2009-02-19 | ザ ファウンドリー, インコーポレイテッド | Apparatus and method for disrupting subcutaneous structures |
US20070066971A1 (en) | 2005-09-21 | 2007-03-22 | Podhajsky Ronald J | Method and system for treating pain during an electrosurgical procedure |
US7879031B2 (en) | 2005-09-27 | 2011-02-01 | Covidien Ag | Cooled RF ablation needle |
JP2009509685A (en) | 2005-09-30 | 2009-03-12 | Tti・エルビュー株式会社 | Iontophoresis device and method for delivery of angiogenic factors to enhance healing of damaged tissue |
AU2006299623A1 (en) | 2005-09-30 | 2007-04-12 | Angiodynamics, Inc. | Implantable medical device |
US20070078453A1 (en) | 2005-10-04 | 2007-04-05 | Johnson Kristin D | System and method for performing cardiac ablation |
US9265605B2 (en) | 2005-10-14 | 2016-02-23 | Boston Scientific Scimed, Inc. | Bronchoscopic lung volume reduction valve |
US8366712B2 (en) | 2005-10-15 | 2013-02-05 | Baxano, Inc. | Multiple pathways for spinal nerve root decompression from a single access point |
US8449535B2 (en) | 2005-12-06 | 2013-05-28 | St. Jude Medical, Atrial Fibrillation Division, Inc. | System and method for assessing coupling between an electrode and tissue |
US8403925B2 (en) | 2006-12-06 | 2013-03-26 | St. Jude Medical, Atrial Fibrillation Division, Inc. | System and method for assessing lesions in tissue |
US10362959B2 (en) | 2005-12-06 | 2019-07-30 | St. Jude Medical, Atrial Fibrillation Division, Inc. | System and method for assessing the proximity of an electrode to tissue in a body |
EP1962710B1 (en) | 2005-12-06 | 2015-08-12 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Apparatus for displaying catheter electrode-tissue contact in electro-anatomic mapping and navigation system |
US8317783B2 (en) | 2005-12-06 | 2012-11-27 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Assessment of electrode coupling for tissue ablation |
WO2007070361A2 (en) | 2005-12-06 | 2007-06-21 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Assessment of electrode coupling for tissue ablation |
US9492226B2 (en) | 2005-12-06 | 2016-11-15 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Graphical user interface for real-time RF lesion depth display |
US8406866B2 (en) | 2005-12-06 | 2013-03-26 | St. Jude Medical, Atrial Fibrillation Division, Inc. | System and method for assessing coupling between an electrode and tissue |
US20090177111A1 (en) | 2006-12-06 | 2009-07-09 | Miller Stephan P | System and method for displaying contact between a catheter and tissue |
US8603084B2 (en) | 2005-12-06 | 2013-12-10 | St. Jude Medical, Atrial Fibrillation Division, Inc. | System and method for assessing the formation of a lesion in tissue |
WO2007072472A2 (en) | 2005-12-19 | 2007-06-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Systems and methods for analyzing and manipulating biological samples |
US20070156135A1 (en) | 2006-01-03 | 2007-07-05 | Boris Rubinsky | System and methods for treating atrial fibrillation using electroporation |
DE602006014206D1 (en) | 2006-01-03 | 2010-06-17 | Alcon Inc | SYSTEM FOR CUTTING AND REMOVING PROTEINOUS TISSUE |
US9357977B2 (en) | 2006-01-12 | 2016-06-07 | Gynesonics, Inc. | Interventional deployment and imaging system |
US7874986B2 (en) | 2006-04-20 | 2011-01-25 | Gynesonics, Inc. | Methods and devices for visualization and ablation of tissue |
US7815571B2 (en) | 2006-04-20 | 2010-10-19 | Gynesonics, Inc. | Rigid delivery systems having inclined ultrasound and needle |
WO2007084508A2 (en) | 2006-01-13 | 2007-07-26 | Mirabilis Medica, Inc. | Apparatus for delivering high intensity focused ultrasound energy to a treatment site internal to a patient's body |
CA3063263C (en) | 2006-02-11 | 2024-01-16 | Genetronics, Inc. | Device and method for single-needle in vivo electroporation |
US20080045880A1 (en) | 2006-02-11 | 2008-02-21 | Rune Kjeken | Device and method for single-needle in vivo electroporation |
US7532928B2 (en) | 2006-02-15 | 2009-05-12 | Biotronik Crm Patent Ag | Atrial defibrillator |
US20070197895A1 (en) | 2006-02-17 | 2007-08-23 | Sdgi Holdings, Inc. | Surgical instrument to assess tissue characteristics |
US9168373B2 (en) | 2006-02-24 | 2015-10-27 | Eastern Virginia Medical School | Nanosecond pulsed electric fields cause melanomas to self-destruct |
EP1991303B1 (en) | 2006-03-03 | 2021-05-05 | OncoSec Medical Incorporated | Method and device for treating microscopic residual tumors remaining in tissues following surgical resection |
US7691151B2 (en) | 2006-03-31 | 2010-04-06 | Spiration, Inc. | Articulable Anchor |
US8548562B2 (en) | 2006-04-04 | 2013-10-01 | John Trachtenberg | System and method of guided treatment within malignant prostate tissue |
CA2649119A1 (en) | 2006-04-13 | 2007-12-13 | Mirabilis Medica, Inc. | Methods and apparatus for the treatment of menometrorrhagia, endometrial pathology, and cervical neoplasia using high intensity focused ultrasound energy |
KR100785882B1 (en) | 2006-04-14 | 2007-12-17 | 경희대학교 산학협력단 | Apparatus and method for detecting anomalies within a body |
US20100056926A1 (en) | 2008-08-26 | 2010-03-04 | Gynesonics, Inc. | Ablation device with articulated imaging transducer |
US8206300B2 (en) | 2008-08-26 | 2012-06-26 | Gynesonics, Inc. | Ablation device with articulated imaging transducer |
GB0609854D0 (en) | 2006-05-18 | 2006-06-28 | City Hospitals Sunderland Nhs | Catheter |
CA2653456A1 (en) | 2006-05-24 | 2007-11-29 | Richard Daneman | Permeability of blood-brain barrier |
US7771401B2 (en) | 2006-06-08 | 2010-08-10 | Angiodynamics, Inc. | Selective renal cannulation and infusion systems and methods |
US20090209955A1 (en) | 2006-06-20 | 2009-08-20 | Forster David C | Prosthetic valve implant site preparation techniques |
US20070295337A1 (en) | 2006-06-22 | 2007-12-27 | Nelson Donald S | Endotracheal cuff and technique for using the same |
US8434487B2 (en) | 2006-06-22 | 2013-05-07 | Covidien Lp | Endotracheal cuff and technique for using the same |
US20080236593A1 (en) | 2006-06-22 | 2008-10-02 | Nellcor Puritan Bennett Llc | Endotracheal cuff and technique for using the same |
US20090018566A1 (en) | 2006-06-30 | 2009-01-15 | Artheromed, Inc. | Atherectomy devices, systems, and methods |
US9314263B2 (en) | 2006-06-30 | 2016-04-19 | Atheromed, Inc. | Atherectomy devices, systems, and methods |
US9492192B2 (en) | 2006-06-30 | 2016-11-15 | Atheromed, Inc. | Atherectomy devices, systems, and methods |
US8628549B2 (en) | 2006-06-30 | 2014-01-14 | Atheromed, Inc. | Atherectomy devices, systems, and methods |
US20080097139A1 (en) | 2006-07-14 | 2008-04-24 | Boston Scientific Scimed, Inc. | Systems and methods for treating lung tissue |
US7763018B2 (en) | 2006-07-28 | 2010-07-27 | Covidien Ag | Cool-tip thermocouple including two-piece hub |
US20080033417A1 (en) | 2006-08-04 | 2008-02-07 | Nields Morgan W | Apparatus for planning and performing thermal ablation |
US20080052786A1 (en) | 2006-08-24 | 2008-02-28 | Pei-Cheng Lin | Animal Model of Prostate Cancer and Use Thereof |
US20080086115A1 (en) | 2006-09-07 | 2008-04-10 | Warsaw Orthopedic, Inc. | Intercostal spacer device and method for use in correcting a spinal deformity |
US7680543B2 (en) | 2006-09-14 | 2010-03-16 | Lazure Technologies, Llc | Tissue ablation and removal |
WO2008063195A1 (en) | 2006-10-12 | 2008-05-29 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Assessment of electrode coupling for tissue ablation |
TR200605770A2 (en) | 2006-10-16 | 2007-10-22 | Ykk Saglik Hizmetleri Anonim Sirketi | Flexible and rigid catheter resector balloon |
US7674249B2 (en) | 2006-10-16 | 2010-03-09 | The Regents Of The University Of California | Gels with predetermined conductivity used in electroporation of tissue |
AU2007310988B2 (en) | 2006-10-18 | 2013-08-15 | Vessix Vascular, Inc. | Tuned RF energy and electrical tissue characterization for selective treatment of target tissues |
USD571478S1 (en) | 2006-10-25 | 2008-06-17 | American Sterilizer Company | Container for reprocessing medical devices |
US20080103529A1 (en) | 2006-10-26 | 2008-05-01 | Old Dominion University | Apparatus and methods for performing cellular electro-manipulations |
US8016022B2 (en) | 2006-11-27 | 2011-09-13 | Honeywell International Inc. | Systems and methods for passive thermal management using phase change material |
US20080132885A1 (en) | 2006-12-01 | 2008-06-05 | Boris Rubinsky | Methods for treating tissue sites using electroporation |
US20080132884A1 (en) | 2006-12-01 | 2008-06-05 | Boris Rubinsky | Systems for treating tissue sites using electroporation |
US20080140064A1 (en) | 2006-12-07 | 2008-06-12 | Cierra, Inc. | Energy delivery apparatus with tissue piercing thermocouple |
EP1930045A1 (en) | 2006-12-08 | 2008-06-11 | BIOTRONIK CRM Patent AG | Implantable medical system with acoustic sensor to measure mitral blood flow |
WO2008068717A2 (en) | 2006-12-08 | 2008-06-12 | Koninklijke Philips Elecronics N.V. | A system, method, computer-readable medium, and use for planning combined therapy |
US8267927B2 (en) | 2007-01-24 | 2012-09-18 | Koninklijke Philips Electronics N.V. | Advanced ablation planning |
US8211099B2 (en) | 2007-01-31 | 2012-07-03 | Tyco Healthcare Group Lp | Thermal feedback systems and methods of using the same |
US8417328B2 (en) | 2007-02-01 | 2013-04-09 | Ls Biopath, Inc. | Electrical systems for detection and characterization of abnormal tissue and cells |
US9566030B2 (en) | 2007-02-01 | 2017-02-14 | Ls Biopath, Inc. | Optical system for detection and characterization of abnormal tissue and cells |
US7655004B2 (en) | 2007-02-15 | 2010-02-02 | Ethicon Endo-Surgery, Inc. | Electroporation ablation apparatus, system, and method |
US20080200911A1 (en) | 2007-02-15 | 2008-08-21 | Long Gary L | Electrical ablation apparatus, system, and method |
US20080210243A1 (en) | 2007-03-02 | 2008-09-04 | Jessica Clayton | Endotracheal cuff and technique for using the same |
US7815662B2 (en) | 2007-03-08 | 2010-10-19 | Ethicon Endo-Surgery, Inc. | Surgical suture anchors and deployment device |
USD565743S1 (en) | 2007-04-12 | 2008-04-01 | Vector Surgical, Inc. | Surgical container with applicators |
EP2155094B1 (en) | 2007-04-13 | 2011-06-22 | Boston Scientific Limited | Radiofrequency ablation device |
US8075572B2 (en) | 2007-04-26 | 2011-12-13 | Ethicon Endo-Surgery, Inc. | Surgical suturing apparatus |
US8100922B2 (en) | 2007-04-27 | 2012-01-24 | Ethicon Endo-Surgery, Inc. | Curved needle suturing tool |
US20080283065A1 (en) | 2007-05-15 | 2008-11-20 | Portaero, Inc. | Methods and devices to maintain patency of a lumen in parenchymal tissue of the lung |
US7620507B2 (en) | 2007-05-24 | 2009-11-17 | Battelle Energy Alliance, Llc | Impedance-estimation methods, modeling methods, articles of manufacture, impedance-modeling devices, and estimated-impedance monitoring systems |
US20080306427A1 (en) | 2007-06-05 | 2008-12-11 | Cook Incorporated | Chronic Hemodialysis Catheter with Balloon |
US7753889B2 (en) | 2007-06-15 | 2010-07-13 | Interrad Medical, Inc. | Anchor instrumentation and methods |
US20110034209A1 (en) | 2007-06-18 | 2011-02-10 | Boris Rubinsky | Wireless technology as a data conduit in three-dimensional ultrasonogray |
US20100255795A1 (en) | 2007-06-18 | 2010-10-07 | The Regents Of The University Of California | Cellular Phone Enabled Medical Imaging System |
US8052604B2 (en) | 2007-07-31 | 2011-11-08 | Mirabilis Medica Inc. | Methods and apparatus for engagement and coupling of an intracavitory imaging and high intensity focused ultrasound probe |
US8262655B2 (en) | 2007-11-21 | 2012-09-11 | Ethicon Endo-Surgery, Inc. | Bipolar forceps |
US8568410B2 (en) | 2007-08-31 | 2013-10-29 | Ethicon Endo-Surgery, Inc. | Electrical ablation surgical instruments |
US20090062788A1 (en) | 2007-08-31 | 2009-03-05 | Long Gary L | Electrical ablation surgical instruments |
US8181995B2 (en) | 2007-09-07 | 2012-05-22 | Tyco Healthcare Group Lp | Cool tip junction |
WO2009036472A1 (en) | 2007-09-14 | 2009-03-19 | Lazure Technologies, Llc | Prostate cancer ablation |
WO2009036457A1 (en) | 2007-09-14 | 2009-03-19 | Lazure Technologies, Llc | Multi-layer electrode ablation probe and related methods |
US20090076500A1 (en) | 2007-09-14 | 2009-03-19 | Lazure Technologies, Llc | Multi-tine probe and treatment by activation of opposing tines |
US20090081272A1 (en) | 2007-09-24 | 2009-03-26 | John Clarke | Medical devices having a metal particulate composition for controlled diffusion |
US8267936B2 (en) | 2007-09-28 | 2012-09-18 | Tyco Healthcare Group Lp | Insulating mechanically-interfaced adhesive for electrosurgical forceps |
WO2009046176A1 (en) | 2007-10-02 | 2009-04-09 | C. R. Bard, Inc. | Drainage catheter with one-way valve |
US8088072B2 (en) | 2007-10-12 | 2012-01-03 | Gynesonics, Inc. | Methods and systems for controlled deployment of needles in tissue |
US8439907B2 (en) | 2007-11-07 | 2013-05-14 | Mirabilis Medica Inc. | Hemostatic tissue tunnel generator for inserting treatment apparatus into tissue of a patient |
US8187270B2 (en) | 2007-11-07 | 2012-05-29 | Mirabilis Medica Inc. | Hemostatic spark erosion tissue tunnel generator with integral treatment providing variable volumetric necrotization of tissue |
US8292880B2 (en) | 2007-11-27 | 2012-10-23 | Vivant Medical, Inc. | Targeted cooling of deployable microwave antenna |
WO2009076246A2 (en) | 2007-12-06 | 2009-06-18 | Massachusetts Institute Of Technology | Methods to treat unwanted tissue with electric pulses |
US8388678B2 (en) | 2007-12-12 | 2013-03-05 | Boston Scientific Scimed, Inc. | Medical devices having porous component for controlled diffusion |
US8353902B2 (en) | 2008-01-31 | 2013-01-15 | Vivant Medical, Inc. | Articulating ablation device and method |
US20090204005A1 (en) | 2008-02-07 | 2009-08-13 | Broncus Technologies, Inc. | Puncture resistant catheter for sensing vessels and for creating passages in tissue |
US8343144B2 (en) | 2008-02-11 | 2013-01-01 | Expandoheat, Llc | Apparatus and method for vessel sealing and tissue coagulation |
USD647628S1 (en) | 2008-02-12 | 2011-10-25 | Stryker Leibinger Gmbh & Co. Kg | Storage module for surgical devices, in particular for boneplate templates |
US8262680B2 (en) | 2008-03-10 | 2012-09-11 | Ethicon Endo-Surgery, Inc. | Anastomotic device |
US20110064671A1 (en) | 2008-03-10 | 2011-03-17 | Cornell University | Modulation of blood brain barrier permeability |
WO2009121009A2 (en) | 2008-03-27 | 2009-10-01 | The Regents Of The University Of California | Irreversible electroporation device for use in attenuating neointimal |
US20100004623A1 (en) * | 2008-03-27 | 2010-01-07 | Angiodynamics, Inc. | Method for Treatment of Complications Associated with Arteriovenous Grafts and Fistulas Using Electroporation |
CN113274496A (en) | 2008-04-04 | 2021-08-20 | 免疫之光有限责任公司 | Non-invasive system and method for in situ photobiomodulation |
US20090270756A1 (en) | 2008-04-23 | 2009-10-29 | Gamache Ronald W | Determining physiological characteristics of animal |
US20090287081A1 (en) | 2008-04-29 | 2009-11-19 | Gynesonics , Inc | Submucosal fibroid ablation for the treatment of menorrhagia |
EP2280741A4 (en) | 2008-04-29 | 2012-06-13 | Virginia Tech Intell Prop | Irreversible electroporation to create tissue scaffolds |
US9198733B2 (en) | 2008-04-29 | 2015-12-01 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for electroporation-based therapies |
US8992517B2 (en) | 2008-04-29 | 2015-03-31 | Virginia Tech Intellectual Properties Inc. | Irreversible electroporation to treat aberrant cell masses |
EP2268189A1 (en) | 2008-05-01 | 2011-01-05 | Spiration, Inc. | Direct lung sensor systems, methods, and apparatuses |
WO2009137609A2 (en) | 2008-05-06 | 2009-11-12 | Cellutions, Inc. | Apparatus and systems for treating a human tissue condition |
WO2009137800A2 (en) | 2008-05-09 | 2009-11-12 | Angiodynamics, Inc. | Electroporation device and method |
US8317806B2 (en) | 2008-05-30 | 2012-11-27 | Ethicon Endo-Surgery, Inc. | Endoscopic suturing tension controlling and indication devices |
US8070759B2 (en) | 2008-05-30 | 2011-12-06 | Ethicon Endo-Surgery, Inc. | Surgical fastening device |
US8114072B2 (en) | 2008-05-30 | 2012-02-14 | Ethicon Endo-Surgery, Inc. | Electrical ablation device |
US8403926B2 (en) | 2008-06-05 | 2013-03-26 | Ethicon Endo-Surgery, Inc. | Manually articulating devices |
US20090306544A1 (en) | 2008-06-09 | 2009-12-10 | Ho-Kin Ng | Instillation/aspiration device |
US20090301480A1 (en) | 2008-06-09 | 2009-12-10 | Mamdouh Elsakka | Diagnostic sample collection system and method of use |
US20090306545A1 (en) | 2008-06-09 | 2009-12-10 | Mamdouh Elsakka | Bronchoalveolar lavage catheter assembly |
USD595422S1 (en) | 2008-06-18 | 2009-06-30 | Wire • Caddy, LLC | Support device for interventional instruments |
WO2009155526A2 (en) * | 2008-06-20 | 2009-12-23 | Angiodynamics, Inc. | Device and method for the ablation of fibrin sheath formation on a venous catheter |
US9681909B2 (en) | 2008-06-23 | 2017-06-20 | Angiodynamics, Inc. | Treatment devices and methods |
DE102008030242A1 (en) | 2008-06-25 | 2010-01-07 | Siemens Aktiengesellschaft | Method for monitoring the image of an irreversible electroporation treatment and associated device |
US20090326570A1 (en) | 2008-06-27 | 2009-12-31 | Kenneth Brown | Treated needle holding tube for use in tattooing |
US8361112B2 (en) | 2008-06-27 | 2013-01-29 | Ethicon Endo-Surgery, Inc. | Surgical suture arrangement |
US8409206B2 (en) | 2008-07-01 | 2013-04-02 | Baxano, Inc. | Tissue modification devices and methods |
US8398641B2 (en) | 2008-07-01 | 2013-03-19 | Baxano, Inc. | Tissue modification devices and methods |
US8262563B2 (en) | 2008-07-14 | 2012-09-11 | Ethicon Endo-Surgery, Inc. | Endoscopic translumenal articulatable steerable overtube |
USD613418S1 (en) | 2008-07-23 | 2010-04-06 | Smiths Medical Asd, Inc. | Tray assembly |
US8221411B2 (en) | 2008-07-28 | 2012-07-17 | Medtronic, Inc. | Systems and methods for cardiac tissue electroporation ablation |
US8216161B2 (en) | 2008-08-06 | 2012-07-10 | Mirabilis Medica Inc. | Optimization and feedback control of HIFU power deposition through the frequency analysis of backscattered HIFU signals |
US8211125B2 (en) | 2008-08-15 | 2012-07-03 | Ethicon Endo-Surgery, Inc. | Sterile appliance delivery device for endoscopic procedures |
US8529563B2 (en) | 2008-08-25 | 2013-09-10 | Ethicon Endo-Surgery, Inc. | Electrical ablation devices |
US8241204B2 (en) | 2008-08-29 | 2012-08-14 | Ethicon Endo-Surgery, Inc. | Articulating end cap |
WO2010028053A1 (en) | 2008-09-02 | 2010-03-11 | Medtronic Ablation Frontiers Llc | Irrigated ablation catheter system and methods |
US8409200B2 (en) | 2008-09-03 | 2013-04-02 | Ethicon Endo-Surgery, Inc. | Surgical grasping device |
US8403924B2 (en) | 2008-09-03 | 2013-03-26 | Vivant Medical, Inc. | Shielding for an isolation apparatus used in a microwave generator |
US8114119B2 (en) | 2008-09-09 | 2012-02-14 | Ethicon Endo-Surgery, Inc. | Surgical grasping device |
US20100100093A1 (en) | 2008-09-16 | 2010-04-22 | Lazure Technologies, Llc. | System and method for controlled tissue heating for destruction of cancerous cells |
US8248075B2 (en) | 2008-09-30 | 2012-08-21 | Vivant Medical, Inc. | System, apparatus and method for dissipating standing wave in a microwave delivery system |
DE102008049709B4 (en) | 2008-09-30 | 2019-12-12 | Siemens Healthcare Gmbh | Method for selectively displaying a movement of the lung, computer program, image processing unit and magnetic resonance apparatus |
US8180433B2 (en) | 2008-09-30 | 2012-05-15 | Vivant Medical, Inc. | Microwave system calibration apparatus, system and method of use |
US8242782B2 (en) | 2008-09-30 | 2012-08-14 | Vivant Medical, Inc. | Microwave ablation generator control system |
US8346370B2 (en) | 2008-09-30 | 2013-01-01 | Vivant Medical, Inc. | Delivered energy generator for microwave ablation |
US20100082083A1 (en) | 2008-09-30 | 2010-04-01 | Brannan Joseph D | Microwave system tuner |
US8287527B2 (en) | 2008-09-30 | 2012-10-16 | Vivant Medical, Inc. | Microwave system calibration apparatus and method of use |
US8174267B2 (en) | 2008-09-30 | 2012-05-08 | Vivant Medical, Inc. | Intermittent microwave energy delivery system |
US8337394B2 (en) | 2008-10-01 | 2012-12-25 | Ethicon Endo-Surgery, Inc. | Overtube with expandable tip |
EP3173043A1 (en) | 2008-11-11 | 2017-05-31 | Shifamed Holdings, LLC | Low profile electrode assembly |
US8157834B2 (en) | 2008-11-25 | 2012-04-17 | Ethicon Endo-Surgery, Inc. | Rotational coupling device for surgical instrument with flexible actuators |
US9144461B2 (en) | 2008-12-03 | 2015-09-29 | Koninklijke Philips N.V. | Feedback system for integrating interventional planning and navigation |
US8172772B2 (en) | 2008-12-11 | 2012-05-08 | Ethicon Endo-Surgery, Inc. | Specimen retrieval device |
US20100152725A1 (en) | 2008-12-12 | 2010-06-17 | Angiodynamics, Inc. | Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation |
US8361066B2 (en) | 2009-01-12 | 2013-01-29 | Ethicon Endo-Surgery, Inc. | Electrical ablation devices |
US8753335B2 (en) | 2009-01-23 | 2014-06-17 | Angiodynamics, Inc. | Therapeutic energy delivery device with rotational mechanism |
US8252057B2 (en) | 2009-01-30 | 2012-08-28 | Ethicon Endo-Surgery, Inc. | Surgical access device |
US8037591B2 (en) | 2009-02-02 | 2011-10-18 | Ethicon Endo-Surgery, Inc. | Surgical scissors |
US8231603B2 (en) | 2009-02-10 | 2012-07-31 | Angiodynamics, Inc. | Irreversible electroporation and tissue regeneration |
US8211097B2 (en) | 2009-02-13 | 2012-07-03 | Cutera, Inc. | Optimizing RF power spatial distribution using frequency control |
US8262574B2 (en) | 2009-02-27 | 2012-09-11 | Gynesonics, Inc. | Needle and tine deployment mechanism |
US20120085649A1 (en) | 2010-03-09 | 2012-04-12 | Virginia Tech Intellectual Properties, Inc. | Dielectrophoresis devices and methods therefor |
EP2413980A2 (en) | 2009-03-30 | 2012-02-08 | Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. | An apparatus, system and method for preventing biological contamination to materials during storage using pulsed electrical energy |
EP2413833A1 (en) | 2009-03-31 | 2012-02-08 | AngioDynamics, Inc. | System and method for estimating a treatment region for a medical treatment device and for interactively planning a treatment of a patient |
US9277969B2 (en) | 2009-04-01 | 2016-03-08 | Covidien Lp | Microwave ablation system with user-controlled ablation size and method of use |
US8632534B2 (en) | 2009-04-03 | 2014-01-21 | Angiodynamics, Inc. | Irreversible electroporation (IRE) for congestive obstructive pulmonary disease (COPD) |
US20100256630A1 (en) | 2009-04-07 | 2010-10-07 | Angiodynamics, Inc. | Irreversible electroporation (ire) for esophageal disease |
WO2010118387A1 (en) | 2009-04-09 | 2010-10-14 | Virginia Tech Intellectual Properties, Inc. | Integration of very short electric pulses for minimally to noninvasive electroporation |
US20100268225A1 (en) | 2009-04-15 | 2010-10-21 | Tyco Healthcare Group Lp | Methods for Image Analysis and Visualization of Medical Image Data Suitable for Use in Assessing Tissue Ablation and Systems and Methods for Controlling Tissue Ablation Using Same |
US20100268223A1 (en) | 2009-04-15 | 2010-10-21 | Tyco Health Group Lp | Methods for Image Analysis and Visualization of Medical Image Data Suitable for Use in Assessing Tissue Ablation and Systems and Methods for Controlling Tissue Ablation Using Same |
WO2010123993A1 (en) | 2009-04-21 | 2010-10-28 | Tuan Vo-Dinh | Non-invasive energy upconversion methods and systems for in-situ photobiomodulation |
IT1394143B1 (en) | 2009-05-04 | 2012-05-25 | Igea S P A | DEVICE FOR REVERSIBLE ELECTROPORATION ACTING TO CURE CELLULAR APOPTOSIS |
WO2010129899A1 (en) | 2009-05-08 | 2010-11-11 | Cellutions, Inc. | Treatment system with a pulse forming network for achieving plasma in tissue |
USD630321S1 (en) | 2009-05-08 | 2011-01-04 | Angio Dynamics, Inc. | Probe handle |
US8246615B2 (en) | 2009-05-19 | 2012-08-21 | Vivant Medical, Inc. | Tissue impedance measurement using a secondary frequency |
WO2010135602A1 (en) | 2009-05-20 | 2010-11-25 | Osseon Therapeutics, Inc. | Steerable curvable ablation catheter for vertebroplasty |
US8394102B2 (en) | 2009-06-25 | 2013-03-12 | Baxano, Inc. | Surgical tools for treatment of spinal stenosis |
WO2011022674A2 (en) | 2009-08-20 | 2011-02-24 | Angiodynamics, Inc. | Multi-electrode energy delivery device and method of using the same |
US10828100B2 (en) | 2009-08-25 | 2020-11-10 | Covidien Lp | Microwave ablation with tissue temperature monitoring |
SG176948A1 (en) | 2009-09-03 | 2012-01-30 | Arakawa Chem Ind | Cleaning agent for removal of, removal method for, and cleaning method for water-soluble, lead-free solder flux |
WO2011028937A1 (en) | 2009-09-04 | 2011-03-10 | The Regents Of The University Of California | Extracellular matrix material created using non-thermal irreversible electroporation |
DE102009048264B4 (en) | 2009-10-05 | 2011-09-22 | Siemens Aktiengesellschaft | Image monitoring method for electroporation treatment and associated image monitoring device |
US20110082414A1 (en) | 2009-10-06 | 2011-04-07 | Wallace Michael P | Ultrasound-enhanced stenosis therapy |
EP2488251A4 (en) | 2009-10-16 | 2014-02-19 | Virginia Tech Intell Prop | Treatment planning for electroporation-based therapies |
US8568401B2 (en) | 2009-10-27 | 2013-10-29 | Covidien Lp | System for monitoring ablation size |
US20110105823A1 (en) | 2009-10-30 | 2011-05-05 | Angiodynamics, Inc. | Medical Template Device and Method for Use in Positioning Therapeutic Probes at a Target Tissue |
US20110112434A1 (en) | 2009-11-06 | 2011-05-12 | Ethicon Endo-Surgery, Inc. | Kits and procedures for natural orifice translumenal endoscopic surgery |
US20110118729A1 (en) | 2009-11-13 | 2011-05-19 | Alcon Research, Ltd | High-intensity pulsed electric field vitrectomy apparatus with load detection |
US20110118734A1 (en) | 2009-11-16 | 2011-05-19 | Alcon Research, Ltd. | Capsularhexis device using pulsed electric fields |
US8394092B2 (en) | 2009-11-17 | 2013-03-12 | Vivant Medical, Inc. | Electromagnetic energy delivery devices including an energy applicator array and electrosurgical systems including same |
US20110118732A1 (en) | 2009-11-19 | 2011-05-19 | The Regents Of The University Of California | Controlled irreversible electroporation |
US20110245756A1 (en) | 2009-12-03 | 2011-10-06 | Rishi Arora | Devices for material delivery, electroporation, sonoporation, and/or monitoring electrophysiological activity |
US20110135626A1 (en) | 2009-12-08 | 2011-06-09 | Alcon Research, Ltd. | Localized Chemical Lysis of Ocular Tissue |
EP2445434B1 (en) | 2009-12-11 | 2018-08-22 | St. Jude Medical Atrial Fibrillation Division, Inc. | System for determining the likelihood of endocardial barotrauma in tissue during ablation |
US20110144638A1 (en) | 2009-12-14 | 2011-06-16 | Alcon Research, Ltd. | Localized Shockwave-Induced Tissue Disruption |
US20110144562A1 (en) | 2009-12-14 | 2011-06-16 | Alcon Research, Ltd. | Localized Pharmacological Treatment of Ocular Tissue Using High-Intensity Pulsed Electrical Fields |
US20110144641A1 (en) | 2009-12-15 | 2011-06-16 | Alcon Research, Ltd. | High-Intensity Pulsed Electric Field Vitrectomy Apparatus |
US10039588B2 (en) | 2009-12-16 | 2018-08-07 | Covidien Lp | System and method for tissue sealing |
US8353487B2 (en) | 2009-12-17 | 2013-01-15 | Ethicon Endo-Surgery, Inc. | User interface support devices for endoscopic surgical instruments |
US20110160514A1 (en) * | 2009-12-31 | 2011-06-30 | Ethicon Endo-Surgery, Inc. | Electrical ablation devices |
US20110172659A1 (en) | 2010-01-13 | 2011-07-14 | Vivant Medical, Inc. | Ablation Device With User Interface at Device Handle, System Including Same, and Method of Ablating Tissue Using Same |
WO2011091847A1 (en) | 2010-01-28 | 2011-08-04 | Brainlab Ag | Method and apparatus for estimating temperature in a body |
US20110202052A1 (en) | 2010-02-12 | 2011-08-18 | Daniel Gelbart | System for treating benign prostatic hyperplasia |
US9675406B2 (en) | 2010-02-16 | 2017-06-13 | Angiodynamics, Inc. | Ablation device with guide sleeves |
US20110208180A1 (en) | 2010-02-25 | 2011-08-25 | Vivant Medical, Inc. | System and Method for Monitoring Ablation Size |
US8425455B2 (en) | 2010-03-30 | 2013-04-23 | Angiodynamics, Inc. | Bronchial catheter and method of use |
US20110288545A1 (en) | 2010-04-22 | 2011-11-24 | Old Dominion University Research Foundation | Method and Device for Ablation of Cancer and Resistance to New Cancer Growth |
GB201006841D0 (en) | 2010-04-26 | 2010-06-09 | Thomsen Lars | Method, device and system for targetted cell lysis |
US9138210B2 (en) | 2010-05-11 | 2015-09-22 | Ethicon Endo-Surgery, Inc. | Fistula cleaning and repair device and method |
WO2012006533A1 (en) | 2010-07-08 | 2012-01-12 | Misbah Huzaira Khan | Method and apparatus for minimally invasive, treatment of human adipose tissue using controlled cooling and radiofrequency current |
WO2012009445A1 (en) | 2010-07-13 | 2012-01-19 | Zoll Medical Corporation | Deposit ablation within and external to circulatory systems |
US8652130B2 (en) | 2010-08-18 | 2014-02-18 | Invasix Ltd. | Method and device for soft tissue ablation |
US9289606B2 (en) | 2010-09-02 | 2016-03-22 | St. Jude Medical, Atrial Fibrillation Division, Inc. | System for electroporation therapy |
US20120089009A1 (en) | 2010-10-11 | 2012-04-12 | Omary Reed A | Methods and apparatus to deliver nanoparticles to tissue using electronanotherapy |
WO2012051433A2 (en) | 2010-10-13 | 2012-04-19 | Angiodynamics, Inc. | System and method for electrically ablating tissue of a patient |
WO2012054560A1 (en) | 2010-10-21 | 2012-04-26 | Highland Instruments, Inc. | Methods for detecting a condition |
US20130072784A1 (en) | 2010-11-10 | 2013-03-21 | Gnanasekar Velusamy | Systems and methods for planning image-guided interventional procedures |
JP2014501574A (en) | 2010-11-23 | 2014-01-23 | ヴァージニア テック インテレクチュアル プロパティーズ,インコーポレーテッド | Irreversible electroporation using tissue vasculature to treat abnormal cell populations or generate tissue scaffolds |
WO2012088149A2 (en) | 2010-12-20 | 2012-06-28 | Virginia Tech Intellectual Properties, Inc. | High-frequency electroporation for cancer therapy |
US9233241B2 (en) | 2011-02-28 | 2016-01-12 | Ethicon Endo-Surgery, Inc. | Electrical ablation devices and methods |
US9072518B2 (en) | 2011-05-31 | 2015-07-07 | Atricure, Inc. | High-voltage pulse ablation systems and methods |
JP2014522714A (en) | 2011-08-08 | 2014-09-08 | ルース,リチャード,ビー. | Method and apparatus for treating cancer |
EP2755716B1 (en) | 2011-09-15 | 2020-04-15 | Cold Plasma Medical Technologies, Inc. | Unipolar cold plasma device and associated method |
US9078665B2 (en) | 2011-09-28 | 2015-07-14 | Angiodynamics, Inc. | Multiple treatment zone ablation probe |
WO2013052138A2 (en) | 2011-10-03 | 2013-04-11 | Fabrico. Inc. | System and method for electrophoretic decellularization |
US20130108667A1 (en) | 2011-10-27 | 2013-05-02 | Soiwisa Soikum | Method, apparatus and system for electroporation |
US20130110106A1 (en) | 2011-10-28 | 2013-05-02 | Boston Scientific Scimed, Inc. | Expandable structure for off-wall ablation electrode |
USD677798S1 (en) | 2012-06-25 | 2013-03-12 | Angiodynamics, Inc. | Medical device package tray |
-
2014
- 2014-06-12 US US14/302,678 patent/US9895189B2/en active Active
-
2018
- 2018-01-08 US US15/864,421 patent/US20180116710A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023034771A1 (en) * | 2021-08-30 | 2023-03-09 | Nanovis, LLC | Devices and methods for treating infected tissue |
Also Published As
Publication number | Publication date |
---|---|
US20210030463A1 (en) | 2021-02-04 |
US20140378964A1 (en) | 2014-12-25 |
US9895189B2 (en) | 2018-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20180116710A1 (en) | Methods of Sterilization and Treating Infection Using Irreversible Electroporation | |
US20210000527A1 (en) | System, method and computer-accessible medium for in-vivo tissue ablation and/or damage | |
US11453873B2 (en) | Methods for delivery of biphasic electrical pulses for non-thermal ablation | |
US11254926B2 (en) | Devices and methods for high frequency electroporation | |
Stewart et al. | Safety and chronic lesion characterization of pulsed field ablation in a Porcine model | |
US20190328446A1 (en) | System and Method for Increasing a Target Zone for Electrical Ablation | |
Pavliha et al. | Patient-specific treatment planning of electrochemotherapy: Procedure design and possible pitfalls | |
US9931161B2 (en) | Coaxial dual function probe and method of use | |
US20160354142A1 (en) | System and Method for Estimating A Treatment Region for a Medical Treatment Device | |
WO2011047387A2 (en) | Treatment planning for electroporation-based therapies | |
Sano et al. | Optimization of a single insertion electrode array for the creation of clinically relevant ablations using high-frequency irreversible electroporation | |
WO2016126811A1 (en) | Radio-frequency electrical membrane breakdown for the treatment of adipose tissue and removal of unwanted body fat | |
US11957405B2 (en) | Methods of sterilization and treating infection using irreversible electroporation | |
Cindrič et al. | Electrodes and electric field distribution in clinical practice | |
Neal et al. | A study using irreversible electroporation to treat large, irregular tumors in a canine patient | |
RU2231991C2 (en) | Method for treating unresectable primary and metastatic hepatic tumors | |
US11952568B2 (en) | Device and methods for delivery of biphasic electrical pulses for non-thermal ablation | |
US20230338081A1 (en) | System and method for minimally invasive treatment with injectable electrodes | |
EP4213753A1 (en) | System and method for minimally invasive treatment with injectable electrodes | |
AU2022252150A1 (en) | System and methods for minimally invasive ablation with injectable wire structure devices | |
WO2023212250A1 (en) | Lesion optimization in the use of pulsed electric fields | |
Zhang et al. | Electrodes Deployment for IRE Tumor Ablation based on the Nelder-Mead Simplex Algorithm |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT Free format text: CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS;ASSIGNOR:ANGIODYNAMICS, INC.;REEL/FRAME:049371/0657 Effective date: 20190603 Owner name: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT, ILLINOIS Free format text: CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS;ASSIGNOR:ANGIODYNAMICS, INC.;REEL/FRAME:049371/0657 Effective date: 20190603 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: ANGIODYNAMICS, INC., NEW YORK Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT;REEL/FRAME:061363/0446 Effective date: 20220830 |